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Breast cancer is the most frequent in women. Scientific knowledge and technology have
created many and different strategies to treat this pathology. Radiotherapy (RT) is in
the actual standard guidelines for most of breast cancer treatments. However, radiation
is a two-sword weapon: although it may heal cancer, it may also induce secondary
cancer. The contralateral breast (CLB) is a susceptible organ to absorb doses with the
treatment of the other breast, being at significant risk to develop a secondary tumor.
New radiation related techniques, with more complex delivery strategies and promising
results are being implemented and used in radiotherapy departments. However some
questions have to be properly addressed, such as: Is it safe to move to complex tech-
niques to achieve better conformation in the target volumes, in breast radiotherapy?
What happens to the target volumes and surrounding healthy tissues? How accurate is
dose delivery? What are the shortcomings and limitations of currently used treatment
planning systems (TPS)?
The answers to these questions largely rely in the use of Monte Carlo (MC) simulations
using state-of-the-art computer programs to accurately model the different components
of the equipment (target, filters, collimators, etc.) and obtain an adequate description
of the radiation fields used, as well as the detailed geometric representation and material
composition of organs and tissues.
This work aims at investigating the impact of treating left breast cancer using differ-
ent radiation therapy (RT) techniques f-IMRT (forwardly-planned intensity-modulated),
inversely-planned IMRT (IMRT2, using 2 beams; IMRT5, using 5 beams) and dynamic
conformal arc (DCART) RT and their effects on the whole-breast irradiation and in the
undesirable irradiation of the surrounding healthy tissues.
Two algorithms of iPlan BrainLAB TPS were used: Pencil Beam Convolution (PBC)
and commercial Monte Carlo (iMC). Furthermore, an accurate Monte Carlo (MC) model
of the linear accelerator used (a Trilogy R© VARIAN R©) was done with the EGSnrc MC
code, to accurately determine the doses that reach the CLB. For this purpose it was
necessary to model the new High Definition multileaf collimator that had never before
been simulated. The model developed was then included on the EGSnrc MC package
of National Research Council Canada (NRC). The linac was benchmarked with water
measurements and later on validated against the TPS calculations.
The dose distributions in the planning target volume (PTV) and the dose to the organs at
risk (OAR) were compared analyzing dose-volume histograms; further statistical analysis
was performed using IBM SPSS v20 software.
For PBC, all the techniques provided adequate coverage of the PTV. However, statisti-
cally significant dose differences were observed between the techniques, in the PTV, OAR
and also in the pattern of dose distribution spreading into normal tissues. IMRT5 and
DCART spread low doses into greater volumes of normal tissue, right breast, right lung,
heart and even the left lung than tangential techniques (f-IMRT and IMRT2). However,
IMRT5 plans improved distributions for the PTV, exhibiting better conformity and ho-
mogeneity in target and reduced high dose percentages in ipsilateral OAR. DCART
did not present advantages over any of the techniques investigated. Differences were
also found comparing the calculation algorithms: PBC estimated higher doses for the
PTV, ipsilateral lung and heart than the MC algorithms predicted. The MC algorithms
presented similar results (within 2% differences). The PBC algorithm was considered
not accurate in determining the dose in heterogeneous media and in build-up regions.
Therefore, a major effort is being done at the clinic to acquire data to move from PBC to
another calculation algorithm. Despite better PTV homogeneity and conformity there
is an increased risk of CLB cancer development, when using non-tangential techniques.
The overall results of the studies performed confirm the outstanding predictive power
and accuracy in the assessment and calculation of dose distributions in organs and tissues
rendered possible by the utilization and implementation of MC simulation techniques in
RT TPS.
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Resumo
O cancro de mama é o mais frequente diagnoticado a indiv́ıduos do sexo feminino. O
conhecimento cient́ıfico e a tecnologia têm permitido a criação de muitas e diferentes
estratégias para tratar esta patologia. A Radioterapia (RT) está entre as diretrizes atuais
para a maioria dos tratamentos de cancro de mama. No entanto, a radiação é como uma
arma de dois canos: apesar de tratar, pode ser indutora de neoplasias secundárias. A
mama contralateral (CLB) é um órgão suscept́ıvel de absorver doses com o tratamento
da outra mama, potenciando o risco de desenvolver um tumor secundário.
Nos departamentos de radioterapia têm sido implementadas novas técnicas relacionadas
com a radiação, com complexas estratégias de administração da dose e resultados promis-
sores. No entanto, algumas questões precisam de ser devidamente colocadas, tais como:
É seguro avançar para técnicas complexas para obter melhores ı́ndices de conformidade
nos volumes alvo, em radioterapia de mama? O que acontece aos volumes alvo e aos
tecidos saudáveis adjacentes? Quão exata é a administração de dose? Quais são as
limitações e vantagens das técnicas e algoritmos atualmente usados?
A resposta a estas questões é conseguida recorrendo a métodos de Monte Carlo para
modelar com precisão os diferentes componentes do equipamento produtor de radiação
(alvos, filtros, colimadores, etc), afim de obter uma descrição apropriada dos campos
de radiação usados, bem como uma representação geométrica detalhada e a composição
dos materiais que constituem os órgãos e os tecidos envolvidos.
Este trabalho visa investigar o impacto de tratar cancro de mama esquerda usando
diferentes técnicas de radioterapia f-IMRT (intensidade modulada por planeamento di-
reto), IMRT por planeamento inverso (IMRT2, usando 2 feixes; IMRT5, com 5 feixes)
e DCART (arco conformacional dinâmico) e os seus impactos em irradiação da mama e
na irradiação indesejada dos tecidos saudáveis adjacentes.
Dois algoritmos do sistema de planeamento iPlan da BrainLAB foram usados: Pencil
Beam Convolution (PBC) e Monte Carlo comercial iMC. Foi ainda usado um modelo
de Monte Carlo criado para o acelerador usado (Trilogy da VARIAN Medical Systems),
no código EGSnrc MC, para determinar as doses depositadas na mama contralateral.
Para atingir este objetivo foi necessário modelar o novo colimador multi-lâminas High-
Definition que nunca antes havia sido simulado. O modelo desenvolvido está agora
dispońıvel no pacote do código EGSnrc MC do National Research Council Canada
(NRC). O acelerador simulado foi validado com medidas realizadas em água e poste-
riormente com cálculos realizados no sistema de planeamento (TPS).
As distribuições de dose no volume alvo (PTV) e a dose nos órgãos de risco (OAR)
foram comparadas através da análise de histogramas de dose-volume; análise estat́ıstica
complementar foi realizads usando o software IBM SPSS v20.
Para o algoritmo PBC, todas as técnicas proporcionaram uma cobertura adequata do
PTV. No entanto, foram encontradas diferenças estatisticamente significativas entre as
técnicas, no PTV, nos OAR e ainda no padrão da distribuição de dose pelos tecidos
sãos. IMRT5 e DCART contribuem para maior dispersão de doses baixas pelos tecidos
normais, mama direita, pulmão direito, coração e até pelo pulmão esquerdo, quando
comparados com as técnicas tangenciais (f-IMRT e IMRT2). No entanto, os planos de
IMRT5 melhoram a distribuição de dose no PTV apresentando melhor conformidade e
homogeneidade no volume alvo e percentagens de dose mais baixas nos órgãos do mesmo
lado. A técnica de DCART não apresenta vantagens comparativamente com as restantes
técnicas investigadas. Foram também identificadas diferenças entre os algoritmos de
cálculos: em geral, o PBC estimou doses mais elevadas para o PTV, pulmão esquerdo
e coração, do que os algoritmos de MC. Os algoritmos de MC, entre si, apresentaram
resultados semelhantes (com dferenças até 2%). Considera-se que o PBC não é preciso
na determinação de dose em meios homogéneos e na região de build-up. Nesse sentido,
atualmente na cĺınica, a equipa da F́ısica realiza medições para adquirir dados para
outro algoritmo de cálculo. Apesar de melhor homogeneidade e conformidade no PTV
considera-se que há um aumento de risco de cancro na mama contralateral quando se
utilizam técnicas não-tangenciais.
Os resultados globais dos estudos apresentados confirmam o excelente poder de previsão
com precisão na determinação e cálculo das distribuições de dose nos orgãos e tecidos
das técnicas de simulação de Monte Carlo usados.
Palavras-Chave:
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1. Technology and Monte Carlo simulations in support of improved
clinical practice in RT
In the recent decades, the radiotherapy (RT) techniques went through major de-
velopments, namely with conformational RT and intensity modulated RT (IMRT).
These technical and technological evolutions were made possible due to the ad-
vances in the linear accelerator (linac) technology and the development and im-
plementation of dose calculation treatment planning systems (TPS).
The modern linacs permit the accurate delivery of a prescribed dose, even in large
3D volumes, with the possibility of following the movement of the target volume
and other organs during the treatments. The treatment planning algorithms and
systems are nowadays an important tool in RT and are of paramount importance
for estimating the doses.
The calculation algorithms are becoming increasingly more accurate allowing dose
distributions in the patient’s organs and tissues closer to real. Such techniques
bring along an improvement of the treatment quality for the tumors in deeper and
radiosensitive locations, such as in the breast, lung and head and neck cases.
Considering the dose calculation, there are two main difficulties when willing to
perform patient dose calculations: on one side, it is necessary the modeling of
the patient’s complex anatomy with a detailed description of the geometry and
materials composition of organs and tissues; on the other side there is the mod-
eling of the physical processes of energy deposition and absorbed dose within the
patient’s body. On what the modeling of the patients anatomy is concerned, com-
puted tomography (CT) offers the possibility to model the patient’s organs and
tissues, discretizing their volumes into small volume elements, called voxels. Each
voxel is associated to a value known as Hounsfield units (HU) that is representa-
tive of the average electronic density of the material that constitutes each specific
element volume. This method permits determining the attenuation power of the
medium for the specific radiation beam. To model the physical processes of energy
transfer and absorption, dose calculation methods and algorithms were developed
to determine an accurate representation of the dose delivered by the treatment
beams.
The calculated dose entails different types of uncertainties associated to the TPS
and the calculation algorithms. The slightly miscalculated doses can reduce the
treatments’ efficacy or increase the risk of complications in the healthy tissues.
Reduction in the dose uncertainties leads to more predictable and reproducible
results to the prescribed dose, given the individual variability of the patients. In
practice, the radiation oncologist validates the dose calculated by an algorithm, if
it is within a theoretical acceptable range. The dose calculation method should be
as accurate as possible in order to decrease its uncertainty in the dose prediction
associated to the treatment.
The dose calculation algorithms calculate the energy deposition and the absorbed
dose in the voxels that model the patient’s organs and tissues, by the treatment
radiation beams. These calculation models are models represent approximations
made for the energy deposition calculation and for the representation of the pa-
tient. Consequently, these provide an approximate representation of the dose
distribution in the patient.
Dose calculation algorithms play a central role for the clinical practice of radiation
therapy. They are the basis for any treatment plan optimization, requirement of
paramount importance with the development of complex techniques such as IMRT.
The increased accuracy of calculation tools such as superposition algorithms or
Monte Carlo (MC) simulations offer substantial advantages for clinical cases which
involve calculations within heterogeneous tissue, but are time-consuming making
them still unpractical for clinical routine.
The remarkable accuracy of MC dose calculation algorithms led to the widely
accepted view that these methods already play a central role in existing RT TPS
and their importance will be even higher in future TPS, heavily based in MC
simulations and modeling. The advantages of using MC clinically are particularly
evident for radiation fields passing through inhomogeneities, such as lung and air
cavities, and for small fields, including those used in IMRT. Many research groups
have however reported significant differences between MC and conventional TPS
algorithms in such complex situations.
Algorithms that use MC methods are known to more realistically model the en-
ergy transfer and deposition mechanisms in the medium. They are efficient tools
to model the patient and the radiation source, and to, calculate the dose distribu-
tion. However, MC methods need significant calculation times, making them still
incompatible for routine clinical practice.
Radiation delivery techniques continue to evolve, with arc therapy and other ad-
vanced delivery techniques which widespread utilization for clinical use in the com-
ing years is anticipated. Some researchers consider that the combination of a fast,
gold standard, MC dose calculation algorithm in the planning stages of advanced
radiotherapy delivery will represent a powerful tool for radiotherapy treatment.
On the other hand, since the 1990’s, existing general purpose MC computer codes
(such as MCNP(x), FLUKA, GEANT, PENELOPE, EGS) have been adapted
to feature to allow medical physics-related, and particularly radiotherapy calcula-
tions. At the end of the 1990’s, a special computational platform, PEREGRINE,
was develop aiming at the implementation, in clinical environment of Real Time
Treatment Planning systems in RT. Other computer programs and algorithms,
such as DPM, PENFAST, MCDOSE, VMC, XVMC, VMC++, MMC, etc, were
developed to perform fast, but accurate, MC simulations especially suited for treat-
ment planning calculations. By 2009, it was estimated that all equipment man-
ufacturers had developed and incorporated MC based algorithms in TPS. Other
computer programs such as EGSnrc and the associated BEAMnrc became powerful
and sophisticated Monte Carlo simulation tools widely used by the community of
experts to perform the modeling and simulation of linacs and to accurate compute
particle fluences and dose distributions in external radiotherapy treatments.
The dissemination of the use of MC techniques and simulations for Radiotherapy
Treatment Planning is also shown by the dramatic increase in recent years of the
number of peer reviewed scientific articles published yearly, as displayed in the
following figure extracted from Emiliano Spezi [1].
2. Breast cancer treatment and dose in the CLB
At present, it is possible to detect breast cancer in early stages due to improved
screening techniques and great awareness from the medical community and the
public in general. Breast cancer mortality has therefore decreased in the last years
due to its increasingly more accurate detection in precocious stages. Moreover, this
permits using techniques to preserve the breast and avoid radical solutions such
as mastectomy (complete breast removal surgically). The use of breast-conserving
treatment approaches for breast cancer has, for some time now, become a standard
option for early stage disease. More than ever, the general public is more aware and
thereby involved in the therapeutical decision, thus being important to identify
and quantify the risks of the conservative approaches.
Figure 1: Monte Carlo papers publication evolution until 2008 (when this investiga-
tion started).[1]
RT is the standard treatment technique after breast conservative surgery, reduc-
ing the chances of local relapse and mortality, mainly for young women. This
therapeutic strategy has proven to increase the probability of free-disease survival.
Several randomized studies have shown equivalent or better results of lumpectomy
followed by RT compared to mastectomy, in the management of breast cancer.
These improvements in overall survival are also achieved due to new and sophis-
ticated equipment and techniques dedicated to RT. More specifically: Cobalt-60
machines were replaced by linear accelerators and TPS has evolved from 2D to
3D using computed tomography (CT) based images with the complete anatomi-
cal information. With these improvements, the tumor volume is irradiated with
greater accuracy; on the contrary, for the healthy organs surrounding the tumor,
efforts are put forward so that these are irradiated with lower doses.
The breast is a particularly complex site to treat due to its concave shape, the
different media that surround it (bones, lung, soft tissue) and its proximity to the
external body contour. Furthermore, the breast moves with breathing, varying
its position during treatment. Breast treatment plans often present heterogeneous
dose distributions, with parts of the breast receiving higher doses than prescribed.
To achieve better irradiation and conformation to the tumor volume, special col-
limators, named multileaf collimators (MLC), were designed. These complex col-
limators allowed the rising of new techniques such as field-in-field, step-and-shoot
and dynamic (sliding-window) MLC conformation. The goal of these techniques
is ultimately to homogenize and improve the dose coverage in the tumor volume.
Despite the documented importance of RT, normal-tissue toxicities, including sec-
ondary radiogenic cancer, can disturb the quality of life and limit the survival
rate.
One concern that has arisen is related to contralateral breast (CLB) cancer after
breast radiotherapy. Although most studies do not show statistically significant
evidence that patients treated with breast RT have an increased risk of developing
CLB cancer when compared to control groups treated with mastectomy alone, the
available data clearly shows that the amount of scattered radiation absorbed by
the CLB during a routine course of breast radiotherapy is considerable (several Gy)
and is therefore within the range that one might be concerned about radiogenic
contralateral tumors.
3. Monte Carlo simulations in support of breast cancer RT (this work)
This work aims at estimating the doses in CLB when considering primary breast
irradiation. The following external beam techniques using a linear accelerator were
investigated: forward-intensity modulated RT (f-IMRT), IMRT using two and five
modulated fields using inverse planning - IMRT2 and IMRT5, respectively - and
dynamic conformal arc RT (DCART).
A 2300C/D Trilogy VARIAN (Medical Systems, Palo Alto, CA) linac used for RT
treatment equipped with a High Definition micro multileaf collimator (HDMLC)
was considered for the purpose of this work. The treatment planning system (TPS)
used for this work was iPlan (BrainLAB AG, Feldkirchen, Germany) TPS v. 4.1,
using two calculation algorithms, Pencil Beam Convolution (PBC) and commercial
Monte Carlo (iMC). A detailed comparison of the techniques was performed and
the main results were published in an article in Physica Medica journal in March
2014.
Regarding the MC independent model of the linac, the first task consisted in
applying an efficient method for the determination of the optimal intensity dis-
tribution of the pre-target electron beam able to accurately reproduce a set of
measured photon field profiles and incident electron beam energy, for the linac
structure used throughout this work. The independent MC model of the linac
was created using BEAMnrc/EGSnrc and DOSXYZnrc/EGSnrc and was later on
validated against measurements for a 6 MV photon beam, at first, for the beam
only with the jaws collimation and then including the modeled micro multileaf
collimator, HDMLC. The results of the first simulations of the HDMLC modeled
were published in Medical Physics journal, in January 2012.
The main goal of these independent MC calculations is to verify the TPS calcula-
tions using both algorithms, for the breast irradiation techniques. The simulation
results were validated against measurements performed in breast-shaped phan-
toms. The EGSnrc MC calculations were compared against the TPS calculations.
The ultimate goal was to assess the CLB doses and to estimate the risk of using the
different conformal techniques. The results are presented in this thesis and were
presented in September 2013 in the International Conference in Medical Physics,
in Brighton (UK).
This dissertation is organized in seven chapters. The first chapter is about breast
cancer and the actual therapeutic approaches. In the second chapter, the funda-
mentals regarding radiotherapy are provided. MC techniques and the first model-
ing, simulation and validation results, in equivalent water phantoms, are presented
in the third chapter. In the fourth chapter, the breast irradiation techniques in-
vestigated and the TPS algorithms are explored. In the following chapter, the
optimized treatment plans were simulated using the Monte Carlo validated model
both for phantoms and patient data and the results are presented. In the sixth
chapter, the contralateral breast doses were assessed and further investigated com-
paring both the irradiation techniques and algorithms. The main conclusions of
this work and what is left to do are put forward in this last chapter.
Introdução
1. Influência das novas tecnologias e simulações de Monte Carlo na
cĺınica prática em Radioterapia
Nas últimas décadas, as técnicas de radioterapia (RT) sofreram grandes desenvolvi-
mentos, com o aparecimento da RT convencional 3D e as técnicas de intensidade
modulada (IMRT). Estes avanços foram posśıveis com a construção de aceleradores
lineares e o desenvolvimento de sistemas de planeamento para cálculos de dose.
Os aceleradores lineares modernos usados em RT permitem a administração de
dose com elevada precisão, mesmo em grandes volumes que são pasśıveis de ser
observados em 3D, e até acompanhar o movimento dos volumes alvo e de outros
órgãos durante os tratamentos. Os sistemas de planeamento (TPS) e os algoritmos
neles implementados assumem atualmente uma importância primordial em RT
para a determinação das doses.
Os algoritmos de cálculo são cada vez mais precisos através de representações cada
vez mais realistas dos pacientes. Todas estas técnicas contribuem para a melhoria
da qualidade dos tratamentos, em localizações profundas e radiosenśıveis, como a
mama, pulmão ou cabeça e pescoço.
Para a realização de cálculos de dose em pacientes, há fundamentalmente duas
dificuldades: por um lado é necessário a modelação da complexa geometria do
paciente através de uma descrição detalhada da geometria e composição dos órgãos
e tecidos; por outro lado é essencial a modelação dos processos f́ısicos envolvidos
na deposição de energia e absorção de dose no paciente. No que diz respeita à
modelação dos pacientes, as tomografias computerizadas atuais permitem modelar
o paciente, discretizando o volume do paciente em pequenos elementos de volume,
chamados voxels. A cada voxel é associado um valor conhecido por unidades de
Hounsfield que é representativo da densidade eletrónica média do material que
compõe cada elemento espećıfico de volume. Este método permite a determinação
do poder de atenuação do meio para o feixe de radiação em questão. Para simular
os processos f́ısicos de transferência e deposição de energia foram desenvolvidos os
modelos de cálculos de dose, para determinar uma representação precisa do dose
administrada pelos feixes de tratamento.
O cálculo de dose compreende tipos diferentes de incertezas associadas ao TPS
e aos próprios algoritmos de cálculo. As imprecisões no cálculo podem reduzir a
eficácia do tratamento ou aumentar os riscos de complicação nos tecidos saudáveis.
Consequentemente, a redução das incertezas conduz a resultados previśıveis e re-
produt́ıveis à dose prescrita, apesar da variabilidade individual das reações dos
pacientes. Na prática, o radioterapeuta valida a dose calculada por um algoritmo
de cálculo de dose, considerando este cálculo aproximado, dentro de limites teori-
camente aceites. Assim, é importante que o método do cálculo de dose seja o
mais exato posśıvel para diminuir as incertezas no cálculo de dose associado ao
tratamento.
Os algoritmos de cálculo de dose determinam a dose depositada pelos feixes de
tratamento, nos voxels que modelam o paciente. Todos estes modelos de cálculo
são, apesar de tudo, modelos; o que quer dizer que representam aproximações feitas
para o cálculo da absorção de energia e para a representação do paciente. Con-
sequentemente, o resultado final, a distribuição de dose, será uma representação
aproximada do que acontece na absorção de dose no paciente. Este grau de aprox-
imação é variável dependendo do algoritmo de cálculo.
A precisão notável que é posśıvel obter através de algoritmos de MC é consensual
quanto ao papel fundamental que estes métodos desempenham em TPS atuais e na
sua importância quanto à continuidade da sua utilização em TPS. As vantagens de
usar MC clinicamente são evidentes em situações que o feixe de radiação atravessa
heterogeneidades, como cavidades de ar (pulmão) e para campos pequenos, como
os de IMRT. Vários grupos publicaram já diferenças significativas entre cálculos
MC e outros algoritmos convencionais usados em TPS, em situações complexas.
Algoritmos que usem métodos MC são conhecidos por serem modelos mais realistas
no que respeita à modelação da transferência e deposição de energia no meio. Estas
são ferramentas eficientes na modelação do paciente e da fonte de radiação para,
posteriormente, calcular a distribuição de dose. No entanto, os métodos de MC
precisam de muito tempo para a realização dos cálculos, não permitindo ainda
a sua utilização na rotina cĺınica, sendo necessário estabelecer um compromisso
entre a precisão e o tempo de cálculo.
As técnicas de irradiação têm evolúıdo, com técnicas como a RT em arco con-
formacional e outras técnicas avançadas e a sua utilização em prática cĺınica nos
próximos anos pode ser agora antecipada. Alguns investigadores defendem que a
combinação de um algoritmo MC com maior velocidade de cálculo seria a solução
ideal para melhorar a precisão no cálculo de dose a usar nos TPS.
Desde os anos 1990, os códigos gerais de MC (tais como MCNP(x), FLUKA,
GEANT, PENELOPE, EGSnrc, etc) têm sido desenvolvidos e adaptados para a
prática f́ısica-médica, nomeadamente nos cálculos de dose em RT. No final dos anos
90, uma plataforma computacional denominada PEREGRINE foi desenvolvida
visando a implementação de TPS em tempo real em RT. Outros programas de
computador e algoritmos, como o DPM, PENFAST, MCDOSE, VMC, XVMC,
VMC++, MMC, etc., foram desenvolvidos para realizar simulações rápidas e pre-
cisas, para cálculos de RT. Em 2009 estimava-se que todos os fabricantes de equipa-
mentos tivessem desenvolvido e incorporado algoritmos baseados em MC nos TPS.
Outros programas, tal como o EGSnrc e o BEAMnrc associado tornaram-se fer-
ramentas de simulação MC muito usadas por comunidades de investigadores para
modelar e simular aceleradores lineares e para determinar computacionalmente
com precisão as fluências das part́ıculas e as distribuições de dose, para tratamen-
tos de EBRT.
A disseminação do uso de técnicas de MC e simulações para planeamento dos
tratamentos de RT é também mostrado pelo aumento dramático de publicações
cient́ıficas publicadas anualmente, tal como apresentado na figure 1, extráıda no
trabalho de Emiliano Spezi [1].
2. Tratamento de cancro de mama e dose na mama contralateral
Atualmente, devido à implementação de programas de rastreio e ao desenvolvi-
mento das técnicas de diagnóstico, uma maior percentagem de casos são detetados
em estadios iniciais, com tamanho reduzido e ainda sem quaisquer gânglios pos-
itivos. A taxa de mortalidade por cancro de mama tem vindo a diminuir, nos
últimos anos. A deteção precoce permite, muitas vezes, a preservação da mama
e evitar o recuso a soluções radicais que podem envolver a remoção completa da
mama (técnica cirúrgica denominada por mastectomia).
O uso de técnicas de conservação da mama, em cancro de mama, tem vindo
a tornar-se a opção standard nos casos de doença detetado em estadios iniciais.
Mais do que nunca, o público está mais desperta e atenta a este problema, estando
inevitavelmente também mais envolvida na decisão cĺınica, sendo portanto impor-
tante identificar e quantificar os riscos destas abordagens conservadoras. Neste
tipo de abordagem, a RT é a técnica standard após a cirurgia de remoção do tu-
mor (tumorectomia), reduzindo a probabilidade de recidiva local e mortalidade,
especialmente em mulheres mais jovens. Esta estratégia terapêutica tem provas
dadas de aumentar a probabilidade de sobrevivência com remissão da doença.
Vários estudos provaram resultados equivalentes ou melhores com tumorectomia
seguida de RT comparativamente com mastectomia. Estes resultados positivos
têm sido observados devido aos novos equipamentos e às novas técnicas especial-
izadas e dedicadas à RT, sendo que: máquinas de cobalto-60 foram substitúıdas
por aceleradores lineares e os sistemas de planeamento evoluiram de 2D para 3D
usando imagens de tomografia computorizadas. Com tudo isto, os volumes tu-
morais são agora encontrados com maior precisão; por outro lado, empreendem-se
esforços para que os tecidos saudáveis recebam menos doses.
A mama é uma localização particularmente complexa de irradiar devido à sua
forma côncava, junto à grelha costal, e aos diferentes tipos de tecidos envolventes
(osso, pulmão e tecido mole) e à sua proximidade com o limite do contorno externo
do corpo. Esta localização tem ainda a dificuldade acrescida do movimento de toda
a caixa torácica devido à respiração, variando o posicionamento durante o trata-
mento. As planimetrias dos tratamentos de mama apresentam frequentemente
distribuições de dose heterogéneas, em que algumas partes da mama recebem dose
mais elevada que a dose prescrita. Para se conseguirem planos de irradiação mais
homogéneos e melhor conformados ao volume tumoral, foram desenvolvidos col-
imadores especiais, denominados colimadores multi-lâminas. Estes colimadores
complexos permitiram o aparecimento de técnicas novas conformacionais como
o field-in-field, step-and-shoot ou sliding-window, que visam homogeneizar a dis-
tribuição de dose no volume do tumor.
Apesar da importância justificada da RT, esta abordagem terapêutica pode ter
implicações na qualidade de vida e até limitar a taxa de sobrevivência das pacientes
devido a aumento da toxicidade, incluindo tumores secundários induzidos pela
radiação.
Uma das preocupações que tem surgido com o aparecimento das novas técnicas
está relacionada com o cancro na mama contralateral. Apesar da maioria dos es-
tudos não evidenciar diferenças significativas entre doentes tratados com terapias
conservadoras da mama que incluem RT de mama e doentes tratados por mas-
tectomia radical no que respeita ao risco acrescido de desenvolvimento de cancro
na mama contralateral, há dados que mostram claramente que a quantidade de
radiação dispersa absorvida pela mama contralateral no decurso de um tratamento
de radioterapia é considerável (podendo ser de vários Gy), estando portanto no
intervalo de doses que eleva os riscos associados a cancros na mama contralateral
induzidos por radiação. Com o aumento da sobrevivência que atualmente se veri-
fica em doentes de cancro de mama é urgente seguir o prinćıpio ’ALARA’ (as low
as reasonably achievable) numa tentativa de minimização da radiação dispersa na
mama contralateral para todos os doentes que realizem RT.
3. Simulações de Monte Carlo: suporte aos tratamentos de RT de can-
cro de mama
Este trabalho tem como principal objetivo a determinação de doses na mama con-
tralateral quando se considera a irradiação primária da mama. Foram estudadas
quatro técnicas de irradiação com feixes de fotões pasśıveis de serem tratados num
acelerador linear: forward-intensity modulated RT (f-IMRT), planeamento direto
para intensidade modulada; IMRT usando planeamento inverso para 2 e 5 campos
modulados - IMRT2 e IMRT5, respetivamente; e arco dinâmico conformacional
RT (DCART).
Todo o estudo foi realizado para o acelerador linear 2300 C/D Trilogy VARIAN
(Medical Systems, Palo Alto, CA) usando para tratamentos de radioterapia ex-
terna, equipado com o High Definition colimador micro multilâminas (HDMLC)
que foi explorado para o propósito deste trabalho. O sistema de planeamento
(TPS) utilizado foi o iPlan (BrainLAB AG, Feldkirchen Alemanha) v. 4.1, usando
dois algoritmos de cáluclo distintos, o Pencil Beam Convolution (PBC) e o Monte
Carlo comercial (iMC). As técnicas de irradiação de mama foram exploradas e
aplicadas neste TPS. Foi realizada uma comparação detalhada das técnicas de ir-
radiação e dos algoritmos de cálculo do TPS. Os resultados foram apresentados
num artigo publicado no journal Physica Medica, em Março de 2014.
Uma parte do trabalho subjacente a esta dissertação consistiu em aplicar um
método eficiente para determinação da distribuição de intensidade ótima do feixe
de eletrões antes do alvo, para, com mais precisão reproduzir perfis de vários cam-
pos de fotões com diferentes configurações para a energia usada neste estudo (6
MV) e a estrutura do acelerador linear utilizado ao longo deste trabalho. Um
modelo independente, usando técnicas de Monte Carlo através do sistema BEAM-
nrc/EGSnrc e DOSXYZnrc/EGSnrc do acelerador Trilogy foi criado e validado
com medidas experimentais para o feixe de 6 MV. Numa primeira fase, o modelo
foi validado até ao colimador primário (jaws); o colimador multi-lâminas, HDMLC
foi introduzido apenas numa fase posterior. A simulação deste colimador foi um
trabalho pioneiro, tendo estes resultados sido apresentados no journal Medical
Physics, num artigo publicado em Janeiro de 2012.
O principal objetivo destes cálculos independentes de MC consiste em verificar os
cálculos realizados no TPS, para os dois algoritmos que este utiliza, para as técnicas
de IMRT. Os resultados simulados foram validados com medições realizadas em
fantomas com forma semelhante à da mama, na mulher.
O objetivo final consiste em determinar as doses na mama contralateral, sendo
este dado essencial para estimar o risco de utilizar técnicas conformacionais mais
complexas. Os resultados são apresentados nesta dissertação e foram apresentados
em Setembro de 2013, na conferência International Conference on Medical Physics,
em Brighton, UK.
Esta dissertação está organizada em sete caṕıtulos. No primeiro caṕıtulo aborda-
se a problemático do cancro de mama e as posśıveis abordagens terapêuticas. No
segundo caṕıtulo são mencionados os fundamentos essenciais sobre radioterapia,
necessários à compreensão desta tese. As técnicas de Monte Carlo e os resultados
da modelação, simulação e validação do acelerador Trilogy e do colimador micro
multi-lâminas (HDMLC) em fantomas de água são apresentados, no caṕıtulo 3. No
quarto caṕıtulo, as técnicas de irradiação e os algoritmos do TPS são explorados
e os resultados são apresentados. No caṕıtulo seguinte simularam-se os planos de
tratamento otimizados usando o modelo de Monte Carlo validado, em fantoma
e em imagens de pacientes e apresentam-se os resultados. No sexto caṕıtulo,
calcularam-se as doses na mama contralateral para as várias técnicas de irradiação
e algoritmos. As conclusões deste trabalho e o trabalho futuro são discutidos no
sétimo e último caṕıtulo.
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Breast Cancer
1.1 Breast cancer epidemiology
Cancer is responsible for a large percentage of deaths worldwide, every year. Ac-
cording to GLOBOCAN most recent studies [2], about 14.1 million new cases and
8.2 million deaths occurred only in 2012.
The term ’cancer’ refers to various diseases characterized by two symptoms: the
unregulated proliferation of cells and the spread of these cells through the body
by the invasion and/or metastasis [3]. Cell proliferation typically results in the
development of neoplasms (more commonly known as tumors).
Cancer develops as a result of genetic abnormalities in proto-oncogenes and tumor
suppressor genes which translate genetic code into proteins that promote and
suppress cell growth, respectively. These abnormalities can be the result of a
mutagen altering genetic information or a spontaneous error in DNA replication.
Substances responsible for these mutations are known as carcinogens [4].
Breast cancer is by far the most frequent cancer among women with an estimated
1.68 million new cancer cases diagnosed in 2012 (25% of all cancers), and ranks
second overall (10.9% of all cancers). It is now the most common cancer both
in developed and developing countries. Cancer incidence profile, in general, has
changed from the 1990s in the USA and most western European countries mostly
due to the improved screening tools and to a greater awareness about the disease
leading to more frequent diagnosis of cancer at earlier stages (see figure 1.1).
The breast cancer risk is more common in the female gender and is associated
with different factors such as: aging (particularly for women with more than 55
1
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Figure 1.1: The first two graphs are related to screening rate per 100,000, in the
United States, 1975 to 2008, for men on the left and women on the right. The graphs
below represent the number of deaths, per 100,000, in the United States, from 1975
to 2008, for men on the left, and women, on the right. There is a notable increase
of screening since the 80s; and a decrease of deaths since the 90s, in general.Study
developed by the SEER program www.seer.cancer.org)[5].
years old), genetic factors (mutation in the suppressor genes of tumors BRCA1,
BRCA2 and p53), the user of replacement hormonal therapy, family history, etc
[6].
In the particular case of breast cancer, earlier diagnoses make it possible to apply
breast conserving therapies. Nowadays there are several techniques for screening
the breast [6]. Routine radiographic studies include bilateral mammograms. If
clinically indicated, these may be complemented with ultrasounds, computerized
tomography (CT) scans, magnetic resonance imaging (MRI), positron emission
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Figure 1.2: Breast constitution and location. On the left, 1 –skin of the peripheral
zone; 2 –skin of the aureole; 3 –skin of the nipple; 4 –Retro–mammary zone of cells and
fat; 5–Ligamentum suspensoria mammaria; 6 –Fascia superficialis; 7 –Pectoralis major
muscle; 8 –Pectoralis minor muscle; on the right: 1 –3rd rib; 2 –7th rib; 3 –9th dorsal
vertebrae.[8]
tomography (PET) or single photon emission tomography (SPECT) scans, bone
scans and chest radiography.
Due to the generalized spread of screening programs, it is estimated that about
two thirds of breast cancers are detected in early stages of the disease [7]. It
is therefore possible to apply breast conserving therapies, preserving the breast,
instead of adopting radical surgery, mastectomy. Despite the increasing breast
cancer diagnosis, recent studies [5] show that the majority of these patients have,
ever since, been treated successfully with long-term survival.
1.2 Breast anatomy
The breasts are organs that serve, in the women’s lifetime, the main purpose of
producing milk, to assure the baby-born feeding. A woman has two breasts, a
left and a right. The female breast lies on the anterior chest wall superficial to
the pectoralis major muscle. The breast can extend from the midline to near the
midaxillary line and cranial-caudally, generally, from the third anterior rib to the
seventh anterior rib. The upper-outer quadrant of the breast extends into the
region of the low axilla and is frequently referred to as the axillary tail of Spence.
This anatomical feature leads the upper–outer quadrant of the breast to contain
a greater percentage of total breast tissue compared to other quadrants.
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The breast is made of mammary gland, fat, blood vessels, nerves and lymphatics.
The surface of the breast has deep attachments of fibrous septa, called Cooper’s
ligament, which run between the superficial fascia (attached to the skin) and the
deep fascia (covering the pectoralis major and other muscles of the chest wall).
The chest wall includes the ribs, intercostal muscles, and serratus anterior muscle,
but not the pectoral muscles.
The breast parenchyma is composed of lobules and ducts. The function of the
lobules is to produce milk whereas the ducts are responsible to transport lactation
products to the nipple. The peripheral ducts converge into major lactiferous ducts,
which then communicate with the nipple-areola complex.
The breast parenchyma is intermixed with connective tissue, which has a rich
vascular and lymphatic network. Mammary gland lymphatics begin in the inter-
lobular or prelobular spaces, follow the ducts, and end in the subareolar network
of lymphatics of the skin. The predominant lymphatic drainage of the breast is
to axillary lymph nodes, which is commonly described in three levels, based on
the relationship of the lymph node regions to the pectoralis minor muscle. The
level I axilla is caudal and lateral to the muscle, level II is beneath the muscle,
and level III (also known as the infraclavicular region) is cranial and medial to the
muscle. A standard axillary lymph node dissection resects the tissue and lymph
nodes within levels I and II. It is very unusual to have involvement of level III
of the axilla without disease in level I or II. The axillary lymph nodes continue
underneath the clavicle to become the supraclavicular lymph nodes, which can be
involved in locally advanced breast cancers.
Lymphatics can also drain directly into the internal mammary lymph node chain
(IMC), which are intrathoracic structures located in the parasternal space. Al-
though these nodes are not usually visualized on computed tomography (CT), the
anatomical region of the IMC can be determined by the internal mammary artery
and vein, which are easily visualized by CT and usually lay 3 to 4 cm lateral to
midline. Regardless of the location within the breast, the axilla is the most com-
mon site of lymphatic involvement. However, breast cancers that develop in the
medial, central, or lower breast more commonly drain to the IMC (in addition to
the axilla) than those occurring in the lateral and upper quadrants.
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Figure 1.3: Pectoralis major muscle and major lymph nodes involved in the breast:
A –Pectoralis major muscle; B –Axillary lymph nodes level I; C –Axillary lymph nodes
level II; D –Axillary lymph nodes level III; E –Supraclavicular lymph nodes; F –Internal
Mammary lymph nodes
1.3 Breast cancer therapeutic approaches
The location and stage of a tumor determine which the available treatment options
can be adopted to treat the primary tumor. The therapeutic approach to be chosen
depends largely on the TNM (tumor, node, metastasis) classification of the tumor:
• T describes the size of the original (primary) tumor and whether it has
invaded nearby tissue,
• N describes nearby (regional) lymph nodes that are involved,
• M describes distant metastasis (spread of cancer from one part of the body
to another).
Among the clinical options available, the most applied are surgical removal, chemother-
apy, hormone therapy, immunotherapy and radiation therapy. These treatments
may also be delivered as part of palliative care, where the aim is to improve the
quality of life of the patient. In the following, these techniques are briefly summa-
rized.
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1.3.1 Surgery
Surgery was one of the first ways found to manage breast cancer. The most ancient
evidence was found in an Edwin Smith papyrus dating from 3000 BC [9].
Surgery is the definitive treatment for breast cancer comprising either a breast
(preferable) conserving operation, which removes the tumor with some surrounding
tissue or mastectomy which involves removal of the whole breast. Both procedures
are usually combined with sampling or removal of the axillary lymph nodes.
Historically, the treatment of breast cancer required mastectomy without excep-
tion. Mastectomy removes all tumor cells including microscopic residual disease
and provides staging information. Nowadays, following mastectomy an immediate
or delayed reconstruction may be performed.
In the 1980s, large randomized trials compared the efficacy of breast conserving
therapy (BCT), in the form of tumorectomy,sentinel node investigation, axillary
node dissection, in case of positive sentinel node, and radiation, with modified
radical mastectomy [10, 11]. In early stage breast cancer, BCT options have shown
to offer equivalent overall survival to mastectomy, improved cosmetic results and
reduced psychological trauma [12–14].
1.3.2 Chemotherapy
Preoperative chemotherapy can be offered to facilitate breast conservation in pa-
tients with tumors of a significant size or in a location that made breast-conserving
surgery unlikely to be done without a decrease in tumor size.
For patients with clinically uninvolved lymph nodes, sentinel lymph node biopsy
and/or axillary nodal dissection generally is performed before initiation of neoad-
juvant chemotherapy.
Patients at risk of distant metastasis are generally administered adjuvant chemother-
apy, in accordance to the actual guidelines. Results of the Early Breast Cancer
Trialists’ Collaborative Group meta-analysis have shown that adjuvant chemother-
apy improves breast cancer specific survival and overall survival [15].
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1.3.3 Hormone therapy
Hormonal therapy is one of the major modalities of medical treatment for cancer.
It involves the manipulation of the endocrine system through exogenous adminis-
tration of specific hormones, particularly steroid hormones, or drugs which inhibit
the production or activity of such hormones (hormone antagonists). Steroid hor-
mones are powerful drivers of gene expression in certain cancer cells, changing
the activity of certain hormones and therefore possibly causing certain cancers to
cease growing, or even undergo cell death. Surgical removal of endocrine organs,
such as oophorectomy can also be employed as a form of hormonal therapy.
Typically, the hormonal treatment is performed after surgery and it is not recom-
mended concomitantly with chemotherapy.
Hormonal therapy is used for several types of cancers derived from hormonally
responsive tissues, including the breast. One of the most frequent example of hor-
monal therapy in oncology is the use of the selective estrogen-response modulator
(SERM), tamoxifen, for the treatment of breast cancer, although another class
of hormonal agents, such as aromatase inhibitors, have an expanding role in this
disease.
1.3.4 Radiation therapy
Radiotherapy (RT) in the breast cancer is a loco-regional technique, generally
integrating the treatment after conserving surgery or after mastectomy when in
respecting specific criteria, in order to eliminate the microscopic residual disease
and to prevent local relapse. According to Holland et al [16], the surgical tumor
bed and the mammary gland risk that contain microscopic disease must be re-
moved with the breast conserving surgery and it is essential to irradiate locally
to eradicate the residual disease. This technique is usually applied 4 weeks after
surgery, after the healing. RT after surgery has proven efficacy with equivalent
or superior free disease survival, when compared to mastectomy [12, 13, 17–19].
Several studies confirmed that surgery followed by RT reduces mortality among
breast cancer women, 5 to 10 years after, being therefore essential to protect the
normal tissues, keeping the severity of the secondary effects as low as possible
[12, 13, 20].
The choice of the irradiation technique (external beam RT or brachytherapy),
the dose to administer to the tumor depend on its location, size, histology, grade
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Table 1.1: Breast cancer five-year survival by stage at diagnosis.
and extension of the disease, the breast size, cosmetic expected result or patient
preference. Adding an extra dose (frequently called a boost) either with photons
or electrons, to the tumor bed, as determined from mammographic and surgical
information, further reduces the risk of local relapse.
In the last years, with the growth and broader know-how of the biology and nature
of the breast tumors, combined with the technological improvements in immobi-
lization accessories (breast board, vacuum bed, etc), planning in 3-dimensional
computed tomography (CT) images, the positioning verification imaging, permit-
ted a great improvement in precision and reproducibility of the patient set up,
in the definition of the target volumes and homogeneity of the dose distributions.
The modern linacs are now equipped with complex collimator systems that permit
a better field size control as well as modeling the beam intensity, conforming the
dose distribution to the volumes to treat.
The goal of RT it is to adequately irradiate all the mammary gland, in initial stage
breast cancer patients while trying to minimize the dose to the adjacent organs at
risk (OAR).
1.4 Breast cancer classification
Breast cancer prognosis and treatment options are generally based on TNM,
tumor-node-metastasis staging. Lymphovascular spread, histologic grade, hor-
mone receptor status, ERBB2 over-expression, comorbidities and patient menopausal
status and age are important factors. The staging at diagnosis can be classified
according to the specification provided in table 1.1 [21, 22].
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1.4.1 Stage 0: in situ
Lobular carcinoma in situ (LCIS) is an incident microscopic finding of abnormal
tissue growth in the lobules of the breast, as represented in figure 1.4, on the left
side. Ductal carcinoma in situ (DCIS) is found in the ducts (see figure 1.4, on the
right side) and can progress to invasive breast cancer.
Figure 1.4: On the left, lobular carcinoma in situ (LCIS): abnormal cells are found
in the lobules of the breast. On the right: ductal carcinoma in situ (DCIS): ab-
normal cells are found in the lining of a breast duct. Figures by Terese Winslow,
http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page2.
1.4.2 Stages I and II: Early Stage Invasive
When classified as stage I or II, the abnormal cells have grown into bigger clusters
and are classified according to their dimensions, as shown in figure 1.5.
In stage IA, the tumor is 2 centimeters or smaller. Cancer has not spread outside
the breast. In stage IB, small clusters of breast cancer cells (larger than 0.2 cm
but not larger than 2 cm) are found in the lymph nodes and either: no tumor is
found in the breast; or the tumor is 2 centimeters or smaller.
Stage II is divided into stages IIA and IIB. In stage IIA, 1 to 3 positive lymph
nodes are found in the axilla or near the breastbone and there is no tumor or it is
smaller than 2 cm; or the tumor is 2 to 5 cm large without positive lymph nodes.
In stage IIB, a tumor larger than 2 cm but not larger than 5 cm is found in the
breast and there are 1 to 3 positive axillary lymph nodes or in the lymph nodes
near the breastbone; or the tumor is larger than 5 cm (with no positive lymph
nodes).
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Figure 1.5: Representation of breast cancer in stages I and II . Figures by Terese
Winslow, http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page2.
1.4.3 Stage III: Locally Advanced
Locally advanced breast cancer (LABC) includes tumors larger than 5 cm, ex-
tensive regional lymph node involvement, direct involvement of underlying chest
wall or skin, tumors considered inoperable but without distant metastases, and
inflammatory breast cancer.
Induction chemotherapy followed by local therapy (surgery, RT, or both) is be-
coming the standard of care. Five-year survival can be achieved in 55% of patients
presenting with non-inflammatory LABC. The most important prognostic factors
are response to induction chemotherapy and lymph node status.
The Stage III can be classified in 3 categories (A, B or C), as represented in figure
1.6.
In stage IIIA:
• no tumor is found in the breast or the tumor may be of any size. Cancer
is found in 4 to 9 axillary lymph nodes or in the lymph nodes near the
breastbone (found during imaging tests or a physical exam); or
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Figure 1.6: Stage III: A, on top; B, in the middle; and C, in the bottom. Figures by
Terese Winslow,
http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page2.
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• the tumor is larger than 5 centimeters. Small clusters of breast cancer cells
(larger than 0.2 centimeter but not larger than 2 centimeter) are found in
the lymph nodes; or
• the tumor is larger than 5 centimeters. Cancer has spread to 1 to 3 axillary
lymph nodes or to the lymph nodes near the breastbone (found during a
sentinel lymph node biopsy).
In stage IIIB, the tumor may be of any size and cancer has spread to the chest
wall and/or to the skin of the breast and caused swelling or an ulcer. Also, cancer
may have spread to:
• up to 9 axillary lymph nodes; or;
• the lymph nodes near the breastbone.
Cancer that has spread to the skin of the breast may also be inflammatory breast
cancer.
In stage IIIC, no tumor is found in the breast or the tumor may be any size.
Cancer may have spread to the skin of the breast and caused swelling or an ulcer
and / or has spread to the chest wall. Also, cancer has spread to:
• 10 or more axillary lymph nodes; or
• lymph nodes above or below the collarbone; or
• axillary lymph nodes and lymph nodes near the breastbone.
Cancer that has spread to the skin of the breast may also be inflammatory breast
cancer. For treatment, stage IIIC breast cancer is divided into operable and inop-
erable stage IIIC.
1.4.4 Stage IV: Metastatic
In stage IV, cancer has spread to other organs of the body, most often the bones,
lungs, liver, or brain, as represented in figure 1.7.
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Figure 1.7: Stage IV: cancer has spread to other organs of the body, most often the
bones, lungs, liver, or brain. Figures by Terese Winslow,
http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page2.
1.5 Management of breast cancer
According to Maughan et al [22], the treatment options to treat breast cancer are
given according to the cancer stage and type as presented in table 1.2. Different
and more detailed options according to several other indicators such as evaluation
of axillary and regional nodes, dimension and extension of the lesion(s), specific
hormone receptor status, can be found in other references such as NCCN (National
Comprehensive Cancer Network, http://www. nccn.org) guidelines, for instance.
1.5.1 Stage 0: in situ
It does not progress to, but increases the risk of, subsequent invasive breast cancer
in either breast by approximately 7% over 10 years. Local and systemic thera-
pies are not indicated, but affected women should undergo rigorous breast cancer
surveillance. The National Comprehensive Cancer Network recommends annual
mammography and clinical breast examination every six months. Patients should
be offered information about chemoprevention with SERM, such as tamoxifen.
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Table 1.2: Treatment options for breast cancer by stage. Information compiled by
Maughan et al [22].
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Conversely, for DCIS, breast-conserving surgery followed by radiation therapy is
standard treatment; however, mastectomy may be recommended for extensive
or multifocal disease. Pathologic lymph node evaluation is not usually performed
because nodal metastasis is rare. There is conflicting evidence regarding endocrine
therapy with tamoxifen in women with DCIS. Given the risks of tamoxifen and
the low risk of recurrence of DCIS, routine use of tamoxifen in women with DCIS
is not recommended.
1.5.2 Stages I and II: Early Stage Invasive
1.5.2.1 Surgery
Modified radical mastectomy has traditionally been the standard of care for early-
stage invasive breast cancers. However, breast-conserving surgery has been favored
more recently. This therapy involves removing the tumor without removing ex-
cess healthy breast tissue, with the outcome of a breast that is more aesthetically
acceptable to the patient than the outcome from radical mastectomy. Radiation
therapy following breast-conserving surgery decreases local recurrence and im-
proves cancer-specific survival rates to rates equivalent to those with mastectomy
[12, 13, 17–19]. Breast conserving surgery has the highest success rate in women
with early-stage breast cancer, but it is not recommended for women at high risk
of local recurrence.
1.5.2.2 Evaluation of regional lymph nodes
The status of axillary lymph nodes (ALN) determines the need for RT and adju-
vant systemic therapy. ALN dissection at the time of surgery was standard care
until the 1990s, but often resulted in pain, numbness, swelling, and decreased
mobility in the affected arm. In patients with clinically negative nodes, a nega-
tive intraoperative sentinel lymph node (SLN) biopsy precludes the need for ALN
dissection.
SLN biopsy reduces arm symptoms compared with ALN dissection. SLN biopsy
has a sensitivity of 95% to 100%, a false-negative rate of 5.5%, and a negative
predictive value of 98%. A prospective analysis provides evidence that patients
with early-stage breast cancer who have a negative SLN have improved disease-free
and overall survival compared with patients who have a negative ALN dissection.
This is most likely because of more accurate axillary staging in patients from the
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SLN group. ALN dissection is indicated for all women with palpable lymph nodes
or a positive SLN [23].
SLN biopsy reduces arm symptoms compared with ALN dissection. SLN biopsy
has a sensitivity of 95% to 100%, a false-negative rate of 5.5%, and a negative
predictive value of 98%. A prospective analysis provides evidence that patients
with early-stage breast cancer who have a negative SLN have improved disease-free
and overall survival compared with patients who have a negative ALN dissection.
This is most likely because of more accurate axillary staging in patients from the
SLN group. ALN dissection is indicated for all women with palpable lymph nodes
or a positive SLN [23].
The risk of microscopical invasion of the supraclavicular lymph nodes is highly
influenced by the number of involved axillary nodes. According to Strom et al
[24], with 4 or more nodes invaded or when level 3 of the axilla is invaded, the risk
exceeds 15 –20%. Invasion of the internal mammary chain varies between 3% and
65% depending on tumor stage and position of the primary tumor in the breast
[25].
There are several randomized trials going on to find out whether these lymph nodes
should be treated with radiation, such as the SUPREMO (Selective Use of Post-
operative Radiotherapy after Mastectomy) trial and the EORTC trial, AMAROS
(Adjuvant Management of the Axilla, Radiotherapy of Surgery) [26] and results
are expected from the EORTC trial 22922/10925, NCIC CTG (National Can-
cer Institute of Canada Clinical Trials Group) and SFRO (Société Française de
Radiothérapie Oncologique) CMI.
1.5.2.3 Radiation therapy
Typically, whole-breast irradiation is performed following breast-conserving surgery
to treat subclinical disease. A review of randomized controlled trials (RCT) com-
paring breast-conserving surgery with and without radiation showed that radiation
in addition to surgery significantly reduced the five-year local recurrence rate, re-
gardless of the use of adjuvant systemic therapy, and appeared to decrease the
15-year breast cancer mortality risk [27, 28]. According to a systematic review
of three RCT, the sequencing of chemotherapy and radiation therapy does not
appear to have a major effect on survival or recurrence as long as radiation is
initiated within seven months of surgery. Radiation therapy is expensive and
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time-consuming, and shorter therapies can be appealing. Five-year results ap-
pear favorable in studies evaluating brachytherapy and compressed schedules of
radiation; however, long-term data are lacking.
1.5.2.4 Adjuvant systemic therapies
Most women with early-stage breast cancer receive adjuvant systemic therapies.
Chemotherapy, endocrine therapy, and tissue targeted therapies enhance definitive
local therapy (surgery, radiation therapy, or both), substantially decreasing cancer
recurrence and disease-specific death. Node-positive disease benefits most from
systemic therapy.
Chemotherapy Chemotherapy is the standard of care for women with node-
positive cancer or with a tumor larger than 1 cm. Hormone receptor–negative
disease derives more benefit from chemotherapy than hormone receptor–positive
disease. Factors such as age and comorbidities also influence the decision to use
chemotherapy. Most studies suggest a small benefit for treatment with anthracy-
clines or taxanes over other chemotherapies, particularly in women with tumors
over expressing ERBB2. A systematic review of 12 studies demonstrated disease-
free and overall survival advantages when using a taxane-containing regimen for
premenopausal and postmenopausal women with early-stage breast cancer. A
meta-analysis of 13 RCT determined that adding a taxane to ananthracycline-
based regimen improved disease-free survival (5-year risk reduction of 5%) and
overall survival (5-year risk reduction of 3%) [29].
Endocrine Therapy Endocrine therapies, such as SERM, aromatase inhibitors,
and gonadotropin releasing hormone agonists, prevent estrogen production or
block estrogen, thereby preventing stimulation of an estrogen-sensitive tumor. In
premenopausal women, ovarian ablation or oophorectomy may be considered.
Endocrine therapy is not effective against cancers that are lacking hormone recep-
tors. 5 years of treatment with tamoxifen reduces the breast cancer death rate
(absolute risk reduction of 9.2% over 15 years) [29].
Aromatase inhibitors should be considered in all postmenopausal women with
hormone receptor–positive breast cancer. They block the conversion of androgens
to estrogen in postmenopausal women. Trials consistently show that aromatase
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inhibitors reduce the risk of relapse of early-stage breast cancer both in direct
comparison with and after completion of tamoxifen. Many women tolerate aro-
matase inhibitors better than tamoxifen. Aromatase inhibitors are not indicated
for premenopausal women.
Tissue-Targeted Therapy Approximately 20 to 30% of early-stage breast can-
cers overexpress ErbB2. These cancers generally have a worse prognosis. A human-
ized anti-ErbB2 monoclonal antibody, trastuzumab (Herceptin), improves disease-
specific and overall survival when added to anthracyclines and paclitaxel (Taxol)
chemotherapy in women with node-positive and high-risk, node-negative breast
cancers overexpressing ErbB2. The combination of trastuzumab and anthracy-
clines must be used with caution, however, because cardiac toxicity will develop
in 2 to 3% of patients over two years of treatment.
1.5.3 Stage III: Locally Advanced
1.5.3.1 Induction systemic therapies
Induction Chemotherapy Patients with LABC who achieve an excellent re-
sponse to induction chemotherapy have outcomes similar to those in patients with
early stage disease. Preoperative chemotherapy downsizes the local tumor, facil-
itating breast-conserving surgery. With induction chemotherapy, 75% of the pa-
tients have a reduction in tumor size greater than 50%. Preoperative chemotherapy
increases breast conservation rates, but also increases the rate of local recurrence.
However, local recurrence is not increased as long as surgery remains part of the
treatment, even after complete tumor regression. Mastectomy may be the best op-
tion in the case of poor response to induction chemotherapy, or based on patient
preference.
Induction Endocrine Therapy Induction endocrine therapy (tamoxifen with
or without aromatase inhibitors) is less effective than chemotherapy and may be
most appropriate for older patients not willing to accept chemotherapy-related
toxicity. Patients with hormone receptor–positive LABC are generally best served
by combined induction chemotherapy and endocrine therapy following surgery.
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Induction tissue-targeted therapy There are few solid data about the use
of tissue-targeted therapy (trastuzumab) as induction therapy. Because of the
benefit of adding trastuzumab to adjuvant chemotherapy in early stage breast
cancer, 12 months of postoperative trastuzumab is recommended for patients who
have LABC with ErbB2 overexpression.
1.5.3.2 Local therapy
Tumor response to induction chemotherapy determines local therapy, such as
surgery (mastectomy or breast conserving surgery), radiation therapy, or both.
Data from uncontrolled prospective studies indicate that 50 to 90% of women
with LABC can be successfully treated with breast-conserving surgery after in-
duction chemotherapy. In patients whose cancer does not respond to induction
chemotherapy, surgery is appropriate only if a complete resection can be attained.
Extensive lymph node involvement (i.e., more than three axillary, internal mam-
mary, or clavicular nodes), residual pathologic tumors larger than 2 cm, multifocal
residual disease, and lymphovascular invasion increase the rate of local recurrence
following breast-conserving surgery after induction chemotherapy and, therefore,
warrant mastectomy. Most patients presenting with LABC have clinically positive
lymph nodes and require ALN dissection. In patients with LABC and clinically
negative nodes, SLN biopsy following induction chemotherapy has been shown
to have a similar detection rate as in early-stage breast cancer without induc-
tion chemotherapy. Even in patients who have clinically complete remission with
induction chemotherapy, radiation therapy following surgery decreases the local
recurrence rate.
1.5.3.3 Inflammatory breast cancer
Inflammatory breast cancer is relatively rare and is characterized by diffuse ery-
thema and edema (peau d’orange), no palpable mass, early age at diagnosis,
poor nuclear grade, negative hormone–receptor status, and poor survival outcome.
Management is similar to that of non inflammatory LABC; however, because of the
aggressiveness of inflammatory breast cancer, SLN biopsy and breast-conserving
surgery are not recommended. After induction chemotherapy, patients are usually
treated with mastectomy followed by chest wall radiation.
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1.5.4 Stage IV: Metastatic
Some women, including those who relapse after treatment of early-stage breast
cancer or LABC, will present metastatic disease. Five-year survival is attained in
only 23.3% of these patients; therefore, it is important to understand the patient’s
treatment goals. Radiation therapy or bisphosphonates, along with endocrine
therapy or chemotherapy, can ease pain from bony complications. Systemic treat-
ment depends on hormone receptor status, rate of disease progression, and patient
willingness to tolerate adverse effects of treatment. Endocrine therapy is generally
better tolerated than chemotherapy. In women with rapidly progressive disease, it
may be better to treat with chemotherapy, which is more likely to induce a timely
response. Trastuzumab with or without chemotherapy is a reasonable choice for
the initial treatment of metastatic disease overexpressing ErbB2. Trastuzumab
can be used in combination with endocrine therapy for susceptible tumors.
1.5.5 Recurrent breast cancer
Following initial treatment, breast cancer can recur locally, regionally (nodes),
or at distant metastatic sites. Approximately up to 20% of patients treated with
adjuvant therapies develop locoregional recurrence within 5 - 10 years, respectively.
Locoregional recurrence is an indicator of an aggressive tumor, and early recurrence
carries a poor prognosis. Recurrence without clinical metastases has a five-year
survival of approximately 40%. Mastectomy is indicated for in-breast tumor re-
currence after breast-conserving surgery, followed by repeat axillary staging. SLN
biopsy is thought to be acceptable if lymph nodes were not removed initially and if
there is no clinical evidence of lymph node involvement, although RCT are lacking.
Wide local excision of the recurrent tumor is recommended for an isolated chest
wall recurrence. If unresectable, induction chemotherapy may facilitate successful
local treatment. If there is evidence of axillary involvement without distant metas-
tases, axillary evaluation is recommended. Radiation therapy is recommended only
in the setting of inoperable or incompletely resected recurrent disease. The ben-
efit of adjuvant systemic chemotherapy for patients with recurrence is uncertain,
and a large randomized trial is underway. Until results are available, chemother-
apy is recommended for recurrent cancer; endocrine therapy is recommend for
hormone receptor–positive cancer; and trastuzumab is recommended for tumors
overexpressing ErbB2.
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1.6 Conclusions
Breast cancer is the most frequent cancer among women. Its classification depends
on the type of tumor, location, extension to the lymph nodes, histology, etc. Based
on that, at present, there are several different therapeutic approaches, that were
reviewed in this chapter. The clinical decision depends on a multi disciplinary
discussion between oncologists, surgeons, radiation physicians, and eventually gy-
necologists and other imaging specialists that may need to be involved.
RT is of utmost importance in actual standards for breast cancer treatment and




2.1 Context and goals
In the first part of this chapter, the basics about a linear accelerator are put
forward. Then, the external beam RT techniques explored in this thesis as well
as the main concepts underlying the RT fundamentals are presented. The dose
calculation methods are also briefly introduced. Finally, some highlights on the
vast theme of dosimetry are presented.
2.2 The modern medical linear accelerator
The medical linacs are cyclic accelerators that accelerate electrons to kinetic ener-
gies from 4 up to 25 MeV using non–conservative microwave radiofrequency (RF)
fields.
The electrons are accelerated in structures called accelerating waveguides. The
high power RF fields used for electron acceleration in the accelerating waveguides
are produced through the process of decelerating electrons in retarding potentials
in special evacuated devices called magnetrons and klystrons.
A typical modern high energy linac has two photon energies (6 MV and 15–18
MV) and several electron energies (e.g. 6, 9, 12, 15, 20 MeV).
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2.2.1 General description of an electron linear accelerator
Linacs are machines as presented in figure 2.1. This linac is a Trilogy 2300 CD
Varian Medical Systems equipment.
Figure 2.1: Example of a linac used in radiotherapy departments for clinical use.
They are typically mounted isocentrically and are mainly constituted by five major
sections:
• computer control system;
• modulator cabinet;
• RF module and Stand drive;
• gantry;
• treatment couch.
In figure 2.2 a simplified scheme of the constitution of a linac is presented.
The main components for the beam production of a modern medical linac are:
• injection power;
• RF power generation system;
• accelerating waveguide;
• auxiliary system;
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Figure 2.2: Simplified scheme of a medical linac used in RT. Image from Varian
Medical Systems, Palo Alto, CA
• beam transport system; and
• beam collimation and beam monitoring system.
The injection system is the source of electrons and consists of a simple electrostatic
accelerator called electron gun. Electrons are thermoionically emitted from the
heated cathode towards the perforated anode through which they drift to enter
the accelerating waveguide.
The acceleration of electrons in the medical linac is achieved through the appli-
cation of microwaves (produced by the RF power generation system: RF power
source and pulse modulator) that are confined and structured by the use of a
waveguide. The input microwaves are generated through use of a klystron and are
typically in the 3000 MHz range. The auxiliary system comprises four independent
systems:
• vacuum pumping;
• water cooling for the accelerating guide, target, circulator and RF generator;
• optional air pressure systems; and
• shielding against leakage radiation.
Electrons originating in the electron gun are accelerated in the accelerating waveg-
uide to the desired kinetic energy and then brought, in the form of a pencil beam,
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through the beam transport system into the linac treatment head, where the clini-
cal photon and electron beams are produced. The beam transport system includes
bending and steering magnets, where to electrons emerging from the accelerating
waveguide are directed to. In the case of the Varian linac series used for this work,
the electrons are directed 270◦ toward the target (in case of photon production)
or to the electron collimation system (for clinical electron beam production). This
bending magnet system permits to filter out and prevent low energy contaminant
electrons from reaching the target and allows a more compact accelerator design.
2.2.2 Production of X-rays
The linac head contains several components that influence the production, shap-
ing, localizing and monitoring of the clinical photon or electron beams. Modern
linacs are typically equipped with: several retractable x–ray targets; flattening
filters and electron scattering foils; primary and adjustable secondary collimators;
dual transmission ionization chambers; a range finder and a light to observe the
field projection; retractable optional wedges and multileaf collimator (MLC). A
simplified scheme of the linac head is presented in figure 2.3.
Figure 2.3: Simplified scheme of a medical linac head. Image adapted from Varian
Medical Systems, Palo Alto, CA.
The primary electron beam enters the treatment head of the linac to be adapt into
a therapeutically useful beam.
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X-rays are produced from the accelerated electron beam predominantly through
the bremsstrahlung process within a target placed in the electron beam path. The
x–ray spectra generated depends strongly on the atomic number (Z) and thickness
of the target. Actually, it is frequent to use targets made of two layers, the first
with a high Z (tungsten, W or molybdenum, Mb) with an adequate thickness
not to attenuate the average energy of the photons, and a second with a low Z
(copper, Cu or aluminum, Al) to absorb the electrons produced and reduce their
contribution. Flattening filters have low Z irrespective of beam energy. Nowadays,
tungsten is commonly used in the first layer for both its high atomic number and
resistance to heat deformation. The ability to resist heat deformation is important
since in a typical tungsten target only about 1% of the incident electron energy
emerges as bremsstrahlung photons. The remaining energy is lost to heat in the
target. The heat is dissipated by the accelerator’s cooling system. Copper is fused
to the downstream face of the tungsten slab and placed in thermal contact with the
accelerator’s cooling system to aid in the heat dissipation and reduce secondary
electron production.
Primary collimation of the photons emerging from the bremsstrahlung target is
performed using a tungsten collimator. The conical beam exiting the primary
collimator is cylindrically symmetric about the beam’s central axis.
Bremsstrahlung photons emerging from the electron target and primary collima-
tor are highly forward peaked, that is, the beam contains a significantly higher
intensity of high energy photons directed along the beam’s central axis.These
forwardly-peaked photons will subsequently bombard a copper flattening filter.
The flattening filter flattens the dose profiles in a water phantom under specific
reference conditions [30]. The combination of target thickness/composition with
flattening filter shape/composition gives rise to the spectral and penetration prop-
erties of the beam. In fact, different (in dimension and material) targets and filters
are used for different energies.
2.2.3 Shaping, flattening and monitoring the beam
The photon beam collimation is achieved with the following collimation systems:
• primary collimator;
• secondary movable user-defined collimators; and
• MLC (optional)
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The beam shaping takes place within the treatment head using a series of colli-
mators. The primary collimator affects initial collimation of the bremsstrahlung
photon beam before the photons reach the flattening filter.
The beam’s symmetry, instantaneous dose rate and integral dose rate are all mon-
itored using a gas filled transmission style ionization chamber. The chamber is di-
vided into sectors to allow acquisition of beam balancing symmetry measurements.
These measurements allow the feedback of alignment corrections to electron beam
steering magnets located upstream within the bending magnet and accelerating
waveguide structures.
Secondary beam collimation occurs on the flattened beam (photon and electron)
using paired sets of tungsten blocks (jaws) and is intended to provide large area
collimation of the beam to approximate treatment field sizes. The Trilogy Varian
linac contains 2 sets of orthogonal adjustable opposed jaws, positioned after the
flattening filter, capable of collimating the field into rectangular fields over a range
from 3 cm up to 40 cm. Each jaw is limited to ± 20.0 cm of travel from the beam’s
central axis thereby allowing a maximum field size of 40.0 × 40.0 cm2 at a distance
of 100 cm from the target.
2.2.4 Multileaf collimators (MLC)
Irregular shaping of the beam is performed with a multileaf collimator (MLC).
These devices are made of several units, called leaves, organized side-by-side, in
two opposed banks. Each leaf is controlled independently and the control of each
leaf (driven independently by motors) allows complex outlines to be defined.
The tungsten leaves (located downstream of the secondary collimator) from the
Varian Millennium MLC are shown in figure 2.4.
For radiotherapy delivery of some brain cancers (astrocytomas, glioblastoma mul-
tiforme, gliomas, etc.) and small cell lung cancers, MLC can be used in a process
known as stereotactic radiosurgery. Such devices consist of narrow leaf banks (≤
2.5 mm width) driven by precision motors capable of highly precise delivery of
radiation.
In our Trilogy Varian linac, such a MLC is installed with inner leaves of 2.5 mm and
outer leaves of 5.0 mm projected at 100 cm. This MLC is the newest Varian MLC,
the High-Definition with 120 leaves. This MLC permits a maximum MLC-defined
field of 40 x 22 cm2 at a distance of 100 cm from the target.
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Figure 2.4: A Varian Millenium multileaf collimator with a leaf arrangement. Image
from Varian Medical Systems, Palo Alto, CA
2.3 External Beam Radiotherapy
The purpose of external beam RT (EBRT) is to treat cancer by delivering the
maximum dose of x-rays produced by linear accelerators (linac) to the tumor,
sparing as much as possible the healthy tissues in the vicinities. Radiotherapy
makes use of complex processes after the acquisition of the anatomic information
of the patients before their treatment in the linac. The planning is an essential
step in RT to define all the ballistic irradiation details such as the number of
monitor units (MU) or the treatment time, the type of particles (photons and/or
electrons) and the energy of the beams. The treatment plan is carried out using
a computerized system (treatment planning system, TPS) which contains at least
one algorithm1 for dose calculation. In theory, these algorithms should be able
to account for all the physical phenomena that are involved in the dose calcula-
tion in the patient. Nowadays, they are able to perform dose calculations in two
modes: in homogeneous mode without tissue density correction; and in heteroge-
neous mode taking into consideration the effect of the heterogeneous tissues. The
dosimetrist or radiophysicist uses the system for planning the treatments in an
interactive way to calculate the dose distributions, optimize the beams orienta-
tions and the shape of the irradiation fields. After the radiophysicians’ treatment
plan approval, the treatment time is calculated according to the validated dose
prescription. Then, the irradiation parameters and the reference images (Digitally
Reconstructed Radiographs, DRR) are sent from the TPS to the linear acceler-
ator through a management software able to track the parameters and all the
irradiation actions, the OIS (Oncology Information System).
1algorithm: step-by-step finite procedure developed to solve a mathematical problem that frequently
involves the repetition of an operation and may involve computer science to speed up the calculations
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2.3.1 3D Conformal RT
Using 3D Conformal RT (3D CRT), the planning is made using static beams, in
3D CT images. In this kind of treatment plan, there is conformation to the target
volumes and the beam incidences are chosen in order to guarantee an adequate
irradiation of the target volumes and to avoid the OAR. This conformation is
better achieved using the MLC. The MLC is fixed for each beam even though
external beam modifiers (such as wedges) may be used.
2.3.2 Conformal RT using Modulated Intensity IMRT
Conformal RT using Modulated Intensity, IMRT, is a RT technique that consists in
delivering the dose to the target volume by varying the intensity inside each beam
(figure 2.5). This technique envisages increasing the dose to the target volume,
to decrease the dose in the tissues in the vicinities of the irradiation target, to
obtain an improved conformation of the delivered dose and, eventually, to obtain a
more homogeneous dose distribution with the target volume. The most significant
examples are the prostate and head and neck tumors [31, 32].
Figure 2.5: Modulated movement of the leaves of the MLC to conform, for each beam
incidence, to the target volume, represented in red.
2.3.3 Arc Conformal RT
Dynamic conformal Arc RT (DCART) is an EBRT technique that uses the ca-
pability of MLC to conform to the target volume during beam on and includes
gantry rotation while irradiating. An example is presented in figure 2.6, for a
brain pathology. This technique is used in clinical routine for brain radiosurgery
and extracranial lesions using stereotaxic RT.
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Figure 2.6: Dynamic conformal arc RT, DCART. Image from BrainLAB AG, Feld-
kirchen, Germany.
2.3.4 Planning procedures for RT treatments
The steps and procedures for planning a treatment are, succinctly, the following
[33]:
• Choice of the immobilization system that will be adapted to the patient.
The patient’s position should be set so that it guarantees comfort to the
patient and therefore treatment reproducibility during the several sessions
and protection of the healthy tissues.
• Acquisition of the anatomic coordinates by a computerized tomography (CT)
scanner and transfer of the images to the treatment planning system (TPS).
The images are in DICOM (Digital Imaging and Communication in Medicine)
format.
• Definition and contouring of the tumor volume(s) and the healthy tissues as
organs at risk (OAR).
• Dosimetry encompasses the choice of the beams, energy, incidences, weight,
conformation of the beams to the target volumes with the multileaf collimator
and possible use of beam modifiers (wedges, bolus, etc).
• Dose calculation and dosimetric optimization which need the choice of the
dose calculation algorithm, determining the number of monitor units and
irradiation time for each beam.
Chapter 2. Fundamentals of Radiotherapy 32
• Evaluation of the treatment plan and dosimetric optimization. The treat-
ment plan validation is performed by visual analysis of the dose distribution
and evaluation of the dose-volume histogram (DVH), see subsection 2.3.6.
• Verification of the calculation of the monitor units for each field of the treat-
ment plan; transfer of the treatment plan to the treatment machine.
• Positioning the patient in the linac.
2.3.5 ICRU recommendations for EBRT
The radiation oncologist uses all the clinical data available of the patient’s tumor,
such as histopathology, surgery, fibroscopy and radiological information to define
the target volumes and the OAR. The target volume location can be determined in
the CT, magnetic resonance imaging (MRI), and/or positron emission tomography
(PET) images.
The definition of the target volumes and concepts of security margins were intro-
duced by the International Commission on Radiation Units and Measurements, in
the reports ICRU50 and ICRU62 [34, 35]. These reports are dedicated to the dose
prescription, administration and aspects related to EBRT with photon beams.
2.3.5.1 Definition of the target volumes and security margins
Figure 2.7 represents the tumor volumes, the volume to treat and the irradiated
volume. As target volumes, the recommendations indicate that the following target
volumes should be contoured:
• GTV (Gross Target Volume): represents the macroscopic volume of the pri-
mary tumor, visible in the diagnostic images.
• CTV (Clinical Target Volume): a margin is given to the GTV to take into
account the subclinical involvement of microscopic dimensions, considering
the biologic features of the tumor and the metastasis ways.
• PTV (Planning Target Volume): it is a geometrical concept that accounts for
all the geometric uncertainties and other uncertainties that may occur (due
to positioning or respiration, for instance), to guarantee the prescribed dose
is administered homogeneously to the CTV. Its shape depends not only on
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the CTV but also on the internal movements of the organs (such as, cardiac
movement, breathing, peristaltic movements, and so on) and the tumor, as
well as the treatment technique used, which will affect the beam orientations
and the patient immobilization.
Despite these volumes, ICRU also defined other non-anatomical volumes, based
on the dose distribution and used for evaluation and plan optimization:
• Treated volume (TV): volume that receives at least the reference dose planned.
It is usually delineated after the planning and verification of the irradiation
parameters. It should permit the evaluation of possible recurrence causes
(close or outside the target volume) and the complications in the normal
tissues, usually located outside the PTV but within the treated volume.
• Irradiated volume (IV): tissue that receives a significant dose taking into
consideration the tolerance dose of the OAR. This volume does substantially
depend on the treatment technique used and this volume is usually increased
with the number of fields. It is the radiation oncologist responsibility to
choose the most adequate irradiation plan.
Figure 2.7: Schematic representation of the target volumes designation, as defined in
ICRU Reports 50 and 62.
2.3.5.2 Organs at risk
The OAR or critical structures which are normal tissues with functional proper-
ties, adjacent to the target volume, can be included in the radiation fields. The
radiation can irreversibly affect the normal function of these organs. Taking this
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into consideration, it is important that these organs receive the lowest possible
dose.
The total dose an organ receives, as well as the exposed volume to a determined
dose are two important variables that can be used to predict the risk of late toxicity
[36]. The late effects depend on the tissues irradiated, which can be categorized
into:
• organs in series, whose complete functionality can be compromised even if a
small portion receives more than the dose limit (eg. medulla, optic chiasm,
optic nerve);
• organs in parallel, in which the damage in a part of an organ does not com-
promise its total function, unless a large volume of the organ is included
within all the radiation fields (eg. liver or lung);
• a combination of both models: being a series-parallel structures (eg. heart,
in which the coronary arteries are parallel and the myocardium is considered
to be series).
The radiotherapy treatment aims at controlling locally the tumor, minimizing the
acute and late effects due to radiation - therapeutic ratio concept. The goal of the
treatment is often reached at some cost, considering the damage inflicted to the
normal tissues, being essential to balance between guaranteeing that the tumor
cells receive a lethal radiation dose and the secondary effects are tolerable [37].
The tolerance of different tissues and organs may vary, being the incidence and
magnitude of the radiation induced complications dependent of some risk factors:[36–
39]
• treatment related: total dose, dose per fraction, dose-volume relation (per-
centage of organ that receives a determined dose), dose rate, beam energy,
treatment volume, technique used, radiation protector or other biologic mod-
ifiers, concomitant chemotherapy, time between fractions and treatment for
re-irradiation patients;
• patient related: existence of other diseases (diabetes, hypertension, pre-
existence of coronary or pulmonary disease, etc), radiation response and age;
• organ related: organs functionality, specific tissue radio-sensibility, organ
functionality or loss before irradiation, development of severe acute toxicity
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(leading to late effects), regional variation of radio-sensibility within an organ
and its hierarchy organization;
• tumor related: type of treated tumor, its extension and influence on adjacent
organs.
The OAR can be classified into three categories:
• Class 1. critical organs, susceptible to severe lesions that may cause death
or severe morbidity;
• Class 2. OAR whose lesion can cause low to moderate lesion; and
• Class 3. OAR whose lesion may cause no or transitory morbidity.
2.3.6 Dose volume histograms
The dose volume histograms (DVH) are quantitative evaluation tools relating the
dose and the contoured volumes. The x axis represents the dose received by a
structure, in absolute dose or in %. The y axis represents the proportion of the
total volume of the structures that receive a specific dose. The proportion of
the volume is expressed in % or cm3. They are used to estimate the dose each
organ/structure receives during the RT treatment.
The DVH represents the relative or absolute volume of a structure that receives a
dose equal or superior to a defined dose. Figure 2.8 presents a typical cumulative
DVH used in routine for the planning in RT. The analysis of the HDV permits to
compare: the average dose , the minimum dose, the maximum dose, the volumes
(expressed in % or cm3) that receive at least a determined dose (Vdose), and the
dose (expressed in % or Gray) received by a given volume, expressed in percentage
of target volume (Dvol).
2.3.6.1 Tumor volume analysis
The ideal treatment plan is characterized by 100% of the treatment volume receiv-
ing 100% of the prescribed dose. In fact, there is always a part of the volume that
receives less or more than 100% of the prescribed dose. According to the ICRU
there may be considered two volumes:
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Figure 2.8: Typical DVH aimed for adequate PTV coverage.
• under dose volume - tumor volume receiving less than 95% of the prescribed
dose;
• over dose volume - tumor volume that receives more than 107% of the pre-
scribed dose.
2.3.6.2 Organs at risk analysis
Against to what was the PTV goal, the OAR should receive the minimum possible
dose, as represented by the green curve in figure 2.8. The decision to choose a plan
versus another is very often made based on the OAR analysis and the lower dose
in the OAR may be preferred to a better PTV coverage. The decision depends on
the radiation oncologist criteria.
2.3.7 The importance of accuracy in radiation delivery
Research efforts over the past decade have focused on techniques to minimize the
normal tissue exposure during an EBRT treatment. The importance of accuracy
in radiation delivery is most apparent by observing the probability of local tumor
control and normal tissue complications as a function of the absorbed radiation
dose in tissue. Predictive models derived from average population radiation ther-
apy responses are shown in figure 2.9. From this figure, tumor control probability
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Figure 2.9: Qualitative plot depicting the predictive models of tumor control proba-
bility (TCP), normal tissue complication probability (NTCP) and uncomplicated tumor
control probability (UTCP) with absorbed dose to tissue.
(TCP) is shown to sharply rise (sigmoid shape) starting from a particular ab-
sorbed dose. The normal tissue complication probability (NTCP) rises sharply
at a slightly higher absorbed dose. A desirable radiotherapy plan is one that
maximizes TCP while minimizes NTCP.
The highly sensitive nature of the TCP and NTCP dose responses combined with
the potentially small differences in dose response curves demonstrate the need for
accuracy in radiation delivery. Small differences in absorbed dose can be seen
to have substantial effects on the treatment’s TCP and NTCP outcomes. The
uncomplicated tumor control probability (UTCP) is also plotted in figure 2.9.
UTCP represents the probability of achieving local tumor control while having no
complications and is simply calculated as TCP × (1-NTCP).
It should be noted that the standard deviations of TCP and NTCP predictive mod-
els have been estimated as high as 15-20%. In addition, the shapes and positions
of the curves may vary between patients and/or tissue type. Recent radiobio-
logical research is aimed at improving the understanding of factors affecting the
TCP and NTCP functions of various patient and tissue response classes. A better
understanding of patient dose response may allow adjustments of prescribed treat-
ment doses based on individual patient dose response evaluation. There is also
an individual variability in the dose response. With the development of molecular
biology, the aim is to perform tailored-to-patient RT.
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2.3.8 Errors in RT
The errors in RT can be of two types:
• systematic: occur when a patient is set up using an incorrect positioning
information. This could be because information has been entered incorrectly
into the record/verify system, or for instance, due to inaccurate determina-
tion of the isocenter in the bunker, or incorrect positioning of the lasers in
the bunker.
• random: occur when the patient’s position is incorrect due to daily fluctu-
ations - for instance, the bladder is a bit fuller than the day before, or the
temperature in the bunker is slightly different so the immobilization devices
have a minor change in their size. Random errors fluctuate around a certain
point.
2.3.9 Main dose uncertainties related to the TPS
The real dose delivered to the patient is not exactly the same as calculated by
the TPS. There are uncertainties in the dose calculation that can be associated
to the patient positioning and the organ’s mobility, the mechanical uncertainties
related to the linac (calibration of the different possible movements and distance
source to the patient skin, field size, dose calibration of the machine) and the dose
calculation mode in the TPS. These uncertainties are resumed in the IAEA 2004
Report, table 19 [40] and presented in table 2.1.
In 1999, Ahnesjö and Aspradakis evaluated the present and the envisaged uncer-
tainties, in the future, in percentage for the dose delivered to the patient during the
complete treatment course, using photon beams [41]. Their evaluation is presented
in table 2.2.
Considering the authors’ analysis, if the dose calculation is 1.0%, the overall uncer-
tainty increases 0.1-0.2%; however if it is about 4.0%, the overall uncertainty can
be 1.6% to 2.3% higher. The dose calculation uncertainty is, therefore important
to decrease the overall uncertainty associated to RT treatments.
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Table 2.1: Main uncertainties related to the TPS [40].
Table 2.2: Evaluation if the uncertainties of the dose delivered to the patient during
all the sessions of the radiotherapy treatment [41].
2.4 Dose calculation methods
2.4.1 Concepts and physical quantities in medical radiation physics
The photons from a linac yield a cascade of interactions, not only in the patient
but also in the treatment machine itself before the energy is absorbed as dose.
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The primary photons energy is absorbed without previous interactions; scattered
photons change their initial trajectory after one or several interactions. The most
preponderant interactions of the high energy photons within the tissues is through
the Compton effect. When treating with photons, the depth dose contributions
are due to:
• primary photons radiant from the target (in the linac head);
• scattered photons originated in the linac head;
• photons scattered in the patient; and
• contaminant electrons from the linac head.
These different components deposit their energy contributing to the dose delivered,
as represented in figure 2.10.
Figure 2.10: Interaction history of the four dose categories commonly referred to
in dose calculations for treatment planning — primary dose, phantom scatter dose,
contaminant charged particle dose and head scatter dose [41].
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Physical quantities in medical radiation physics





TERMA (Total energy released per unit mass): quantifies the total energy
released per mass unit, in J/kg or gray (Gy). It is characterized by the linear
attenuation coefficient2, measured in cm−1. It depends on the energy (E), the







where Ψ is the energetic fluence of the beam.
KERMA (Kinetic energy released per unit mass): is the kinetic energy
released and transferred from photons to the charged particles, in elemental mass
of the medium dm, measured in Gy. It is characterized by the linear transfer








Monitor Unit (MU): in EBRT, the linac delivers the dose to the patient in
this unit. The linear accelerator is calibrated to deliver a certain dose in reference
conditions, which may be, for instance: 1 UM = 1 cGy for a 10 × 10 cm2 field, at
a source detector distance of 100 cm, at the maximum dose depth.
Beam interaction properties in a homogeneous medium
For dosimetry purposes, a water phantom is the basic element to investigate the
beam properties for the treatment machine calibration and TPS configuration
according to these properties. Several regions can be defined, as presented in
figure 2.11.
Region:
2 linear attenuation coefficient: interaction probability of the particle by path unit
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Figure 2.11: Definition of the different regions of a beam, according to the dose
gradient in each region.
• δ1is for data points on the central beam axis beyond the depth of dmax, the
high dose and small dose gradient region;
• δ2 for data points in the build-up region, in the penumbra, and in regions
close to interfaces of inhomogeneities: the high dose and large dose gradient
region;
• δ3 for data points beyond dmax, within the beam but outside the central beam
axis: again this region is a high dose and small dose gradient region; and
• δ4 for data points off the geometrical beam edges and below shielding blocks,
generally beyond dmax: the region is a low dose and small dose gradient
region, for instance below 7% of the central ray normalization dose.
Profiles determined in these regions look like those presented in figure 2.12 [42].
The process of energy deposition in the tissues can be divided into two steps,
analyzing figure 2.12a:
1. build-up: represents the dose longitudinal electronic equilibrium achievement,
related to the secondary electrons’ displacement. The higher the energy
is, more energy is transferred to the electrons, the further away occurs the
maximum dose.
2. exponential decrease, according to the different attenuation coefficients of
the traversed media.
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Figure 2.12: Representation of the different regions for comparison of measured and
calculated dose: a. depth dose profile; b. dose profile [42]. δ50−90 is the distance
between the 50% and the 90% point (relative to the maximum of the profile) in the
penumbra, which is sometimes called ’beam fringe’; RW50 is the radiological width,
defined as the width of a profile measured at half its height compared to the value at
the beam axis.
When a photon beam interacts in a medium, the beam energy transfer to the
electrons does not occur at the level of the photon with matter. This is due to
the free mean path of the secondary electrons produced. In an ideal situation, in
a medium, the energy losses due to the electrons that leave the volume of interest
are compensated by the energy entering associated to the particles arriving from
other sites: this phenomena is the condition of electronic equilibrium. However,
the electronic equilibrium is not fulfilled at all points.
Beam interaction properties in a heterogeneous medium
At the surface or near the surface of a new medium, the energy absorbed is lower
than the transferred energy (collision kerma): there is lack in electron equilibrium
between the charged particles entering and exiting the region of interest. At a
characteristic depth of the beam energy, the two components compensate: the
collision kerma Kc is equal to the absorbed dose D. The equilibrium ratio or





About the yield in depth, the electronic disequilibrium arises at the region of for-
mal electronic equilibrium and the dose increases before the exponential decrease.
Typically for the depths between the surface and the depth of maximum dose,
there is β ≤ 1 or β ≥ 1. The degree of electronic equilibrium in the beam axis
decreases with the field size.
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This phenomena occurs at the air-skin interface and in the interfaces between
different media with different densities composing an heterogeneous anatomic vol-
ume. The low density causes an increased flux of scattered photons and secondary
electrons. This leads to a dose decrease in the nearby tissues, which depends on
the energy and on the geometry and size of the beams.
2.4.2 Precision and tolerance of the dose calculation by an algorithm
The accurate and fast calculation of a 3D dose distribution within the patient is
one of the most central procedures in modern radiation oncology. It creates the
only reliable and verifiable link between the chosen treatment parameters, and the
observed clinical outcome for a specific treatment technique, i.e., the prescribed
dose level to the tumor, the number of therapeutic beams, their angles of incidence
and a set of intensity amplitudes result in a distribution of absorbed dose which
is the primary physical quantity available for an analysis of the achieved clinical
effects of this specific treatment.
The dose calculation algorithms have twofold application:
• plan optimization in the treatment planning process; and
• establish the correlation between treatment parameters and clinical outcome.
They also have two conflicting goals in what the dose calculation is concerned:
• it has to be fast enough so that the treatment planning process can be ac-
complished in clinically acceptable time frames; and
• the result of the calculation has to be sufficiently accurate so that meaning-
ful and reliable correlations between delivered dose and clinical effects are
obtained.
The dose calculation algorithm should calculate the dose with good accuracy, as
well as take into count the physical processes and the primary and secondary par-
ticles transport, to consider the patient tissue heterogeneities and at the interface
tumor-tissue. The dose calculation accuracy depends directly on the accuracy of
the algorithms’ dose calculation which are implemented in the TPS. Their are
meant to calculate the spatial dose distribution in the patient according to the ra-
diation oncologists’ dose prescription and the dosimetrist choices for planning the
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treatment. The TPS contains the specific geometric and dosimetric characteristics
(PDD, profiles, outputs, etc) of each specific linac. For the different regions consid-
ered in figure 2.11, Venselaar et al [42] proposed the tolerances and acceptability
criteria presented in table 2.3.
Table 2.3: Proposed values of the tolerances for δ for application in different test
configurations [42].
It is inherently difficult to report the specific inner processes of commercial treat-
ment plan optimization algorithms as the material is, in general, proprietary.
2.4.3 Classification of the dose calculation methods
2.4.3.1 Correction based algorithms
In the past, dose calculations for RT used to be performed strictly based on directly
measured data such as lateral and percentage depth dose profiles for different field
sizes and configurations, measured in water phantoms. These algorithms are being
put aside and replaced by other methods.
2.4.3.2 Global methods based on the separation of primary and scattered
radiation
This method was, some time ago, used by the TPS. It was developed by Clarkson
(1941) [43] and later on by Cunningham (1972) [44, 45]. Cunningham introduced
the concept of scatter-air ratio, SAR, that describes the scattered dose in the
beam axis at a depth, z, of a square field, with s′ width. This method consists in
calculating separately the primary and scattered doses by decoupling the fields in
circular sectors. The total dose in a point is the primary dose (P) and the scatter
dose (S) contributions.
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Primary dose calculation
Results from the first interaction of the photons in the phantom, can be mathe-
matically translated by:
P = DA × TAR(z, 0)× F, (2.5)
, where DA is the dose in the air;
TAR(z, 0) is the tissue-air ration in the beam axis, at a z depth, extrapolated to
a field of null size (s′ = 0);
F represents the dose variation within the field, taking into account the penumbra.
Scatter dose calculation
Is the dose deposited by photons that interacted with the medium, at least, once.
The irradiation field is decomposed in circular sectors with a center defined with
an angle ∆θi and radius ri. The scattered contribution in a point is the sum of all







SAR(z, s′) - air-scatter ratio at the z depth for a s′ field size;
SAR(z, ri)- air-scatter ratio at the z depth for a circular field with radius ri;
n - the number of sectors.
The scattered dose is:
S = DA × SAR(z, s′) (2.7)
Total dose calculation
The total dose is the sum of the primary and scattered dose, given by:
D(x, y, z) = P (x, y, z) + S(x, y, z) = DA × [TAR(z, 0)× F + SAR(z, s′)] (2.8)
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2.4.3.3 Methods based in fundamental physics
These algorithms calculate the dose deposition from fundamental physical phe-
nomena related to the particles interactions. They take into consideration the
anatomic information of the patients such as the geometry ant electronic density.
Then can be divided into two categories:
• A. kernel3 - superposition based models
• B. Monte Carlo methods
A. Superposition-convolution kernel based methods
Definition The convolution methods based in Pencil Beam were proposed in the
beginning of the 1980’s. These can be Monte Carlo based algorithms [46–50] and
the dose is obtained in two steps that involve the calculation of the TERMA and
the kernels:
• TERMA: transferred energy by all the primary photons in a unit of mass;
and
• kernels: point spread functions, are the energy fraction by volume unit de-
posited by the secondary particles, photons and electrons.
This method takes into account the dose deposited by all the photon interactions.
There are two types of kernels:
• Point Spread Kernel; and
• Pencil Beam Kernel.
1. Point Spread Kernel With this model, TERMA is determined by tracing
the radiologic path of the particles along a line through a series of voxels, and




×Ψ(x′, y′, z′), (2.9)
3Kernel or core of energy deposition: describes the distribution of energy deposited in an infinite
medium around a primary interaction site, known as kernel-point.
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, where µ
ρ(x′,y′,z′)
× is the mass attenuation coefficient of the medium (in m2.kg−1);
and
Ψ(x′, y′, z′) is the energetic fluence in the point (in J.m−2).
The dose D(p) in a P point with coordinates (x, y, z), is obtained by the su-
perposition of all the kernels at the points q(x′, y′, z′) with dV volume and the
corresponding TERMA at point q by equation 2.10.
D(p) =
∫ ∫ ∫
T (q)×K(x− x′, y − y′, z − z′)dV q, (2.10)
, where
- T= TERMA;
- K is the kernel; and
- dV q = dx× dy × dz is the voxel of elementary volume.
The dose model can be calculated using the Monte Carlo method and generalized
considering the spectral variations of the photon beams. Several methods were
investigated to speed up the dose calculation, such as the Fast Fourier Technique,
FFT [46], and a specific technique called Collapsed Cone Convolution [48].
Dose calculation in heterogeneous media
The application of this model in heterogeneous media is based on the TERMA
calculation and scaled in all the poli-energetic point kernels by the average elec-








c2(~r, ~s).hρwater (c(~r, ~s)(~r − ~s)) .V~s (2.11)
, where
- T (s) is the TERMA contribution;
- hρwater (c(~r, ~s)(~r − ~s)) is the (monoenergetic) energy deposition kernel generated
in water;
- c2(~r, ~s) is the factor to calculate the mean density along the line between the
interaction point and where the dose is deposited.
An assumption made is that the energy transport through the kernel between
the interaction point to the dose point occurs through a straight line, i.e., within
the kernel, an interval ray tracing is introduced. Along each internal ray, the
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contribution of the kernel is scaled with the average electron density encountered
along the line connecting the two points - density-scaled dose deposition kernels.
The direct application of this is hypothetically represented in figure 2.13. It can
be clearly seen that the kernel extends further from the interaction point if the
internal energy transport encounters a medium with an electron density smaller
than water on its way to the dose deposition point. The dimensions of the scaled
dose kernel are shrinking in comparison with the original dose kernel in water if
higher electron densities represent an additional obstacle for the energy transport
within the dose kernel.
Figure 2.13: Isodose curves of density-scaled kernels of the superposition kernel. The
tissue inhomogeneities are corrected in the dose kernels leading to a deformation of the
isodose lines behind the inhomogeneities. Image adapted from Oelfke et al [52].
2. Pencil Beam Kernel Pencil Beam was introduced by Ahnesjö et al, in 1992
and the basic idea is to decompose the initial beam into elementary beams of
semi-infinite section to reduce the calculation time. It relies on the pre-calculated
kernel point along the path of the primary particles. The dose is given by:
D(p) =
∫ ∫ ∫
Ψ(E)(x′, y′)KPK(E, x− x′, y − y′, z)dx′dy′dE, (2.12)
with - ΨE(x
′, y′) being the energetic fluence of the primary photons at the point
of coordinates (x′, y′) at the entrance of the phantom;
-KPK , the pre-calculated mono-energetic Pencil Beam Kernel at the given medium.
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Dose calculation in heterogeneous media
The idea is to calculate the 3D dose and apply a correction factor. Pencil Beam
method is frequently used for the three-dimensional dose calculation. However,
this algorithm is limited and is not accurate in non-homogeneous conditions: it
does not consider the density variations along the beam axis, does not account
for photons’ lateral scattering; neglects the penumbra effect and does not consider
scatter radiation.
In figure 2.14 [53], the depth dose curves obtained by the PBC algorithm without
corrections (water phantom) and two correction based methods (ETAR and MB
- Modified Batho) are presented in A and C, for a 4 × 4 cm2 field and in B and
D, for a 10 × 10 cm2 posterior field for 8 MV (in A and B) and 15 MV (in C and
D) energy beams, traversing a media composed of chest wall from the skin up to
3.5 cm in depth; lung, from 3.5 cm to 18.5 cm; and chest wall.
Figure 2.14: Comparison of percentage depth doses calculated by MB, ETAR and
Monte Carlo methods and measurements for posterior lung irradiations by 8 ((A) and
(B)) and 15 MV ((C) and (D)) photon beams. (A) and (C) Field size = 4× 4cm2, (B)
and (D) Field size = 10× 10cm2 [53].
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Mesbahi et al [53] showed that the first ”build-up” is followed by a ’build-down”,
when the beam traverses the lung and enters the chest wall, for small field sizes. It
is here proved that the Pencil Beam correction based methods are not capable of
accurately predicting in the ”build-down” region in the lungs. Concerning larger
fields, the correction based methods present comparable curves to those obtained
by Monte Carlo.
The conclusion from this study is that the PBC and the correction methods do
not accurately model the dose for the tumors localized in heterogeneous regions
or in the lung interface.
B. Monte Carlo methods The Monte Carlo method is the most accurate
method for dose calculation. With this method histories of millions of photons
and secondary electrons are simulated to calculate dose deposition based on the
physics of interactions in matter.
The main photon interactions simulated are the photoelectric effect, Compton
effect and pair production which lead to electron interactions (ionization, excita-
tion, bremsstrahlung and ultimately dose deposition). There are other effects that
contribute to dose such as neutron production which may or may not be modeled.
The MC method uses known probabilities and probability distributions in sam-
pling to predict the interactions results. The MC obeys to the law of large numbers:
the average of the results obtained from a large number of histories should be close
to the expected value and will tend to become closer as more trials are performed.
Programming subroutines and interaction probabilities are used to calculate dose.
The question that arises is ’if MC is the most accurate method for dose calculation,
why to develop other algorithms?’ The answer is time. Processing time makes MC
calculations impractical for clinic within the TPS engine and for plan optimization.
However, MC may be used for treatment plan verification. Moreover, with the
reduction of the cost of higher performance computing over the last years, it is
now possible to use more sophisticated algorithms employing MC calculations,
with pre-calculated phase space files.
MC accuracy is highly dependent on the modeling of the components of the linac
head. As input, the programmer needs to introduce the following information:
finite photon source size characteristics; open fluence distribution; head scatter
sources, flattening filter, collimators, wedges and monitor backscatter, when ap-
plicable; fluence modulation; and other specific details.
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Patient dose calculation using MC can be done with the electrons exiting from
the accelerator vacuum window and tracking them and their descendants through
the linac head including the patient dependent beam configurations (collimation
system) and then the patient geometry. This is, however, inefficient, since the first
part of the linac is fixed for each beam energy and is not patient dependent. The
radiation beam information can be stored in a phase space file [54], which contain
a complete characterization of the particles, or a source model [55], at the plane
below the fixed components of the linac head. The phase space data is generated
by MC simulation; the source model is derived from the phase space data [55–59]
or measured beam data[60].
MC-based algorithm calculations simulate the particle transport and interaction in
the patient-dependent field-defining components in the treatment delivery system
together with patient dose calculation. The particles (primary and descendants)
are transported in the beam collimation system and through the patient geometry
until they exhaust their energy or escape to the free space. Direct MC simulation
of the particle transport through the collimation system is time consuming be-
cause most particles are absorbed before they can reach the patient geometry. To
improve the simulation efficiency, a variety of strategies have been applied, such
as using high-energy cutoffs for photon and electron particles or to disregard the
secondary Compton scattering photons [61] or the secondary electrons because
they deposit most of their energy locally.
Since the MC method is based on random sampling, the calculated doses always
contain statistical uncertainties. The doses calculated using analytical methods do
not have statistical uncertainties; however, they usually contain larger systematic
errors in heterogeneous media compared to the MC method. Simulating a pre-
determined number of particles, the statistical uncertainty of a MC result can be
reduced to values that are considered clinically insignificant (e.g.: inferior to 2%)
but these results are clinically useful and meaningful.
The patient dose calculation can be reported whether as dose-to-water or dose to
the local medium. By default, when considering MC, dose-to-medium is reported;
in the conventional methods, it was excepted that these would report the results in
dose-to-water, however, large discrepancies are usually observed, when MC dose-
to-medium is converted to dose-to-water and compared to the dose determined by
conventional algorithms.
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2.4.4 Dose correction methods for photon beams
The density correction issue is well-known and several correction algorithms were
developed. These algorithms can be grouped in different ways, considering how
they take into account the density variations (heterogeneities): the correction
dimension of the heterogeneities considered (1D or 3D) and how they handle the
electron transport, as presented in table 2.15 [62].
Figure 2.15: Categorization of different inhomogeneity correction algorithms accord-
ing to the level of anatomy sampled (1D or 3D) and the inclusion or exclusion of electron
transport [62].
The correction methods use a factor to correct the dose in an heterogeneous
medium. The dose calculation is performed in two steps:
• dose calculation supposing the patient is homogeneous with a density equiv-
alent to the water density ρ = 1g/cm3;
• correct the dose with a correction factor, Fc that depends on the correction
method.





There are several correction methods, such as Batho Power Law [62, 63], modified
Batho Power Law [64, 65], ETAR (Equivalent Tissue Air Ratio) [66], and others.
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Nonetheless, these correction methods do not take into account the secondary
electrons transport. These electrons are most relevant for high-energy photon
beams and within the low density tissues, such as in air cavities. Moreover, the
dose calculation is not accurate in the build-up regions and in the interface tissue /
tumor, which becomes more relevant for high energy beams and in case the tumor
is located in the vicinities of air cavities and there can be loss of lateral and/or
logitudinal electronic equilibrium [63].
The majority of treatment planning optimization algorithms have performed cal-
culations of the dose delivered from each beam or fluence element using a pencil
beam convolution/ superposition type algorithm [46, 47]. In this approach, the
dose delivered is calculated at each calculation point within the patient using a
convolution of the TERMA [30].
The accuracy of convolution/superposition pencil beam algorithms has been thor-
oughly investigated. In particular, their ability to correctly determine the dose in
the presence of tissue inhomogeneities was examined. Ma et al [67] have shown
a commercial implementation to miscalculate dose by up to 20% within the OAR
where inhomogeneities exist. Significant differences with MC dose calculation have
also been reported by Wang et al [68]. Cranmer-Sargison et al [69] have shown
inaccuracies (overestimation of the dose to lung) in lateral profiles across a sharp
lung-water interface by as much as 16%. Knoos and Wieslander [70, 71] have also
observed differences in a mediastinum water-cork geometry by as much as 14%.
The above findings have recently prompted several improvements to commercial
convolution pencil beam algorithm. For example, Varian’s new anisotropic ana-
lytical algorithm (AAA) accounts for tissue heterogeneity anisotropically in the
three dimensional neighborhood of an interaction site by using photon scatter
kernels along multiple lateral directions [50]. Studies on the accuracy of the algo-
rithm have found significant improvements. Confidence limits on the lung-water
interface test was found to be within 4% [72]. Sterpin et al [73] has found the
algorithm accurate to within 5% at interfaces and 1.7% differences in the mean
planning target volume dose for a clinical case.
The improvements to the algorithm come at a computational cost. The algorithm
cannot be implemented in the iterative stages of the optimization at present due to
the required computational time. The algorithm is used only after the optimization
completes as a final dose calculation.
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2.5 Radiation detectors
There are many types of dosimeters such as ion chambers, solid state detectors,
thermoluminescent detectors (TLD), radiographic or radiochromic films, among
others. Each of these detectors features different suitability in radiotherapy ap-
plications. Depending on the situation, different requirements may be necessary
such as high spatial and time resolution, very small dependence of response on
photon or electron energy or good temperature and radiation type stability. In
these devices, the absorbed energy has the capability of producing a measurable
change in their properties, as for instance a change in the measured charge, in the
ionization chambers; a visible chemical reaction, in photographic films; any light
output, in TLD, and so on.
The exploited dosimeters in this work were mainly, ionization chambers and pho-
tographic films, which are briefly described next.
2.5.1 Ionization chamber dosimetry
In this work, the ionization chambers (IC) were responsible for absolute calibra-
tion and also for checking beam flatness and symmetry. These dosimeters have
long-term stability, high accuracy, direct readout and are easy to use. The IC
is a dosimeter which is available in a variety of designs such as free-air standard
chamber for measuring of the exposure for primary calibrations, thimble air cavity
chamber for measuring the absorbed dose and high-pressure IC for measuring the
low intensity γ radiation or cosmic radiation, etc.
A typical ionization chamber used in RT is made of a thin wall of a specific ma-
terial, generally graphite filled with a defined volume of gas, as depicted in figure
2.16. This specific chamber represents cylindrically shaped IC (also known as
thimble or compact chambers) which are most commonly used in photon dosime-
try. However, there are chambers in a variety of designs and sizes, related to the
required sensitivity.
The following cylindrical IC, presented in figure 2.17 were used for the dosimetric
measurements:
• Semiflex IC (model PTW 31010), with a sensitive volume of 0.125 cm3 appro-
priate for measuring high-energy photon (nominal useful energy range from
30 kV to 50 MV) and electron (nominal useful energy range from 6 MeV
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Figure 2.16: Scheme of an ionization chamber commonly used for radiation therapy
purposes.
and 50 MeV) radiation in air, water and phantom material. Graphite is the
wall material and it possesses a protective acrylic cover. This chamber is a
good option for small size fields with reasonable spatial resolution and large
sensitive volume for precise dose measurements. Furthermore it can be used
for high precision absolute dose measurements and has no significant dose
rate or energy dependence. Its usability is limited to fields larger than 3 x 3
cm2, due to its dimensions.
• PinPoint IC (model PTW 31016), with a sensitive volume of 0.015 cm3 this
chamber was designed for application where superior spatial resolution is
required. It consists of a 2 mm diameter and 5 mm long cylindrical air
chamber with a central steel electrode with a PMMA (covered with graphite)
wall. It is an adequate chamber for field measurement between 2 x 2 cm2
and 10 x 10 cm2.
Figure 2.17: PTW Semiflex ionization chamber of 0.125 cm3, on the left; and PTW
PinPont chamber of 0.015 cm3 on the right side. Images from www.ptw.de
Dosimetry protocols with ionization chambers
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When measuring absorbed dose with an IC several corrections need to be made to
ensure that the measurement of absorbed dose gives the same result regardless the
operational conditions such as radiation quality, dose rate and ambient conditions
(temperature, pressure, humidity, etc). The International Atomic Energy Agency
(IAEA) and other institutions such as the American Association of Physicist in
Medicine (AAPM) published dosimetry protocols for the dose determination in
EBRT. These protocols define all the different correction factors needed to achieve
a clinically relevant accuracy of the measurements of absorbed dose.
The IAEA TRS-398 code of practice [74] has been taken as a reference for the
dosimetric measurements performed in the present work. A brief description of
the methodology and recommendations given by this protocol are given next.
IC for absolute dosimetry are usually calibrated in secondary standard laboratories
using reference conditions under a known field of radiation, usually a 60Co beam.
The calibration is based on determined absorbed dose in water by international
primary standard laboratories in so-called standard conditions of pressure 1013.0
kPa and temperature 20◦C. In order to use the IC in other conditions different from
those of the chamber calibrations, it is essential to consider many issues concerning
either the IC or the measurement circumstances and correct the measured signal
for the specific conditions. The IAEA TRS-398 code of practice is based on a
calibration factor ND,w,Q0 in terms of absorbed dose to water for a reference beam
of quality Q0 (usually a
60Co beam) and is applied to photon beams generated by
electrons with energies in the range of 1 MeV to 50 MeV. According to this code,
the absorbed dose in water for a megavoltage beam is given by:
Dw,Q0 = MQ0 ×ND,w,Q0 (2.14)
where theND,w,Q0 calibration coefficient has been traceable from the standards lab-
oratory and relates the reading of the dosimeter MQ0 , formed by the IC and the
electrometer, to dose to water Dw,Q0 in a reference field under reference conditions.
These reference conditions are air pressure, temperature, field sizes, measurement
depth, phantom size and quality index Q directly linked to the energy of the ir-
radiation beam. In general, when a IC is used for clinical dosimetry, only a few
of the defined reference conditions can be usually reproduced. Thus, deviations
due to several influence quantities need to be accounted for by the application of
a product of multiplicative factors of two classes. The first class of corrections ac-
counts for changes in the beam quality, Q, compared to the reference beam quality
Q0. These corrections are represented by the beam quality correction factor which
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is denoted as kQ,Q0 . This factor corrects all differences from the ideal conditions
of the Bragg-Gray cavity theory and includes the following parameters:
- pwall: Correction for the non-medium equivalence of the chamber wall and the
surrounding water where the chamber is placed.
- pcav: Correction for scattering differences between the air cavity and the sur-
rounding material, usually water.
- pcel: Central electrode perturbation correction accounting for the central elec-
trode in a thimble ionization chamber.
- pdis: Factor accounting for the fact that the air cavity of a cylindrical chamber
causes less attenuation or build-up than the water displaced by it and causes the
upstream shift of the effective point of measurement. The effective point of a
chamber is usually shifted from the position of the center towards the source by a
distance which depends on the type of beam and chamber.
- s∆w,a: Restricted stopping power ratio of water to air considering the fraction of
the total collision stopping power that includes all the soft collisions and those
hard collisions resulting in δ-rays with energies less than a cutoff value ∆.













The second type of corrections relates to the reading of the electrometer and in-
clude:
- kelec: Calibration factor of the electrometer.
- kP,T : Temperature and pressure correction for the varying density and humidity
of the air in the user facility with respect to the conditions specified by the stan-
dards laboratory.
- kpol: Polarity correction for the effect of altering the measured charge.
- ks: Recombination correction for ions that recombine before they reach the elec-
trodes, leading to the incomplete collection of charge in the chamber.
In summary, the absorbed dose to water Dw,Q in a user’s beam, measured with an
IC dosimeter, is determined by:
Dw,Q = MC ×ND,w,Q0 × kQ,Q0 (2.16)
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ki = M × kelec × kP,T × kpol × ks (2.17)
The factor ND,w,Q0 is a calibration factor valid under reference conditions for the
quality Q0 and it is obtained at a standards dosimetry laboratory under a set of
well-established reference conditions. All these factors are generally provided by
the protocol or the chamber manufacturer for the various IC and beam qualities,
requiring to maintain the geometrical reference conditions.
2.5.2 Film dosimetry
Film dosimetry has been used extensively as a convenient and rapid mean of mea-
suring dose distributions of therapeutic electron and photon beams. In radiation
dosimetry, there are numerous problems associated with the measurements of two-
dimensional dose distributions or depth-dose distributions in high-gradient dose
regions, where automated dosimetry systems using IC cannot easily be employed.
Dosimetry with films have resulted in a suitable solution to overcome these diffi-
culties due to their high spatial resolution. The films are easy to develop and give
a permanent record of dose distributions with an acceptable accuracy.
In film dosimetry, the effect produced in the film by the radiation is measured
in terms of light opacity of the film using a densitometer. Opacity is defined as
I0/I, where I0 is the light intensity measured in the absence of the film and I the
intensity through the film in a direction perpendicular to its plane. Based on this












, where T is the transmittance defined as I
I0
.
A relationship between the OD and the dose is generally defined for each combina-
tion of film and densitometer or scanner. This relation is known as sensitometric
curve and provides the characteristics of the film. This type of curves are also an
important tool for quantifying contrast and dynamic range of a radiographic film
and depend strongly on the processing conditions.
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The radiochromic films used were EBT2 Gafchromic films from ISP (International
Specialty Products: www.ispcorp.com).
In this work, all radiochromic films were scanned using the Epson Expression
10000XL flatbed scanner. The subsequent analysis of the data was performed
with the software FilmQA.
Radiochromic film is a recent type of film for radiotherapy dosimetry. The ra-
diochromic films (based on polydiacetylene) are most used when high spatial res-
olution, weak energy dependence are required.
According to the manufacturer, the GafChromic EBT2 film is composed of one
adhesive layer of 25 µm, a top coat 5 µm thick and an active substrate layer
of 30 µm. These layers are coated with two clear polyester sheets with different
thicknesses: 50 µm, on top and 175 µm, at the bottom, as presented in figure 2.18.
Figure 2.18: Composition of an EBT2 Gafchromic film.
The active component of EBT2 films is nearly tissue equivalent with an effective
atomic number Zeff of 6.84. Its overall atomic composition is H (40.85%), C
(42.37%), O (16.59%), N (0.01%), Li (0.10%), K (0.01%), Br (0.01%) and Cl
(0.04%). Radiochromic films are expected to be independent of the energy of the
incident ionizing radiation. These kind of films contain a special yellow marker dye
that is polymerized upon exposure to radiation. The polymer absorbs the light
and the transmission of light through the film is measured with a densitometer.
The dosimetry with radiochromic films has several advantages compared with pre-
vious films, like radiographic films, such as ease of use, elimination of the need for
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darkroom facilities and film processing, dose rate independence, better energy
characteristics and (almost) insensitivity to ambient conditions. All these advan-
tages have subsequently consequences in the accuracy of the dosimetry performed




3.1 The Monte Carlo method
The Monte Carlo (MC) is a method of approximately solving mathematical and
physical problems by the simulation of random variables [76]. Given a specific prob-
ability density function (PDF), the ability to generate random numbers according
to the PDF provides a means to simulate physical systems. This is achieved in the
MC method through the transformation of a set of uniformly distributed (pseudo)
random numbers (easily generated on a modern computer) into the desired distri-
bution of random numbers.
3.1.1 Transformation of random numbers by integral inversion
Considering the known probability density function (PDF) p(x), for which random






, where G is a set of uniformly distributed numbers, and Xmin is the lower bound
of the range of desired X values [76]. The example presented below demonstrates
a method to transform a uniform random variable.
Integral inversion sampling of interaction probability
The following PDF determines the probability of interaction for a photon pene-
trating an infinitely thick slab of material:
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p(x) = µe−µx, for 0 ≤ x ≤ ∞, (3.2)
where µ is the sum of linear attenuation coefficients for all photon interaction
types (e.g. pair production, Compton scattering, photoelectric effect, coherent
scattering, triplet production, etc.) for a certain material and energy. The set of
random numbers G with uniform PDF can be transformed into the set of numbers





G = 1− e−µX ,
X = − 1
µ
ln(1−G), for 0 ≤ G ≤ 1.
By binning X for a set of random numbers G, the resulting histogram is isomorphic
to the shape of p(x). However, p(x) can not always be inverted to solve for X. An
alternative method is the acceptance-rejection MC method.
3.1.2 Transformation of Random Numbers by Acceptance-Rejection
This transformation is used when it is not possible to obtain the inverse of p(x). It
was first used by George-Louis Leclerc, in the 18th century in a technique known
as Buffon’s needle. This technique was later formalized by John von Neumann
[77].
Given the PDF, p(x), a rectangular sampling envelope is constructed which com-
pletely encloses the area under p(x). Suppose N random points uniformly dis-
tributed over the sampling envelope, as represented in figure 3.1 are chosen by
generating a pair of uniform random numbers G1 and G2 such that
xmin ≤ G1 ≤ xmax and
pmin(x) ≤ G2 ≤ pmax(x)
form the coordinates of the point (G1,G2). For each x = G1 generated, p(G1)
is evaluated and compared to G2. If G2 ≤ p(G1), the random value is accepted,
otherwise it is rejected and another set of G1 and G2 are generated. In this
way, a random set of values G1 distributed as p(x) can be generated from two
uniform distributions of random numbers. The disadvantage of this method is
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Figure 3.1: Representation of the Acceptance-Rejection method by transformation of
random numbers. The green points represent the accepted numbers, that are contained
with the function’s envelope; the red points represent rejected numbers.
that a portion of random numbers are wasted and each accepted value requires
two random numbers to be generated.
The approach of continually sampling PDF is inefficient, as many of the histories
(and therefore computational time) will not contribute to the final result (the
particles that for some reason do not reach the patient/phantom or travel out of
field).
3.2 Monte Carlo codes for linac simulations
MC techniques were used in the early days of linac design in the 1970s to aid in
the optimization of the photon beams [78]. The first simplified models of photon
beams were presented by Patau et al [79], Nilsson and Brahme [80], Mohan et al
[81]. Extensive literature review of modeling of photon beams was provided by
Verhaegen and Seuntjens 2003 [82].
Clinical used photon beams in RT are usually within the energy range of 4 to
20 MeV. The linac essential modular structure is presented in figure 3.4 and are
required in a MC model. The most commonly employed MC codes are EGS4 [83]
or EGSnrc [84], in conjunction with the user interface BEAM [54], Penelope [85],
MCNP [86] and GEANT4 [87].
EGSnrc simultaneously with BEAMnrc and DOSXYZnrc was used throughout
this work for Monte Carlo simulation purposes.
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3.3 Efficiency improvements and variance reduction tech-
niques in Monte Carlo sampling
The clinical applications of MC techniques are, at a first glance, very attractive for
the possibility of rigorous results regarding particle transport simulation. However,
there are two major issues directly related to MC: the time to produce results and
the efficiency.
Variance reduction is the application of techniques that attempt to improve this
efficiency, that is, to achieve the desired statistical uncertainty with fewer simula-
tions.
BEAMnrc has introduced several techniques to allow variance reduction and im-
prove simulation efficiency. An overview of the most common techniques will now
be presented.
The unconditional acceptance probability is calculated to be the ratio of parti-
cles accepted to those generated. Sampling is more efficient when the uncondi-
tional acceptance probability is high (equal to unity in integral inversion sampling).
In acceptance-rejection sampling, the efficiency can be increased through careful
choice of the sampling envelope, by constructing, for example, a non-rectangular
envelope.
Other techniques have been developed in an effort to increase sampling efficiency
such as the Ziggurat algorithm [88] and the Box-Muller transform [89]. In these
cases although the unconditional acceptance probability is less than 1, computa-
tional tricks have been implemented to reduce their computation times.
3.3.1 Importance sampling
The variance in estimating the properties of a particular random distribution may
be reduced, in some cases, through the use of an importance sampling technique.
In this technique one samples from a distribution other than the uniform G of
above. In importance sampling one attempts to avoid taking samples in regions
where the PDF is less important to the problem at hand, and to concentrate
on those regions contributing more to the problem. To account for this bias
the samples are weighted appropriately by the inverse of the applied importance
function. A careful choice of the biased distribution to encourage the important
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regions of the input variables is imperative as the reward can be significant run-
time savings. Poor choice of distribution can result in longer run times than
sampling without importance sampling [90].
3.3.2 Calculation Efficiency
The accuracy of any MC calculated mean value is limited by its statistical uncer-
tainty and is dependent of the number of histories, N , simulated. The uncertainty
is given by the variance and provides a measure of the statistical fluctuations
of the calculated mean value around the true value of that quantity. Thereby
the concept of efficiency ε, establishing a relationship between the variance and





, where T is the CPU simulation time and s2 is an estimate of the statistical
variance. Efficiency increasing methods can be classified as either reducing T ,
by increasing the CPU power available to the simulation, or reducing s2, which
is equivalent to requiring fewer simulations to attain the same level of statistical
variance.
3.3.3 Variance Reduction techniques
MC calculations can be time consuming, especially for applications in RT. There-
fore, it is essential to use variance reduction techniques (VRT) to speed up the
simulations. VRT, by definition, must not influence the expected result of an in-
finitely long simulation not using VRT. However, in the literature, approximate
methods are often denoted as VRT, as for example, condensed history (CH) tech-
nique.
3.3.3.1 Range Rejection
Most of the computation time in MC simulation is devoted to tracking electrons.
Range rejection can allow significant time savings during computations of electron
transport. In this technique, the residual range of each charged particle is calcu-
lated and the history is terminated if it cannot escape from its current region. The
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threshold for cutoff is defined using ECUT (defined in MeV, including rest mass)
which can be set independently in each region of the accelerator model. Because
any potential photons (produced via bremsstrahlung) are assumed to deposit their
energy within the current region, range rejection introduces an approximation into
the simulation. Care must therefore be taken to select an appropriate value for
ECUT [54]. As a general rule, ECUT is set such that an electron of energy ECUT
has a range of less than 1
3
of the smallest dimension of the geometric dose scoring
region of interest. The ECUT used was 700keV, for BEAMnrc simulations.
Range rejection is a popular VRT that involves terminating histories where further
simulation would not contribute to the final result. BEAMnrc applies this VRT
for electrons traveling through the treatment head. Basically, the method consists
in calculating the residual range of a charged particle and terminating its history if
it cannot escape from the current region, not depositing there its energy. However,
by terminating an electron’s history preliminarily, no bremsstrahlung photons can
be created or escape the region (depositing their energy somewhere else), possibly
leading to an dose underestimation for high energies and high Z materials. There-
fore, an energy threshold, ESAVE, is defined, above which no range rejection can
occur. This parameter has to be chosen taking into account the Z of the medium
(may vary from region to region) and so that the bremsstrahlung production at
lower energies has a negligible effect. In this work, all simulations used ESAVE of
1 MeV, justified by a study of Rogers et al [54] as the best compromise between
accuracy and simulation speed.
3.3.3.2 Uniform Particle Splitting
Photons are produced in a medical linac via bremsstrahlung within the electron
target. A significant portion of the computations in a photon beam accelerator
simulation involve tracking electrons within the target. A VRT called ’particle
splitting’ is often used to increase the number of bremsstrahlung photons cre-
ated in the simulation geometry of a photon treatment machine. The statistical
uncertainty in the photon fluence, for a given number of incident electrons, can
be significantly reduced by sampling multiple bremsstrahlung photons at each
bremsstrahlung interaction site [54].
This technique is often used for the simulation of an electron hitting the target of
a medical linear accelerator and producing one bremsstrahlung photon. In gen-
eral, several photons can be produced by one electron in the target. However,
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for simplicity purposes, consider the case of one bremsstrahlung photon generated
by one electron. In an analog MC simulation, this photon carries a statistical
weight of w = 1. To statistically account for the split, each photon is weighted
by the inverse of the number of photons split into (splitting factor). Consid-
ering, for instance a particle splitting factor of Nsplit = 5, instead of one, five
independent bremsstrahlung photons are sampled from the same bremsstrahlung
production distribution of the given electron. If all photons are created with the
same probability independent of their energy, each carry a statistical weight of
w = 1/Nsplit = 1/5, which means that one realistic photon is represented by five
photons in the simulation to preserve the total weight. This strategy permits in-
creasing the number of photons, increasing the the statistical accuracy by lowering
the variance. As most of the electrons that hit the target are absorbed, they do
not contribute to the final result.
The most efficient implementation is directional bremsstrahlung splitting (DBS)
which is featured in EGSnrc/BEAMnrc. DBS combines particle splitting and
range rejection, with the following aim: only photons that aim into a field of
interest are split, saving calculation time by ignoring those that are unlikely to
reach the scoring region. Further details in Rogers et al [91].
3.3.3.3 Russian Roulette
Together with bremsstrahlung splitting, Russian Roulette can be used to restrict
the number of electrons produced by the split photons. Since, in general, these
electrons contribute little to the dose in the patient, it is not practical to simulate
the many interactions required for each electron. Using Russian Roulette, the
number of electrons can be reduced back down to that without splitting. This is
carried out through comparison of a uniform random number, generated for each
particle, to a survival threshold and terminating each particle above this threshold.
To statistically account for the termination, each surviving electron is weighted by
the applied splitting factor. This technique permits to reduce the number of par-
ticles simulated and thus the time needed to simulate their transport. Further im-
provement to the bremsstrahlung splitting technique was achieved using DBS [92].
Using DBS, multiple bremsstrahlung photons are sampled at each bremsstrahlung
interaction site as before. Resulting photons that are aimed into the field of inter-
est (defined by the user) are kept. All photons aimed outside of the field undergo
Russian Roulette. To reduce the number of charged particles in the defined field,
all photons about to undergo pair production, incoherent, or photo-electric events
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are forced to take part in Russian Roulette. DBS was found to increase efficiency
by approximately 20 times over uniform bremsstrahlung splitting. However, DBS
must be used appropriately as it will result in only a few charged particles exiting
the accelerator model outside of the defined field.
3.3.3.4 Photon Forcing
Photon forcing is the process by which photons are forced to interact in specific
regions of the accelerator model where relatively few interactions occur statisti-
cally. A copy of the photon is created and is forced to undergo an interaction.
The weight of the scattered photon is changed by the interaction cross section.
The original photon continues on its path “unscattered” but scaled by a weight of
1 minus the interaction cross section. Photon forcing is commonly used to deter-
mine the electron contamination from particular regions of the accelerator model
(such as in the air within the accelerator). Using this technique the variance of a
simulation investigating particle scatter can be reduced when photon interactions
are sparse.
3.3.3.5 Further techniques
The aforementioned techniques were implemented in EGSnrc code, but there are
other efficient approaches that could be used. Simultaneous Transport Of Parti-
cle Sets (STOPS) can improve total calculation time by grouping particles with
the same energy and transporting them simultaneously. This permits material
independent quantities to be calculated just once whereas material dependent
properties are sampled separately. This VRT is implemented in VMC++ code
[93].
Other VRT are Macro Monte Carlo, history repetition, boundary-crossing algo-
rithms, precalculated interaction densities, Woodcock tracing, correlated sam-
pling, interaction forcing, exponential transform and others. Quasi-random se-
quences are also considered as a strategy for increasing the efficiency in simula-
tions.
A detailed description of these and other VRT used is provided by Sheikh-Bagheri
et al [94].
Chapter 3. Monte Carlo 71
3.3.4 Hardware Performance Improvements
The introduction of greater processing power can also reduce the time required for
accurate simulations. To decrease the calculation time, the calculations should be
performed in faster computers or implementing parallel calculation processes on
multicore workstations and computing clusters. Parallel computing is a technique
that can provide significant increase in power. MC simulations can be performed
in a parallel mode as the simulation of one history is independent of the simulation
of any other history, and there is no difficulty in splitting the tasks into smaller
components. Parallel computing can be implemented in single systems or over a
network of systems.
Single system parallel computing requires computers with multiple processors or
cores which are typically identical. For instance, for a dual core system, a MC code
could assign half the desired number of histories to each core, and then combine
the results when each allocation is completed. The performance in this case would
increase near-linearly with the number of processors or cores available.
Multiple system parallel computing, which is more often referred to as distributed
computing, is another possibility in which multiple systems are networked and
one system (a server) manages the tasks and allocates the tasks to the remaining
systems (nodes). This is a much more complex implementation as the resources
have to be shared over a network and the nodes may not offer identical performance
(and the jobs shouldn’t be split evenly). This distributed computing method has
become more popular for scientific computation, as it is a cost-effective method
for providing high performance.
Most of the simulations performed during this project were done in Centro de
F́ısica Nuclear of Universidade de Lisboa, on the high performance computing
cluster ALFC, that contained 100 processing cores of 2.2 GHz AMD Opteron
processors. The EGSnrc package exb was configured to use the available batch
submission software, allowing parallel job submission to be performed.
3.4 Simulation of radiation transport with EGSnrc
The MC methods briefly described in the previous section have been applied to
many of the known interactions a particle may undergo with matter. Using these
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methods the ability to transform distributions of random numbers to model in-
dividual particle interactions is realized. However, in order to model the passage
of a particle through, for example, a slab of lead, a particle detector, or even
the human body, the ability to link the outcomes of successive interactions and
particle trajectories forming the particle shower is required. The EGS (Electron-
Gamma-Shower) code [83], developed at the Stanford Linear Accelerator Center,
represents an mixture of particle interactions for the coupled simulation of elec-
trons and photons in an arbitrary material geometry from a few keV up to several
hundred GeV. Using EGS, quantities of interest can be calculated by averaging
over a given set of MC particle cases or histories.
Further refinements of the physics within EGS to improve its use in the model-
ing of radiotherapy were implemented by the Omega group in the mid 1990’s
within the National Research Council of Canada (NRC). The named EGSnrc
contained enhancements specifically to the electron transport algorithm, vari-
ance reduction techniques (bremsstrahlung splitting, Russian roulette, range rejec-
tion) and several of the physics models (bremsstrahlung angular sampling, photo-
electric/Compton electron relaxations). A detailed account of the physics insti-
tuted in EGSnrc can be found in NRC Technical Report PIRS-701 [93].
The EGSnrc code is written in a programming language called MORTRAN. This
code relies on two user codes that simplify the simulation process:
• a. The BEAMnrc code [91] is a Monte Carlo simulation tool for the mod-
eling of radiation beams from any radiotherapy units, including orthovoltage
units, 60Co units and linear accelerators.
• b. The DOSXYZnrc code [95] is an EGSnrc-based code dedicated to
the calculation of dose distributions within phantoms consisting of rectilin-
ear volume elements (voxels) which contain a specific physical density and
material. Voxel dimensions are independently variable in all 3 directions (x,
y and z). The code allows to select between different source types, including
monoenergetic diverging or parallel beams, phase-space data generated by
BEAMnrc simulations, or a model-based beam reconstruction produced by
the BEAMDP software.
Patau et al [79] were among the first to simulate a complete photon beam linac
using MC techniques and and McCall et al [78] attempted to use EGS3 code [96],
focused on the optimization of the target and flattening filter composition which
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affects the depth of the dose maximum in water and the average energy of the
photon spectrum exiting the linac for 10-25 MV photon beams. Bielajew et al [97]
implemented bremsstrahlung angular sampling in EGS4, leading to a significant
difference in the degree of the target absorption. Cross sections accuracy for
bremsstrahlung production still remains a matter of study.




It also provides other tools such as particle tagging according to interaction types
and sites. Lovelock [98] modeled the radius of a uniform primary electron beam
hitting the target and achieved good results.
Information on the particles crossing a plane can be stored in a called, phase-space
file. The simulations are done in stages and the phase-space information from one
plane can be used as an input source for a subsequent stage.
3.4.1 Photon interaction cross-sections within EGSnrc
The interaction of photons with matter occurs via four basic processes [93]:
1. (i) Coherent (Rayleigh) scattering with atoms or molecules in the medium
(figure 3.2.d);
2. (ii) Photoelectric absorption (figure 3.2.b);
3. (iii) Incoherent (Compton) scattering with atomic electrons (figure 3.2.a);
and
4. (iv) Materialization into an electron/positron pair in the presence of the
electromagnetic field of an atomic nuclei and surrounding electrons (pair
production) (figure 3.2.c).
With the exception of coherent scattering, each process transfers energy from
the incoming photons to electrons of the media. The interaction probabilities
are dependent on the media in which the processes occur and on the energy of
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Figure 3.2: Diagram of the main photon interactions: a. Compton scattering; b.
photoelectric effect; c. pair production; d. Rayleigh scattering. E - energy of the
incident particle; Ee - electron energy; E’ - energy of the resulting photon; Ui - lost
energy; E− - electron pair; E+ - positron pair.
the photons.The interaction probabilities in water below 100 MeV for the above
processes are shown in figure 3.3. It is evident that the pair production process
dominates at higher energies (above 5 - 10 MeV), Compton scattering dominates
at intermediate energies (from 0.5 to 5 MeV), and at lower energies (below 0.5
MeV), photo-electric absorption occur more often.
Figure 3.3: Photon interaction probabilities in water depending on the medium and
energy of the photons [99].
A thorough description of the cross-sections adopted within EGSnrc is available
in NRC Technical Report PIRS-701 [93]. A summary is compiled in table 3.1.
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Table 3.1: Summary of interaction cross-sections implemented in EGSnrc
Interaction Cross-Section
Coherent Storm and Israel [100] (atomic form factors [101]) or XCOM [102]
Photoelectric Storm and Israel [100] (Sauter distribution for photon-electron direction [103]) or XCOM [102]
Incoherent Klein-Nishina (binding effects and Doppler broadening [104])
Pair /Triplet Relativistic first Born approximation [105] (Coulomb corrected ≥ 50 MeV)
The cross-section databases for photon and electron interactions are provided in
look-up tables for the materials found in the simulation geometries. These ta-
bles are generated with PEGS4 program, the cross section data preprocessor for
EGSnrc. It generates energy dependent photon attenuation coefficients and elec-
tron stopping powers based on experimental data and theoretical cross section
calculations. By specifying elemental composition, density and energy range, data
tables are generated for use in the EGS simulation.
3.4.2 Electron interactions and transport within EGSnrc
An electron traveling through matter loses energy in two ways [93]:
(i) Inelastic collisions with atomic electrons
(ii) Radiative energy loss
Radiative energy losses (ii) occur in the form of bremsstrahlung and annihila-
tion events with positrons. Inelastic collisions (i) dominate at lower energies.
Bremsstrahlung production dominates at high energies. In addition, electrons un-
dergo a large number of elastic collisions with atomic nuclei leading to frequent
changes in direction.
Electron Transport: PRESTA II
The modeling of charged particle transport is inherently difficult. Cross-sections
for electron interaction become infinite as the kinetic energy approaches zero. The
cross-sections are, in fact, finite but the exact values are not well known [83]. How-
ever, low momentum transfer events do not significantly affect the shower results
and so multiple steps can be lumped together in some cases without significant
loss of simulation accuracy and approximated using a continuous slowing down
type approximation (CSDA). Lumping electron scattering events is known as a
condensed history (CH) technique, introduced by Berger [106]. A major difficulty
with this technique arises in the region of material boundaries where the approach
breaks down because one cannot account for the ensemble of paths occurring in
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the adjacent medium. Solving this problem required the development of new mul-
tiple scattering theories and more complex algorithms for transporting electrons,
including reverting to modeling single scattering events near material boundaries.
EGSnrc makes use of an algorithm PRESTA II [107] (acronym for Parameter Re-
duced Electron-Step Transport Algorithm) that automatically selects the optimum
step-size saving time to the user, permitting the use of fewer and larger electron
steps without compromising the simulation accuracy. The size of the condensed
history step is regulated by the parameter ESTEPE which limits the fractional
loss of energy for the continuous process. With the PRESTA-II algorithm, the
typical ESTEPE value is set to 25% to ensure the convergence for the correct
spatial distribution.
It has been shown, however, that PRESTA is not adequate for simulating the
dose deposited in a small air cavity or in the neighborhood of high-Z interfaces.
This led to the introduction of a new algorithm, EXACT, which allows the user
to revert to a single scattering model in the close neighborhood of boundaries,
thereby reducing the minimum path length to very small values. This appears to
solve the problem in these circumstances.
3.5 Monte Carlo modeling of Radiotherapy linacs
One of the most frequent and important applications of MC modeling in external
beam RT is the creation of a virtual model of the radiation source.
By modeling it is meant the necessary fit of some parameters of the CM and
incident electron beam on a trial-error basis until a good match between the sim-
ulations and the experimental data is attained.
One approach, extensively adopted in the last years, to characterize clinical photon
beams, has been to perform a full MC simulation through the linac head. The
implementation of a complete model of a linac head is not a trivial task due to
its complexity and need of detailed modeling to obtain accurate dose calculations.
However, the task is worth the effort because once the MC model is validated, it
will provide the most accurate dose predictions, particularly in irregular geometries
and inhomogeneous media. Additionally, MC simulations permit attain angular
and energy distributions or other quantities difficult to obtain experimentally.
A potentially limiting factor in the MC dose calculation process remains the ability
to accurately represent the radiation field emerging from the accelerator head.
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Figure 3.4: Schematic representation of the components that integrate a Trilogy
VARIAN head linac.
The subject has been extensively researched with proposed solutions coming from
a variety of modifications such as to the physical densities of components (target,
flattening filter) in the accelerator head model [108], modifications to geometric
components of the model (flattening filter, primary collimator, lead shielding, etc.)
[108], variations in incident electron beam spectrum [109, 110], modifications to
the EGSnrc interaction models.
Several MC models for the major three linac manufacturers (Elekta, Siemens and
Varian) were carried out by different groups [58, 110–116]. Some studies were
dedicated to investigate the sensitivity of MC simulations to the characteristics
of the initial electron beam incident on the target, with particular focus on its
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energy and radius, as well as other treatment head components, such as the flat-
tening filter and the primary collimator [110, 116]. Other work was devoted to the
characterization of the produced beam, in terms of their spectral distributions for
different beam energies [58, 114, 117].
Despite all the works carried out so far, each linac has its own specificity and
characteristics. Therefore it is necessary to model this accelerator for its calibration
and curves. In a first attempt, M. D. Anderson Cancer Center provided the PSF
before the jaws to avoid a detailed modeling of this part of the linac, as at the
time, I still did not have the data with the detailed linac geometry from Varian.
However, discrepancies were found between the simulations and the measurements
and the data was not used (results not presented). The necessity for modeling is
due to the need to finely tune the initial energy and radius of the primary electron
beam. An accurate beam model of the linac is essential to guarantee accurate dose
calculations in the patient, in the subsequent work. All the presented results are
from original simulations.
3.6 Simulation of radiation transport within the accelera-
tor head: BEAMnrc
EGSnrc is a tool to accurately model a particle shower using MC methods within
a defined geometry. The software package BEAMnrc [54], represents a specialized
user code of EGSnrc for the simulation of radiation beams from RT units including
high-energy electron and photon beams, Cobalt-60 (Co60) beams and orthovoltage
machines.
Geometries of the accelerator’s components are defined through the use of compo-
nent modules (CM) which consist of a wide choice of building blocks of a variety
of geometrical shapes such as disks, cones, trapezoids, parallelepipeds and others,
that can be assembled to build the RT unit. The CMs are re-usable, independent
and can even be tested separately. They can not overlap in the beam direction.
Typical CM used in linac modeling are FLATFILT for flattening filters, SLABS
for the X-ray target, CONESTAK for the primary collimator, JAWS for the jaws,
and so on.
The ability to score particle characteristics in a phase space file (PSF) is an integral
part of the BEAMnrc code, allowing the stopping/restarting of simulations, anal-
ysis of particle characteristics, modification of particle characteristics, etc. The
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characteristics recorded in the PSF include each particle’s energy, position, direc-
tion cosines, weight, LATCH history, and optionally, the Z coordinate of the last
interaction.
All future simulations can be started from this plane using a PSF as a particle
source, effectively eliminating the need to remodel many of the unchanging linac
components for each simulation. A second PSF is commonly created to record
the final output of the BEAMnrc simulation and acts as the source for particle
transport into a patient model or phantom.
As addressed by Sempau et al [118], the use of phase space techniques in MC sim-
ulation introduces a baseline level of statistical variance that cannot be suppressed
through the use of particle recycling1 techniques. To obtain low uncertainty re-
sults from two-step MC simulation, the size of the PSF must be rather large. To
further reduce statistical uncertainty in the MC simulation, one can either increase
the size of the intermediate PSF (increase particle density) or recycle the particles
that have already been recorded. When a particle is recycled, the PSF record
for the particle is reused. The recycled history differs from the original history
only by the random number chosen to restart the particle’s transport through the
remainder of the accelerator model.
These PSF are accompanied with summaries containing fluence results, phase
space outputs, processing time and energy deposition.
BEAMDP (BEAM Data Processor) [119] is a utility that permits beam data pro-
cessing and ultimately display fluence, energy distribution and angular distribution
data extracted from the PSF.
3.7 Components of a MC model of a linac in photon beam
mode
The first requisite of utmost importance is to have an accurate geometric and
materials description of the components that integrate the linac head, usually
provided by the manufacturers, including the position, dimensions and shape of
the several components; their motion and limits; the composition of materials and
alloys and their mass densities. After implementation, MC linac models need to
1Particle recycling or history repetition: particles’ complete history are precalculated with all their
histories and saved for reuse
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be validated against a set of dose measurements, such as depth and lateral profiles
and output factors in water using different setups.
The most important linac components to consider in a photon linac model are the
target, flattening filter (FF) and secondary collimators, namely the jaws and the
multileaf collimator (MLC).
After the accelerated primary electron beam exits the flight tube, it possesses a
narrow-energy, angular and spatial distribution. The electron beam impinges on
the target, consisting of a high atomic number (Z) metal in which the electrons
produce bremsstrahlung photons. These photons are then collimated initially by
the primary collimator and the photon fluence is differentially attenuated by the
FF to produce a reasonably flat dose distribution in water at a certain depth. The
target and FF are the most important source of contaminant electrons. The mon-
itor unit chambers and the field mirror may also be simulated but both present
small attenuation to a photon beam, being therefore often omitted from MC mod-
els [120], [121]. The photon beam is finally shaped and modulated by secondary
collimators and beam modifiers such as jaws, blocks, MLC and/or wedges, as
represented in figure 3.4.
3.7.1 Monte Carlo simulation parameters
MC simulations were made using the BEAMnrc [54] and DOSXYZnrc [122] MC
code system, based on the underlying EGSnrc [93] particle transport code. The
following MC transport parameters were used in all simulations:
• AP = PCUT = 0.010MeV
• AE = ECUT = 0.700MeV (including rest mass)
, where AP and AE are the low-energy thresholds for the production of secondary
bremsstrahlung photons and knock-on electrons, respectively, while PCUT and
ECUT define the global cutoff energy for photon and electron transport, respec-
tively.
Range rejection was employed by setting ESAVE to 1.0 MeV for all linac compo-
nents modeled except the target, where it was set to 0.7 MeV, to guarantee the
production of lower energy photons.
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Directional bremsstrahlung splitting (DBS) was used with a splitting factor NBR-
SPL=20, to increase the number of photons created in the target. Russian roulette
was turned on whereas the photon forcing option was not.
The accelerator model, a Varian Trilogy 2300CD (Varian Medical Systems, Palo
Alto, California) linac, was defined exactly by specifications provided by the 2008
Varian Oncology Systems Monte Carlo Project package.
3.7.2 Measurements
Measured data for depth dose and lateral profile comparisons were obtained from
departmental quality assurance measurements. Ionometric measurements were
performed using a PTW 31010 (volume of 0.125 cc) ionization chamber, a PinPoint
chamber, in a PTW water phantom or a solid water phantom. Some measurements
were also performed with EBT2 Gafchromic films, afterwards processed in a Epson
10000XL flatbed scanner. More specific details are provided throughout the thesis
on the measurements performed.
3.7.3 Primary electron beam distribution and photon target
The photons produced in the target are mostly derived from a relatively thin
layer on the upstream side, due to the high energy degradation of the electron
energy in a high-Z material, the dependence of the bremsstrahlung cross section
on the electron kinetic energy for high energies, and electron scattering in the
target. At high electron energies, the average bremsstrahlung photon emission
angle is approximately given by m0c
2/E0, where the numerator is the electron’s
rest energy and the denominator, its total energy, yielding a strongly forward-
peaked angular distribution. Targets must be thick enough to completely stop the
primary electrons.
In some accelerators, some years ago, a gold target was used to generate bremsstrahlung
photon beams. However, this target material implied having a complex water cool-
ing system directly in the path of the beam. In order to simplify the circuitry,
this material has been replaced by a bi-layer target of W and Cu with the purpose
of generating a photon beam (through W) and being able to self-cool (function
performed by Cu). There are, however, some slight differences in the spectral
distributions on the central axis of each beam that do not affect the dosimetric
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characteristics of the beam, as can be seen figure 3.5. In fact, there are no signif-
icant differences in the depth and lateral dose profiles for the different targets of
Au, W and W-Cu.
Figure 3.5: Photon energy spectra scored below the jaws, for Au, W and W-Cu used
in the final target design.
For the 6 MV beam, the differences observed between the different target ma-
terials are not significant. However, for higher photon beam energies, there are
considerable differences [123].
The photon angular distribution is spread out due to electron multiple scatter-
ing, resulting in a strongly anisotropic photon fluence and an isotropic photon
spectrum, not possible to obtain with analytical methods.
The focal spot size of the photon beam and the primary electron beam affects
the calculated dose and fluence distributions. Jaffray et al [124] found that the
x-ray source has an elliptical shape with full width half maximum (FWHM). A
fine tuning to the initial electron beam energy and FWHM was performed. How-
ever, differences are observed when measuring with different chambers, as can be
observed in figure 3.6. The Pinpoint chamber presents a better agreement (about
2%) in the build-up region than the 0.125 cm3 chamber (inferior to 5%); however,
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the agreement after dmax (depth of maximum dose) is better for the 0.125 cm
3
chamber (about 2%).
Figure 3.6: Depth dose curves for the 6 MV beam for the square 30 × 30 cm2 field.
The black curve represents the simulation result whereas the green and red curves
are the measurements performed with the PinPoint and 0.125 cc ionization chamber,
respectively.
3.7.3.1 Pre-target electron beam parameters
The sensitivity of megavoltage MC simulations to the pre-target electron beam
parameters in medical linear accelerator MC models has been thoroughly inves-
tigated. A comprehensive review of past research in this area is presented by
Verhaegen and Seuntjens [82] and more recently by AAPM TG report No. 105
[59]. The intensity distribution of the pre-target electron beam is among the most
sensitive parameters of a medical linac model [108, 110]. It is well known that
off-axis dose profiles are particularly sensitive to the pre-target electron intensity
distribution [108–110, 125, 126]. A Gaussian pre-target electron beam intensity
distribution has been consistently implemented in MC simulation of Varian accel-
erators with variations of energy and FWHM of the beam intensity.
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The assumption of a Gaussian electron intensity distribution is, in part, based
on an educated guess by the physicist (derived from beam line optics/accelerator
physics), approximate recommendations by accelerator manufacturers, and in part
implied from focal spot measurements sparsely published thus far in the literature
[124, 127–130].
Using a technique similar to that of Loewenthal et al [129], Jaffray et al [124] used
a CT reconstruction technique to make quantitative measurements of the size and
shape of the focal spot from a total of 9 accelerators. Jaffray et al determined a
range for the Clinac 2100C focal spot intensity FWHM of 1.2 - 1.4 mm for the
6 MV beam. Huang et al [130] have published measurements of the focal spots
of electron beam’s for the Clinac 21EX using the beam spot camera technique of
Lutz et al [127]. The work is also useful in the determination of pre-target electron
intensities for photon beam models. The measurements of Huang et al [130] were
the first and only measurements made to date for the purpose of MC simulation.
They concluded varying elliptical eccentricities of the focal spot (up to 21%) for
electron energies from 6 to 16 MeV with FWHM in the range of 1.69 mm to 2.24
mm. Lateral shifts in the focal spot were also observed with reported displacements
of as much as 7.79 mm. Some of the first published focal spot measurements
were produced by Lutz et al [127] who performed measurements of the emerging
radiation field from the target using a beam spot camera technique. Based on
the above measurements performed thus far in the literature it is clear that the
electron focal spot intensities deviate from the ideal Gaussian shape assumed in
MC simulation. So far, no measurements of pre-target electron beam intensity
distributions specifically for use in megavoltage MC photon therapy simulations
have been published.
A common method for the determination of the pre-target electron beam param-
eters for a particular MC simulation (as outlined by Sheikh-Bagheri and Rogers
[110]) is to begin with a best guess of the electron beam energy and FWHM and
subsequently perform iterative trial-error adjustments of these parameters until
acceptable agreement with measured the dose distribution is achieved. Typically,
the energy is determined first by varying the electron energy until optimal agree-
ment with measured depth dose profiles is obtained. Adjustments of the FWHM
of the Gaussian intensity distribution are then applied until acceptable agreement
with lateral (off-axis) profiles is met. It has been shown that the correlation be-
tween FWHM and central axis depth dose profile shape is minimal beyond the
depth of maximum dose deposition [108, 109, 114]. However, further fine-tuning
of the electron beam parameters may be required if the initial guess of FWHM
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was sufficiently inaccurate during the energy tuning stages. For the remainder
of this chapter, the above method will be referred to as trial-error commissioning
method. It was noticed that calculated depth dose profiles in water are relatively
insensitive to the primary electron energy but the horns of the lateral dose profiles
are a good indicator of the primary electron beam energy, introducing a tuning
procedure to estimate its energy (usually not known).
Using this method, the commissioning of a MC model can be laborious, as the
time required for the high-statistics simulation of each parameter adjustment is
generally large and achieving the optimal combination of electron parameters using
a so-called blind search of the solution space is not guaranteed. The process/results
from using the conventional method to commission MC linacs are presented by
several groups [108, 110, 125].
Another error-trial type method for determining both the pre-target electron en-
ergy and FWHM for commissioning a MC model is through comparison of MC
calculated lateral profiles in air with measurement. Tonkopi et al [126] have inves-
tigated the influence of ion chamber response on the MC-based measurement of
in-air off-axis ratio profiles for megavoltage photon beams. Their work confirmed
the conclusions of Sheikh-Bagheri and Rogers that in-air off-axis ratio profiles can
be useful in the MC beam commissioning process. The use of off-axis ratio profiles
could potentially reduce the time required to commission a MC beam by reducing
the number of in-water simulations.
The sensitivity of the MC model to the incident energy has also been thoroughly
investigated [81, 109, 114, 125, 131]. It has been shown that while the simulation
is highly sensitive to the mean electron energy, the energy distribution has little
effect on the resulting beam [109, 110].
The method began with the determination of a pre-target electron energy range to
be optimized by observing the agreement of MC calculated depth-dose curves with
measurement. Because of the relatively weak dependence of depth-dose curves
with modification of the incident electron intensity distribution [108, 110], those
energies producing unacceptable depth-dose curve agreement (≥ 2%) beyond the
build-up region were not used in the optimization. The range of incident electron
energies examined was chosen in accordance with energies examined by Keall et al
[108] for the Clinac 21EX and based on experience from previous commissioning
efforts by the authors.
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For modeling the linac, the energy and FWHM were adjusted on a trial-error
basis and the best fit, when comparing with the measurements. The results are
presented in [132]. The best fit was obtained for an incident electron energy of 5.8
MeV and a Gaussian intensity profile with a FWHM of 0.12 cm.
3.7.4 Flattening Filter
The flattening filter (FF) is a component with major influence on the beam, gen-
erating flat dose distributions at a certain depth in water. McCall et al [78] were
among the first to perform simulations of different FF materials recommending
these should be made of medium-Z materials such as steel or copper. Mohan et
al [81] developed a BEAMnrc CM for easier implementation of the FF for MC
simulation purposes and proved that the FF causes significant spectral hardening
both on and off the beam axis.
The influence of the FF was investigated in this work. The figure 3.7 displays the
result of the simulations performed with and without the FF. When the FF is
present, curve in black, the lateral profiles are more flat within the jaws aperture;
when it is absent, the profile presents a maximum dose in the central axis and
decreases with the jaws opening.
Figure 3.7: MC linac lateral profiles simulated with and without flattening filter, in
black and red, respectively.
Further investigation was also performed on the material density of the FF and
the results are presented in figure 3.8.
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Figure 3.8: Lateral profiles calculated at a 5 cm depth in a water phantom for a 10
x 10 cm2 field, for different densities of a copper flattening filter, for the 6 MV beam:
7.0 g/cm3, in red; 8.933 g/cm3, in black; and 11.0 g/cm3, in green.
The density of the FF material does influence the lateral profiles. The density used
was 8.933 g/cm3 for being the data provided by the manufacturer, Varian Medical
Systems. No significant differences were observed in the depth dose curves.
3.7.5 Modeling the multileaf collimator (MLC)
For a given treatment, the MLC may be static, such as in conformal radiotherapy
and aperture based IMRT, or dynamic, such as in dynamic IMRT and volumetric
modulated arc therapies. Transport through the MLC has been documented in
the following ways [59]:
1. Explicit transport of each history through a detailed model of the MLC
[91, 115, 133];
2. Explicit-approximate transport in which the MLC is explicitly modeled but
approximations are employed in the Monte Carlo photon/electron tracking
scheme to improve simulation efficiency [61, 134, 135];
3. Pseudo-explicit transport where an MLC characterization model or “toy-
model” is used to describe the modulation effects [57].
Examples of explicit transport (1.) include the BEAMnrc CM:
• MLC, MLCQ, VARMLC [91] and DYNVMLC [133] for the Varian Millenium
MLC, and
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• MLCE [115] for the Elekta MLC.
Explicit transport is inherently the most accurate method of modeling the MLC
since a particle shower is transported through a detailed MLC geometry. However,
it is also the most computationally demanding. In the case of modeling a dynamic
MLC, where only a small area of the field may be exposed throughout the leaf
motion, the explicit transport method can result in a large number of particles
terminating within the MLC [61].
Examples of explicit-approximate transport (2.) methods include the work of
Liu et al [134], Siebers et al [61] and Tyagi et al [135]. The approximations
introduced include simplifications to the MLC geometry [134], modeling only a
single Compton scattering event for each photon passing through the MLC [61] or
modeling only primary electrons created within the MLC [135].
An example of pseudo-explicit transport (3.) is presented by Chetty et al [57] in
which a virtual source model is developed for simulating arbitrary, external beam,
intensity distributions. The pseudo-explicit transport method is expected to be
the least computer intensive method of modeling the MLC.
For the body of research presented in this dissertation, the explicit-approximate
method of Siebers et al [61] further developed by Heath et al [133] was chosen
and adapted for modeling of the MLC. This method was selected to optimize the
balance of accuracy and simulation efficiency.
The most important components to achieve beam conformation are the jaws and
the multileaf collimator. The first are usually two movable block pairs made of
tungsten. Their opening dimensions are defined depending on the tumor dimen-
sions through square or rectangular opened fields.
The first part of the linac modeling consisted in benchmarking the linac simulations
up to the jaws. 2
To achieve higher conformation, two banks of tungsten leaves are installed in the
linac head. For Varian linacs, the MLC are usually placed below the jaws and
are among the most challenging geometrical structures to model in a linac due
to the complex design of the leaves. Furthermore, these leaves can move during
beam delivery in step-and-shoot and dynamic treatments (such as IMRT). The
MLC collimation can be considered either by a direct MC simulation of particle
2These results without the MLC were presented on the Second European Workshop Monte Carlo
Treatment Planning (MCTP), held in Cardiff, in October 2009.
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transport and interaction in the MLC leaf geometry or by ray tracing through the
MLC leaf geometry to determine whether the particles can go through the MLC
opening.
BEAMnrc contains pre-prepared CMs for several types of MLCs. However, the
HD120 MLC had never been previously modeled and no simulations were ever
performed before. Therefore it was necessary to model and validated it with
further measurements. This was a complex work and the modeling was based on
the Millenium MLC CM, DYNVMLC, developed by Heath et al [133]. The details
of this work and the creation of a new CM, HDMLC, are presented in section 3.9.
3.8 Simulating radiation transport into the phantom/pa-
tient: DOSXYZnrc
For the commissioning of the linac, the MC simulations performed in DOSXYZnrc,
were done in a homogeneous water voxelized phantom.
For the patient simulations, a 3D voxelized phantom converted from the patien-
t/phantom CT scan was used for dose calculation. The density and material for
each voxel were converted based on the CT number.
3.8.1 CTCreate
A phantom is constructed using a 3-D matrix of voxels (volume elements) for
which each voxel contains a physical density and material assignment. There
are two ways by which this matrix is most commonly created. The first way is
by simply defining a set of x, y, and z boundaries and assigning densities and
material types to these voxels using an (.egsinp) input file. The second way, used
commonly for simulations on patient geometries, is to create the phantom from a
set of CT images taken of the patient. From this set of images, the CT densities in
Hounsfield units (HU) are interpolated onto a 3-D matrix of voxels and converted
into equivalent physical densities
Typically, the CT-numbers range between -1000 HU (air) to +1000 HU (bone).
The conversion function for any individual CT scanner is unique and obtained
based on the CT calibration with a standard phantom. The material type (com-
position) and mass density data within each voxel are derived from the Hounsfield
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number exported from the CT using a CT conversion curve, included in table 3.2.
More details on the HU and calculation considerations can be found in 4.2.2.1.
Table 3.2: CT numbers and density range for the four materials used in the ramp for
converting CT numbers to material parameters (composition and density).
Air Lung Tissue Bone
CT number range 0 - 50 50 - 300 300 - 1125 1125 - 3000
Density range 0.001 - 0.044 0.044 - 0.302 0.302 - 1.101 1.101 - 2.088
The conversion from CT densities to physical densities is achieved through inter-
polation of optical-to-physical density relations forming a CT ramp. The matrix
of physical densities is then written to a file (.egsphant). Also included in this
file is a list of media present in the patient model, as well as a map of individual
voxels to material type. It should be noted that, in general, not every material
type is defined in this file. Instead, only the most common material types may be
included.
The BEAMnrc software package includes CTCreate, a tool for creating phantom
models, as part of the distribution. The DICOM (Digital Image and Communi-
cations in Medicine) image format provides a standard format by which the CT
scanner data can be exported. The image resolution is not fixed, although 512 ×
512 pixels is commonly used. The spacing of the pixels is determined by the size
of the area that was imaged and is uniform along each axis. The number of CT
images or slices is generally determined by the volume of the prescribed region to
be imaged and the slice spacing specified by the oncologist.
3.8.2 DOSXYZnrc
DOSXYZnrc [122] is another user code for the EGSnrc system dedicated to the
calculation of dose distributions within phantoms that can be defined either by
voxels or extracted from CT data.
Once particle transport through the accelerator head has been simulated with
BEAMnrc, the output can be transported into the constructed patient phantom
using the DOSXYZnrc user code (included in the BEAMnrc distribution). There
are several ways in which the particles emerging from the accelerator head may be
passed on to DOSXYZnrc. First, through the use of a phase space file generated
in BEAMnrc. Second, by characterizing the particles from BEAMnrc into a series
of histograms and sampling from the derived particle source model. Lastly, by
incorporating the BEAMnrc simulation as a shared library in DOSXYZnrc such
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that each particle requested by DOSXYZnrc is transported through the BEAMnrc
simulation on-the-fly.
DOSXYZnrc is specifically written for obtaining the dose (and accompanying un-
certainty) in a cartesian geometry. In DOSXYZnrc, a spherical coordinate system
is defined to describe the beam incidence on the phantom with an origin set to
the isocenter, as defined by (xiso,yiso,ziso) the x, y, and z distances from the de-
fined (0, 0, 0) origin of the phantom. The incident beam angle is specified by
θ, φ, and φcol (see figure 2.7 from DOSXYZnrc manual). In practical use of the
accelerator, the incident beam angle is more commonly defined by specifying a
gantry angle, couch rotation angle, and collimator rotation. A coordinate trans-
formation is then required. The absorbed dose is recorded or scored in a 3-D array
of voxels with boundaries as defined in the CT phantom. The user can choose to
omit specific voxels from the scoring array. By default, the dose, uncertainties,
and voxel boundaries are all written in American Standard Code for Information
Interchange (ASCII) format to a (.3ddose) file.
When PSF are used as input of the DOSXYZnrc, there is a strategy to increase
the number of particles simulated in a run that consists in re-using the PSF. The
number of times the PSF is used/recycled is defined through the NRCYCL input
parameter. Along with this particle recycling strategy, ISMOOTH is used to redis-
tribute the recycled particles about the central axis of the linac beam. Recycling
can, nonetheless have a significant effect on the final statistical uncertainty of the
dose , possibly creating correlations between particles in the PSF. This effect is
much more considerable for electron than for photon beams [95]. In this work, a
maximum of 20 recycling factors was used in the dose calculations except for the
closed fields, for the adjustment of the MLC parameters.
The results of MC simulations are not immediately comparable to absolute dose
calculations and in the commissioning process, relative (normalized) curves are
generally used. However, for the calculation of dose distributions, absolute dose
is important and depends on the MU necessary to administer the patient in pre-
determined conditions. In the case of the linac used, 1 UM corresponds to 1 cGy
at an SSD of 100 cm, at 10 cm in depth, for a 10 x 10 cm2 field. It is not possible
to simulate all the particles that are present in a single MU (6.23× 1010 keV per
cm3, of water). The number of source particles are restricted to the smallest value
capable of producing the desired statistical accuracy, in order to minimize the
calculation time. A calibration process is required to obtain the desired absolute
dose values.
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3.9 Simulation and validation of the High Definition MLC
using Monte Carlo
This section presents the MC simulations performed for the modeling and valida-
tion of the Trilogy linac equipped with a HD120 MLC, never previously modeled
and simulated. These results were published in Medical Physics journal [132].
Monte Carlo modeling and simulations of the High Definition (HD120) micro
MLC and validation against measurements for a 6 MV beam
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Purpose: The most recent Varian
VR
micro multileaf collimator (MLC), the High Definition
(HD120) MLC, was modeled using the BEAMNRC Monte Carlo code. This model was incorporated
into a Varian medical linear accelerator, for a 6 MV beam, in static and dynamic mode. The model





(2300C/D) accelerator model was accurately implemented using
the state-of-the-art Monte Carlo simulation program BEAMNRC and validated against off-axis and
depth dose profiles measured using ionization chambers, by adjusting the energy and the full width
at half maximum (FWHM) of the initial electron beam. The HD120 MLC was modeled by develop-
ing a new BEAMNRC component module (CM), designated HDMLC, adapting the available
DYNVMLC CM and incorporating the specific characteristics of this new micro MLC. The leaf
dimensions were provided by the manufacturer. The geometry was visualized by tracing particles
through the CM and recording their position when a leaf boundary is crossed. The leaf material
density and abutting air gap between leaves were adjusted in order to obtain a good agreement
between the simulated leakage profiles and EBT2 film measurements performed in a solid water
phantom. To validate the HDMLC implementation, additional MLC static patterns were also simu-
lated and compared to additional measurements. Furthermore, the ability to simulate dynamic MLC
fields was implemented in the HDMLC CM. The simulation results of these fields were compared
with EBT2 film measurements performed in a solid water phantom.
Results: Overall, the discrepancies, with and without MLC, between the opened field simulations
and the measurements using ionization chambers in a water phantom, for the off-axis profiles are
below 2% and in depth-dose profiles are below 2% after the maximum dose depth and below 4% in
the build-up region. On the conditions of these simulations, this tungsten-based MLC has a density
of 18.7 g cm 3 and an overall leakage of about 1.1 6 0.03%. The discrepancies between the film
measured and simulated closed and blocked fields are below 2% and 8%, respectively. Other meas-
urements were performed for alternated leaf patterns and the agreement is satisfactory (to within
4%). The dynamic mode for this MLC was implemented and the discrepancies between film meas-





(2300 C/D) linear accelerator including the HD120 MLC was
successfully modeled and simulated using the Monte Carlo BEAMNRC code by developing an
independent CM, the HDMLC CM, either in static and dynamic modes. VC 2012 American Association
of Physicists in Medicine. [DOI: 10.1118/1.3671935]
Key words: Monte Carlo, linear accelerator, radiotherapy, micro multileaf collimator, dosimetry
I. INTRODUCTION
Micromultileaf collimators are widely used in the treatment
of lesions, in techniques such as stereotactic radiotherapy and
radiosurgery,1 mainly applied to brain cancers, nonmalignant
brain lesions,2,3 and small-cell lung tumors.4 Typically, these
are small lesions which require high doses, being extremely
important to minimize the exposure to radiation of the sur-
rounding healthy tissue. Therefore, highly conformed fields
are required. The HD120 multileaf collimator (MLC) is the
most recent Varian (Varian Oncology Systems, Palo Alto,
CA) MLC which fulfills this requirement, possessing 64 inner
415 Med. Phys. 39 (1), January 2012 0094-2405/2012/39(1)/415/9/$30.00 VC 2012 Am. Assoc. Phys. Med. 415
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and 56 outer leaves whose width projects to 2.5 and 5.0 mm,
at the linac isocenter, respectively.
Multileaf collimators consist of banks of tungsten leaves5
that allow shaping of conformal or intensity modulated
fields. Due to the complex design of these devices, they are
among the most challenging geometrical structures to imple-
ment in a linac model to perform Monte Carlo (MC) simula-
tions. The leaf openings can be individually user-defined to
set irregular shapes to conform to nonsymmetric volumes.
Furthermore, the leaves have complex geometries and can
even move during beam delivery (dynamic MLC). Modeling
the details of the MLC using MC methods is considered of
primordial importance to fully account for the loss of elec-
tronic equilibrium and for the effects of the MLC tongue
and groove,6 leaf transmission, leaf side and end transmis-
sions, and abutting leaf leakage, which have a significant
impact on the penumbra and ultimately on patient dose
calculations.7
BEAMNRC (Ref. 8) is a tool used worldwide to model
and simulate the behavior of linear accelerators used in
radiotherapy. There are several multileaf collimators
available in the market from different manufacturers.
Their characteristics change according to the linac speci-
fications. Several papers have been published on BEAMNRC
simulations of different MLCs: Elekta,9 BRAINLAB M3,10
Millennium 120.11
In BEAMNRC, there was no component module (CM) that
could directly be adapted to adequately model the Varian
HD120 MLC as its design is unique, so far. The BEAMNRC
CM VARMLC,12 one of the first CM developed for MLC,
does not fully account for some physical properties of Varian
MLCs such as the leaf tips, driving screw holes, and support-
ing rail grooves. However, some studies prove that this CM
can be used, with modifications and approximations to simu-
late MLCs.10,13
The most commonly MLC implemented in radiotherapy
facilities, using Varian
VR
accelerators, is the Millennium
MLC, which has three types of leaves: full, half target and
half isocenter with projected widths at 100 cm of 10 mm,
5 mm, and 5 mm, respectively. This collimator was modeled
in an independent CM, DYNVMLC, by Heath and Seunt-
jens.11 The strategy to fully model the MLC consists in
dividing the leaves into geometrical regions. The leaves are
composed by several individual simple regions that attenuate
the particles as they traverse the entire MLC.14 Nevertheless,
due to its specificities the HD120 MLC cannot be modeled
using the DYNVMLC CM.
The main purpose of this work was to develop a Monte
Carlo model of this particular micro MLC and to incorporate
it into the 6 MV photon mode of the 2300C/D Varian accel-
erator model either in static and dynamic modes.
II. MATERIALS AND METHODS
In this section, the methods and materials used for the
simulations on BEAMNRC and the measurements, necessary
for the validation of the linac without and with the HD120
MLC, are presented.
II.A. Monte Carlo simulations





head was implemented using the Monte Carlo software
BEAMNRC (Refs. 15 and 16) (version 4-2-2-3). The detailed
geometry of the linac head was kindly provided by Varian
VR
and the specificities of each module in BEAMNRC were set
according to the technical documentation provided. The ac-
celerator model includes the target, the primary collimator,
the flattening filter, the shield, the secondary collimator, the
backup jaws, and the micro HD120 MLC. As the attenuation
of the photon beam by the monitor ion chambers and the
field mirror is negligible, these were not considered in the
simulations.17
The code implementation for this accelerator was per-
formed using BEAMNRC/EGSNRC (Refs. 15 and 16) and DOS-
XYZNRC (Ref. 18) was used for dose calculation in the
phantom. Each simulation was run using four parallel jobs in
a cluster of 2.2 GHz AMD Opteron processors at the Nuclear
Physics Centre of the University of Lisbon.
In order to improve the efficiency and to decrease treat-
ment head simulation times, some variance reduction techni-
ques were used, such as range rejection, which terminates a
charged particle’s history and depositing all its energy in the
current region, by setting ESAVE to 1.0 MeV except for the
target, where it was set to 0.7 MeV, to guarantee lower
energy photon production; uniform bremsstrahlung splitting
was set to 20 to increase the number of photons created in
the target; russian roulette was turned on and the photon
forcing option, whereby photons are forced to interact in
specified CMs, was not used. For both BEAMNRC and DOS-
XYZNRC simulations, the following transport parameters
were defined19: PCUT¼AP¼ 10 keV and ECUT¼AE
¼ 700 keV, where PCUT and ECUT define the global cutoff
energy for photon and electron transport, respectively, and
AP and AE are the low-energy thresholds for the production
of secondary bremsstrahlung photons and knock-on elec-
trons, respectively.
For the linac simulations, the phase space files containing
the details of the position, direction and energy of the par-
ticles (photons, electrons, and positrons) at the exit of the
treatment head, were generated for different sized-fields.
After the phase space data were obtained, it was used as an
input for DOSXYZNRC to calculate off-axis (inplane and cross-
plane) profiles at the source-to-surface distance (SSD) of
100 cm and percentage depth dose (PDD) profiles in the cen-
tral axis.
The particle transport validation through the accelerator
was performed in two steps: primarily only up to the jaws, to
validate the model of the accelerator without the MLC, and
afterward including the HD120 MLC.
II.A.1 Accelerator up to the jaws




linac head modeled and simulated and the components con-
sidered are displayed in Fig. 1.
Among the physical components of the linac head operat-
ing in photon mode, the modeling of the target is of
416 Borges et al.: MC modeling, simulations and validation of the HD120MLC 416
Medical Physics, Vol. 39, No. 1, January 2012
Chapter 3. Monte Carlo 94
paramount importance as it is the component where the
beam main particles are produced.20 The primary electron
beam hits the high density target originating, mainly by
bremsstrahlung interactions, photons. For the 6 MV beam,
the target is made of two layers of different materials, tung-
sten and copper.21 The manufacturer provided precise
dimensions of the flattening filter which is meant to flatten a
beam at a specific depth. The flattening filters’ composition
and density strongly influence the average energy of the
beam.22,23
The jaws are the first collimators controlled by the user
by changing their aperture to set the shape to the volume to
irradiate. There are two pairs of tungsten jaws, one pair in
the crossplane and the other pair in the inplane.
The initial electron beam energy was modeled as a paral-
lel beam, with a Gaussian intensity distribution and a mono-
energetic spectra, as also described in previous studies.24,25
There are different methods to determine the parameters of
the electron beam incident on the target, as these may vary
within linacs of the same model.26–28 The method applied in
this study was an iterative approach, described by Sheikh-
Bagheri and Rogers.22 According to this work, combinations
of energies and radius [full width at half maximum (FWHM)
of the 2D Gaussian distribution in the X-direction] of the ini-
tial electron beam that impinges on the target were simulated
in order to achieve a satisfactory match between the simula-
tions and the experimental measurements.29,30 The beam
energy was tuned to match the PDD curves and the size of
the initial electron beam was varied to match lateral dose
profiles for a 30 30 cm2 field. The energy of the incident
electron beam was varied from 5.6 to 6.8 MeV in steps of
0.2 MeV. Three values for the radius of the initial electron
beam were investigated: 0.8, 1.0, and 1.2 mm.
The simulations of the accelerator were run in two parts:
first, the linac was simulated only with its fixed components
(before the jaws, see Fig. 1); this output phase space file was
then used to simulate the patient-specific part of the acceler-
ator which consists on the jaws and, if present, the MLC con-
figurations under investigation. The phase space files were
scored at a distance of 100 cm from the front face of the tar-
get. These phase space files were then provided as input to
the DOSXYZNRC to calculate the dose distributions in a water
phantom. The calculated lateral and PDD profiles of squared
fields of 3, 5, 10, 15, and 30 cm2 were compared to the corre-
sponding experimental measurements.
About 5 108 electrons were run in BEAMNRC for simulat-
ing the fixed part of the accelerator. This phase space file,
containing mainly photons but also electrons and positrons,
was then used for the simulation of jaw-defined fields: for
smaller than 5 5 cm2, about 1.5 109 particles (mainly
photons) were used whereas for the larger fields (larger than
10 10 cm2), 109 particles scored in the phase space file
were simulated. In DOSXYZNRC, about 109 photons were simu-
lated in the water phantom for the smaller fields and about
2 109 particles for the larger opened fields, in order to
obtain a maximum uncertainty of 2% (2 SD) and to avoid
excessive incident particle recycling. Recycling particles
affects the statistics by increasing the dose uncertainties;
however, these effects are less dramatic for photons along
the central axis.31
II.A.2. Accelerator including the HD120 MLC
The micro HD120 MLC consists of two banks with 60
leaves pairs each, driven by independent motors, computer
controlled from a remote location. This specific MLC has
two different types of tungsten leaves: 32 central leaves of
2.5 mm in width (quarter leaves) and the 28 outer leaves of
5.0 mm width (half leaves). All reported dimensions are pro-
jected at the linac isocenter. Furthermore, these two types of
leaves are arranged in an alternated way in which isocenter
leaves (thicker end of the leaf is toward the isocenter) and
target leaves (thicker end of the leaf is toward the target) are
intercalated. The material of the leaves is a tungsten alloy
whose density may vary, depending on the alloy composition
and leaf manufacturing. The geometry and constituent mate-
rials of the HD120 MLC were implemented according to the
manufacturers’ data. The tungsten-based MLC alloy used in
the simulations was composed by 90% 74W, 6% 28Ni, 2.5%
29Cu, and 1.5% 26Fe, as it is the same material as for the Mil-
lennium MLC.11 The upper edge of the MLC, Zmin, was
specified to be 47 cm below the target; the interleaf gap was
set to 0.0047 cm. The leaf ends are rounded with a radius of





The different components considered in the model are displayed. The
HD120 MLC may be present (if not retracted) after the jaws to conform to
the volume to be irradiated.
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curvature of 16 cm and the leaves are 6.9 cm thick. A sche-
matic drawing of the MLC is shown in Fig. 2.
A new BEAMNRC CM, designated HDMLC CM was
developed to include the specific characteristics of this
MLC by making modifications to the original DYNVMLC
CM to include half target and half isocenter leaves as outer
leaves and quarter target and quarter isocenter leaves as
inner leaves. Their geometries were changed in the
DYNVMLC_macros.mortran and DYNVMLC_cm.mortran
files of BEAMNRC and these files were called HDMLC_
macros.mortran and HDMLC_cm.mortran, respectively. In
the input file, the details of the leaves such as the dimen-
sions of the tongue, groove, screw holes and rails were
specified at Zmin.
The maximum opening dimensions of this MLC, projected
at the isocenter are 22 cm by 40 cm, in the inplane (y) and in
the crossplane (x), respectively, with the collimator at 0. The
leaves of this MLC can be set moving along the x direction,
to different shapes and to guarantee conformity to the volumes
to treat.
The MLC model in the DYNVMLC component module
divides the MLC leaves into several geometrical regions
which together represent, as realistically as possible, the MLC
geometry. The relevant simulation parameters, namely, the
abutting leaf gap, the MLC density, and Zmin, were adjusted
in order to minimize the discrepancies between the simulation
results and the measurements performed. In order to avoid
damages that would result from physical collisions between
the leaves, there is a small air gap between opposing leaves.
Due to this feature, and the fact that the leaf ends are rounded,
simulations of the leakage between opposing leaf pairs had to
be further investigated. Therefore, simulations of a closed
field (MLC closed at the center x¼ 0 and the jaws set to
10 10 cm2) were done to determine the abutting leaf gap.11
An open 10 10 cm2 field with the MLC retracted and the
same field with the MLC leaves closing beyond the jaws
(blocked field), varying the MLC material density, were simu-
lated in order to estimate the transmission properties of the
HD120 MLC. Zmin was adjusted by comparing simulated and
measured alternated leaf pattern fields. The blocked and
closed fields were measured using film dosimetry in a solid
water phantom and the alternated fields using a diode in a
water phantom, at the SSD of 100 cm, at 5 cm depth. For the
closed and blocked fields, 16 109 particles were simulated
in BEAMNRC. For the closed field about 4 107 particles
reached the water phantom surface; whereas for the blocked
field, the number of particles at this level was approximately
of 2.4 107 particles. These particles were used in the DOS-
XYZNRC for simulating 1.0 109 particles in the phantom. The
voxel size used was 1 1 mm2 for both the inplane and the
crossplane and 2 mm in depth. On these simulations, incident
photons were recycled about 20 times for the closed field and
approximately 40 times for the blocked field, to guarantee a
3% (1 SD) statistical uncertainty.
To perform the validation of the MLC, taking into consid-
eration the rounded edge leaves implemented in the model,
opened MLC-defined fields of different sizes were simulated.
The computational conditions were similar to the opened
fields only defined by the jaws, as previously defined.
Other fields with irregularly shaped patterns were also
simulated, in order to validate the model of tongue and groove
design implemented with the HDMLC CM.
Accurate dose calculations for segmental MLC or
dynamic MLC (dMLC) is even more challenging and Monte
Carlo simulations are recognized as the most accurate meth-
odology for patient dose assessment. For simulating complex
types of treatments in radiotherapy such as IMRT (Intensity
Modulated Radiation Therapy), all the characteristics of the
MLC leaves have to be taken into account.11,14,32 The
method for implementing the dynamic mode was the same
used by Heath and Seuntjens.11 An MLC sequence file gen-
erated by the planning system or the user with the different
MLC projections at 100 cm as a function of the fractional
monitor units of the total beam delivery was used in the
FIG. 2. Schematic representation of the HD120 MLC geometry. This MLC has half and quarter tungsten-based alloy leaves. Both types of leaves have target
and isocenter leaves. Drawings not to scale.
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input file for transporting the particles through the MLC.
The particles that traverse the MLC are written to a phase
space file that is used as input for MC calculations in the
water phantom.14
II.B. Measurements
In order to validate the simulations, measurements were




linac using a 0.125 cm3
PTW
VR
, model 31001, ionization chamber in a water phantom
PTW FREIBURG
VR
, model 41006. The phantom was con-
nected to the PTW
VR
software MEPHYSTO MCC to automatically
control the phantom for data acquisition of dose distribution
and analysis of radiation profiles. A p-type silicon PTW
VR
diode, model 60016, was used for measuring fields smaller
than 5 5 cm2 and to measure the alternated MLC field. The
uncertainties associated with the ionization chamber system
acquisition are estimated to be about 2%, according to the
IAEA TRS 398 protocol.33
For the validation of the HDMLC, measurements were
also performed using GAFCHROMIC
VR
EBT2 films placed
into a solid water phantom. Measurements were performed
at the SSD of 100 cm, at 5 cm depth in the phantom, to
match the conditions defined in the simulations. The films
were processed in an Epson 10000XL flatbed scanner and an-
alyzed in the software FILMQATM. The EBT2 film uncertainty
is considered to be about 3% according to recent work.34
An independent perpendicular film calibration was per-
formed, to convert optical density into dose for each profile,
by exposing different parts of the film to different monitor
units (MU), ranging from 0 cGy to 230 cGy, at 5 cm in a
solid water phantom.
For the blocked field, the film was irradiated with 10 000
MU and the closed field was irradiated with 800 MU. An
opened field of 10 10 cm2 was irradiated with 200 MU to
assess the transmission characteristics of the MLC. To verify
irregular shaped-fields, a repeated pattern consisting of one
leaf closed and two leaves opened was measured using a
photon diode in a water phantom. The dose distributions of
the dynamic fields were measured using film dosimetry.
III. RESULTS AND DISCUSSION





linear accelerator for the 6 MV
beam was done by comparison of the measurements per-
formed without and with the HD120 MLC incorporated.
III.A. Accelerator up to the jaws
The best agreement between the Monte Carlo simulation
results and the measurements performed was obtained for an
incident electron energy of 5.8 MeV and a Gaussian intensity
profile with a FWHM of 0.12 cm. The comparison between
the calculated PDD and off-axis profiles and the measure-
ments performed using ionometric dosimetry are displayed
in Fig. 3, for several square fields.
Analyzing the phase space files, in all the opened fields,
more than 5 107 particles were scored after the jaws, from
which 99.7% were photons whilst the remaining were elec-
trons and positrons.
For the beam profiles, the MC statistical uncertainty is
below 2% (2 SD), for all fields. Differences of about 2%
were obtained for the flat region of all the fields when com-
paring the experimental results with the simulations.
When comparing the simulated PDD curves with the cor-
responding measured curves, the results in the build-up
region present discrepancies lower than 4% and 2% before
and after the build-up region, respectively.
III.B. Including the HD120 MLC
The geometry and constituent materials of the HD120
MLC were implemented according to the manufacturers’
FIG. 3. Validation of the simulations of the Trilogy accelerator up to the jaws using ionometric dosimetry: on the left, lateral profiles, of the squared fields 30,
15, 10, 5, and 3 cm2, at 5cm depth; on the right, depth dose profiles of the squared fields 3, 5, 10, 15, and 30 cm2. The maximum dose values of the profiles of
30, 15, 10, 5, and 3 cm2 fields were normalized to 1, 0.8, 0.5, 0.35, and 0.25, respectively. The continuous lines correspond to the film measurement whereas
the full dots correspond to the MC simulation.
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data. The relevant simulation parameters, namely the abut-
ting leaf gap, the MLC density and Zmin, were adjusted in
order to minimize the discrepancies between the simulation
results and the measurements performed. The abutting leaf
gap was assessed by simulating a closed MLC field; the
MLC material density was determined with a blocked field
in which the MLC closed beyond the jaws opening and Zmin
was adjusted using alternated leaf pattern fields. The blocked
and closed fields were measured using film dosimetry in a
solid water phantom and the alternated fields using a diode
in a water phantom, at the SSD of 100 cm, at 5 cm depth.
III.B.1. Ray tracing
After the HD120 MLC was implemented, its geometry
was visualized by tracing particles produced through the CM
and recording their position when a leaf boundary is crossed.
These positions were then plotted in 2D projections, as
shown in Fig. 4.
On Fig. 4, from the left to right, there are the 14 half, 32
quarter, and 14 half leaves, respectively, in each bank; target
leaves are intercalated with isocenter leaves. It is possible to
visualize the details of the leaves such as the driving screw
holes, as air gaps, in the widest part of the leaves, and top
and end details of the leaves.
III.B.2. Tuning of the MLC: assessment of the density
of the leaves and of the abutting gap
The MLC leakage radiation, obtained by Monte Carlo sim-
ulations varying the MLC material density was compared
with film measurement in a direction perpendicular to the leaf
motion. Simulations were performed with densities ranging
from 17.0 to 19.0 g cm 3 and it was observed that the mate-
rial density is one of the properties that affect the radiation
profile that traverses the MLC. For the densities of 17.0, 17.5,
18.0, 18.5, 18.7, and 19.0 g cm 3, the following average
interleaf leakage values obtained were 1.55%, 1.44%, 1.26%,
1.15%, 1.10%, and 1.03%, respectively. The MC simulation
uncertainties are about 2% (1 SD). The best agreement
between simulation results and measurements is displayed in
the left plot of Fig. 5 and was obtained for a density value of
18.7 g cm 3. With this result it is possible to estimate an av-
erage interleaf leakage of about 1.10% 6 0.03%, in the central
part of the MLC. The profiles presented in Fig. 5 are normal-
ized to the open 10 10 cm2 field. The maximum discrepancy
between the dose peaks and troughs comparing film dosimetry
with the simulations is of 15%. The average discrepancies
between the simulation and measurement are about 8%. These
discrepancies were accepted as the film is only exposed to
low doses and its response in this range of doses is sensitive
making these measurements very challenging, even using
radiochromic EBT2 films.35
FIG. 4. Ray tracing of the HD120 MLC. The leaf geometry (XZ plane) was
visualized by tracing particles through the CM and recording their position
when a leaf boundary is crossed.
FIG. 5. Comparison of 6 MV MLC leakage profiles at the positions indicated by the lighter lines on the figures located inside the graphs, on their top right cor-
ners. On the left, determination of the leaf density using a MLC-blocked field, profile taken at 1 cm offset from the central axis, with a density of 18.7 g cm 3.
On the right, assessment of the abutting gap between leaves of 0.03 cm, in the central axis. The continuous line corresponds to the film measurement whereas
the full dots correspond to the MC simulation. The results were normalized to the opened 10 10 cm2 field.
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The abutting gap was determined by simulating a closed
field in the central axis, with the collimator set to 0. Several
simulations were performed in these conditions, with abut-
ting gaps ranging from 0.002 to 0.04 cm (in 0.002 cm steps
up to 0.01 and 0.01 cm steps from 0.01 to 0.04 cm). The sim-
ulation result that best reproduces the measurements is dis-
played in Fig. 5 (right) and corresponds to an abutting gap of
0.03 cm. The leakage between abutting leaves is estimated
to be 20.5 6 1%. The MC relative uncertainties are about
2% (1 SD) and the discrepancies between measurements and
simulations are within 2%.
III.B.3. Irregular MLC pattern
A MLC static pattern was performed in order to evaluate
how accurately the tongue and groove effect is handled by
this new CM. This field is defined by a repeated pattern of
one leaf closed and two leaves opened beyond the backup
jaws which were set to 10 10 cm2. The measurements
were performed with the p-diode in a water phantom, at
5 cm depth, at the SSD of 100 cm. The profiles were taken in
the inplane direction, at an offset of þ1 cm from the central
axis, as shown in the right side of Fig. 6. The relative dose
distribution as function of the position is displayed in the
graph of Fig. 6. Both the MC profile and the measurements
were normalized to 1 as maximum relative dose. The MC
relative uncertainties are about 2% (1 SD). A good agree-
ment is visible, with discrepancies between the simulation
results and the measurements below 4%.
III.B.4. Ionometric measurements
With all the details of the MLC defined, the opened fields
of 2 2, 3 3, 5 5, 10 10, 15 15, and 30 22 cm2
with the jaws set to 4 4, 5 5, 7 7, 12 12, 17 17, and
32 22 cm2, respectively, were simulated. The obtained
results were compared against the ionometric measurements
performed using a water phantom with a 0.125 cm3 ioniza-
tion chamber for fields larger than 5 5 cm2 and a photon
diode for smaller fields. The off-axis profiles along the cen-
tral axis, at 5 cm in depth and depth dose distribuitions are
displayed in Fig. 7.
For the relative dose profiles, on the left, a good agree-
ment between the computational results and the measure-
ments is evident, as for most points, the simulated profiles
agree with the measurements to within 2%; as for the PDD
profiles, the discrepancies between the calculated and the
measured profiles are at the level of 2% after the build-up
region and within 4% in the build-up region, for all fields.
III.B.5. Dynamic mode
As the HD120 MLC has been designed to perform IMRT
treatments, its dynamic mode of operation was implemented
in BEAMNRC. The implementation method used was similar to
the one existing for the DYNVMLC CM. The comparison
FIG. 6. Comparison of 6 MV off-axis profiles, at þ1 cm off-axis from the
central axis for a static MLC pattern with two leaves opened and one closed
alternately, as represented by the film image placed in the right side of the
figure. The results are normalized to 1, for the maximum dose; the continu-
ous line represents the measurements, whereas the dots correspond to the
simulation result using the HDMLC CM.
FIG. 7. Comparison of off-axis (on the left) and PDD (on the right) profiles of the opened MLC-defined fields of 2 2, 3 3, 5 5, 10 10, 15 15, and
30 22 cm2, normalized to the 0.15, 0.25, 0.35, 0.5, 0.8, and 1.0 the maximum dose, respectively, at 5 cm in depth. The dots correspond to the MC simulation
results whereas the continuous lines correspond to the measurements.
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between the obtained simulated result and the film measure-
ment performed is displayed in Fig. 8.
The MC uncertainties are at the level of 2% (2 SD). The
discrepancies between the simulated results and the meas-
urements are below 5% with exception of the penumbrae
region, presumably due to the poor response of EBT2 films
to low dose. It is also possible to notice that the higher
discrepancies occur at the field edges presumably due to
inadequate resolution of the film calibration curve at low







(2300 C/D) linear accelerator
including the HD120 MLC was successfully modeled and
simulated using the Monte Carlo BEAMNRC code and the
newly developed CM, HDMLC CM.
In a first step, the linac was modeled in the absence of
MLC; the nominal value of the mean energy and the parame-
ters characterizing the spatial distribution of the primary
electron beam used in the MC simulations were determined
as those values which minimize the discrepancies between
the Monte Carlo simulation results and the measurements
performed, for the depth dose distributions and off-axis pro-
files in a water phantom.
Overall, a good agreement between the MC simulations
and the measurements performed using ionometric and film
dosimetry was obtained; for the off-axis profiles the discrep-
ancies between the simulation results and the measurements
are smaller than 2%, whilst for the PDD distributions the dis-
crepancies are smaller than 2% after the build-up region and
below 3% in the build-up.
In a second step, the HDMLC CM, was implemented in
BEAMNRC in order to model the specific characteristics of the
new High Definition multileaf collimator (HD120 MLC)
equipping the aforementioned Varian
VR
linac. The HDMLC
CM was developed adapting the DYNVMLC CM created by
Heath and Seuntjens.11 With the HDMLC CM it is possible
to simulate the micro HD120 MLC using either static or
dynamic fields and taking into account the transmission,
effect of tongue and groove design of the leaves.
The specific characteristics of the HD120 MLC were
assessed using film dosimetry (GafChromic EBT2). The
agreement achieved for the closed and blocked fields was
about 2% and 8%, respectively, considered satisfactory due
to the nature of the measurement involving low doses. The
validation of the implemented computational model against
measurements was also performed for other irregular static
MLC patterns. The discrepancies between MC simulation
results and measurements for an alternated pattern are about
4%. Measurements on off-axis and PDD profiles using ioni-
zation chambers were compared to the correspondent simu-
lations for opened MLC-defined fields. The discrepancies
were found to be about 2% for the off-axis profiles and
below 5% in the build-up region and about 2% after the
point of maximum dose for the PDD profiles. The dynamic
mode of the MLC was implemented in BEAMNRC and a rea-
sonable agreement was obtained, with discrepancies within
4% between simulated results and measurements using film.
The newly developed HDMLC CM fully models the
details of the four different types of leaves taking into
account the contribution of leaf leakage scatter and tongue
and groove effects. This is of paramount importance when
patient dose distributions are considered. The new High
Definition MLC is now modeled by an independent BEAMNRC
CM, HDMLC, to accurately simulate radiotherapy treat-
ments, using Monte Carlo techniques, either in static and
dynamic modes.
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Is the delivered dose, the real dose prescribed by the radiation oncolo-
gist?
There are three important and distinct concepts to the dosimetrists and physicists
realities: what we want; what we see; what is real but we can not see.
In this chapter, the breast treatment techniques are presented along with the
treatment plan calculation algorithms used throughout this work. The evaluation
criteria for each of the techniques and algorithms are also provided.
4.1 RT to the breast
Breast cancer is a challenging site to treat due to its particular shape: the breasts
are prominent concave structures, typically of homogeneous tissue, that are on
top of the ribs (bone), right after the lungs and the heart (in the case of left
breast) which are critical and essential organs. These are also highly heterogeneous
media. Furthermore, with the lungs right underneath and the necessity of women
to breath, there is also movement of the thoracic cavity. The skin is also an
important tissue as radiogenic issues should be avoided.
The treatment plan in RT contains all the irradiation parameters of the treat-
ment that will be administered to the patient. These included: the number of
beams, their position, orientation, fluence distribution as well as the MU. These
dose distributions are calculated by algorithms, given the prescribed dose and the
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constraints. In a treatment plan, the dose distribution should be uniform on the
target volume and the critical OAR should receive a dose inferior to the tolerance
levels, specified by the institution protocol or the radiation oncologist. In the
breast, it is difficult to obtain homogeneous dose distributions, due to the shape of
the breast and the different densities of the types of tissues. Therefore, for some
treatment plans of breast cancer, the dose distributions may be heterogeneous,
with regions receiving doses superior to the prescription, leading to an increase
in toxicity in the normal tissues and poor cosmetic results, or with under-dose
regions which may result in the failure of tumor control and ultimately the goal
of the treatment.
In particular for breast cancer, one of the main concerns is the occurrence of acute
and late secondary effects, induced by radiation, once there are many patients
being treated to this pathology and the survival rate is high, when compared to
other pathologies. The acute symptoms induced by radiation can occur up to 6
months after RT, changing then to a chronic fibrous state. The complications due
to breast RT can be classified into:
• Acute secondary effects (occur between the 2nd and the 3rd week after the
RT start): radiodermitis, skin erythema, desquamation of the inframammary
fold or the axillar fold (specially in large breasts), pruritis, fatigue and aching
breast.
• Late secondary effects (occur 3 to 6 months after the RT conclusion): breast
fibrosis, arm lymphedema, brachial plex dysfunction, reduction and/or breast
hardening, pain and breast sensibility, shoulder tension, arm paralysis, rib
fracture, pulmonary toxicity (such as radiogenic pneumonitis or apical pul-
monar fibrosis) or cardiac toxicity (such as cardiac ischaemia symptomatic
cardiac lesion, accelerated atherosclerosis or pericarditis). Some patients may
even develop secondary tumors, related to the radiation exposition.
Moreover, the RT treatment after breast conserving surgery may be related to
the increase of acute and late secondary effects, due to the unwanted exposure
of healthy tissues to radiation, affecting the life quality of the patients and their
survival possibilities. Thereby, the effects in the OAR are significant and constitute
a real clinical problem, in breast cancer, in which the secondary effects may reduce
the survival results aimed with RT. The awareness of the potential effects induced
by radiation has been contributing to an extra effort to reduce the dose in the
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healthy tissues, through new RT schemes, the re-definition of the target volume
and new dose constraints.
However, it is not possible to completely avoid the exposure of the healthy tissues
to the radiation. For left breast cancer patients, where the heart is unavoidably
involved in the treatment radiation fields, there is scientific evidence [136, 137] in
the increase of complications, especially on what the cardiovascular disease and
mortality are concerned, when compared to right breast cancer patients. In this
particular case, the cardiac mortality may decrease the survival rate of the breast
patients and it is therefore important to analyze the risk of complications when
planning the treatment.
Understanding the risk of late toxicity in the dose-volume relationships is clinically
more relevant with the active investigation of new treatment techniques. However,
the aim of increasing the cure has to be balanced with dose given to the normal
tissues and their response to radiation. Any change in the treatment regimen, such
as the use of advanced techniques, dose escalation, introduction of chemotherapy
or other biologic agents, will change the therapeutic ratio. The challenge of the
radiation oncologist is to guarantee that any change will improve this ratio and
that a dose increase won’t lead to secondary effects.
Current breast irradiation schemes in RT are whole breast irradiation or partial
breast irradiation, as presented in the following.
4.1.1 Whole breast irradiation (WBI)
The principle of WBI is based on irradiating microscopic foci of mammary car-
cinoma in the mammary gland and in node-positive patients also loco-regional
lymph nodes with doses of 50 Gy in 25 fractions delivered as daily treatment 5
days per week for 5 weeks. Large trials demonstrated this is a safe procedure
with local failure rates of 0.5 –1% per year of follow-up and acceptable side ef-
fects and cosmetics [27]. The Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) systematic review [138] confirmed a 75% reduction in local recurrence
risk after RT.
Over recent years, different techniques have been established for irradiating the
breast. The techniques explored in this work for WBI are presented in section 4.4.
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4.1.2 Accelerated Partial Breast Irradiation (APBI)
The local recurrence rate after breast conserving strategy has decreased steadily
over the last decade due to improved surgery techniques, more effective chemother-
apy and hormonal therapy, CT-based RT and also the criteria for offering the
patients adjuvant therapy have decreased so that fewer patients are now classified
low risk. The incidence of early breast cancer has peaked in the USA, and since
2002 also in Europe, and adjuvant breast RT is a heavy burden in the RT facilities
[139].
The rationale for APBI is derived from studies reporting that the majority of first
local relapses are in or close to the surgical cavity; on the assumption that ra-
diotherapy does not prevent the development of new primary tumors developing
elsewhere in the breast and on the wish to spare the patient late radiation morbid-
ity. The reduction on treatment volume and increasing fraction dose, this form of
treatment can be completed in a single week (significantly reducing the duration
of the treatment when compared to WBI), allowing more patients to benefit from
BCT. ASTRO Society recently published the first guidelines for APBI [140].
Many centers are now investigating partial breast irradiation in phase I and II
trials. Large randomized phase III trials are running at the present time in North
America (NBSABP/RTOG), Canada (OCOG\RAPID), Europe (GEC–ESTRO,
IMPORT–LOW), Milan and UK (Targit) [141, 142].
The eligibility for BCT is assessed by clinical examination, imaging studies, pathol-
ogy, individual preference, and expected cosmetic outcome (best with small tumor
to large breast size). Considering a cost-effectiveness perspective [143] if a patient
is randomized to APBI it can be performed using:
• RT delivered as 3D-CRT;
• intraoperative radiotherapy (IORT);
• interstitial brachytherapy: 34 Gy/10 fractions, with 2 fractions daily (5 days)
using HDR (High Dose Rate); and
• MammoSite device
APBI and hypo-fractionated WBI are treatment approaches that promise both
reduced overall treatment times and the potential for increased use of breast-
conservation therapy [144, 145].
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4.2 Breast cancer patient in the RT department for EBRT
4.2.1 Medical decision
The patient is indicated to the RT department after a multidisciplinary medical
decision meeting. It is essential that the medical community identify the risk
factors involved in the probable complication caused by radiation. The patient
then goes to a first consultation with the radiation oncologist where she/he is
informed of the benefits and risks when undergoing RT treatment. The patient is
told about the treatment and how to minimize the probable radiation late effects.
In some cases, the late damage effects are unavoidable when the cure is aimed.
After all the indications, the patient decides whether to perform the treatment (or
not) and in case of agreement, she/he signs an informed consent declaration.
4.2.2 Imaging
After the medical consensus that the patient gathers all the necessary conditions
to perform RT, the patient undergoes a CT scan that is required for treatment
planning.
4.2.2.1 CT considerations
For the purpose of this study, the slice thickness used was 3 mm and the images
were acquired with the Siemens Biograph 64R, CT scanner that can be seen in
figure 4.1.
The CT scanner is composed by two main systems:
• acquisition;
• signal treatment.
The acquisition system is made of a X-ray source and a detector. It provides the
necessary information for the image reconstruction. The treatment signal system
reconstructs the 2D or 3D image according to the scanner characteristics and the
applied reconstruction methods. The CT slices provide 3D information on the
tissue density distribution. The slices are then transferred to the TPS, so that:
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Figure 4.1: CT scanner used for scanning the phantoms and the patients.
1. the radiation oncologist contours the target volumes and the OAR for plan-
ning the treatment; and,
2. the patient treatment dose calculations take into account the density varia-
tions of the different tissues involved.
4.2.2.2 Heterogeneities and electronic densities
The CT represents a precise geometry model of the patient, providing electronic
density data necessary for the 3D dose calculations, taking into account the het-
erogeneities in the different tissues.
In practice, the patient is viewed as a volume divided into small elements, or
voxels. To each voxel, it is associated a Hounsfield number (HU). The HU value
of each voxel permits, through a calibration curve, to determine the electronic
density of the tissue within the voxel and to characterize the x-ray interactions
within that volume.
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, where µ is the linear attenuation coefficient at the pixel position, which are
dependent on the x-rays spectra of the CT-machine. In general, the CT numbers
range between +1000 HU and -1000 HU from bone to air, respectively, while, by
definition, the water has a CT number of 0 HU.
4.2.2.3 Breast patient CT scan
The patient is laid down in an immobilization device, the breast board (see figure
4.2), in supine position, with the ipsilateral arm lifted up, for arm comfort and
to ensure a stable and reproducible position that will be repeated during the
treatment course.
Figure 4.2: Breast board immobilization device.
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Before the scan, the technician imprints marks at the patients’ skin along the
midline and the external border of the breast, for guidance while planning the
treatment fields. A radiopaque wire is placed to mark the tangential field borders,
which will remain marked during, at least, all the treatment sessions. The superior
and inferior field borders are placed at about 2 cm beyond clinically palpable
breast tissue. The medial border is set in the midline of the sternum, and the
lateral border along the midaxillary line. A radiopaque wire may also be used to
cover the surgical scar.
A representation of the imprinted marks is given in figure 4.3.
Figure 4.3: Schematic representation of the marks placed on the breast patient skin
for helping contouring and positioning.
Then, the scan is acquired from the midneck (just below the mandible) to several
centimeters caudal to the breasts, ensuring that the entire breast and the markers
at the skin near the ipsilateral and contralateral lower axilla are included in the
scan volume.
The CT planning is clearly superior to the previous 2D calculations based on
orthovoltage orthogonal images, permitting to easily and precisely evaluate, the
tumoral bed, the mammary gland and the adjacent structures like the heart, lung
or contralateral breast exposed during the RT treatments, in terms of volume
included in the beams and the dose they are exposed to. These conformal fields
lead to using more beams, which are adjusted with the aid of the BEV (Beam’s
Eye View), to provide conformation confined to the target volume.
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The 3D planning techniques demand rigorous quality control measurements, repro-
ducibility of the patient positioning, using imaging acquisition so that the patient
receives the planned dose and treatment. Conformal RT has reduced significantly
the incidence of late adverse effects and improved the life quality of the patients,
by reducing the healthy tissues volume irradiation.
4.2.3 OAR volumes involved in breast RT
Before planning, it is necessary that all the target volumes and OAR are contoured.
The main OAR involved in breast RT treatment are:
• the lungs - mainly the ipsilateral one;
• the heart - particularly in left breast cancer;
• the medulla;
• the contralateral breast; and
• the esophagus.
Other considered structures may be the muscles and the ribs. The dose that reach
these structures can be quantified visually by analyzing the dose distribution and
graphically through dose-volume histograms. The dose tolerances are defined by
the radiation oncologist and despite the goal to adequately irradiate the PTV, the
dosimetrist plan aims at respecting these constraints.
The OAR can be located at a significant distance, in the vicinities or inside the
PTV, and should be considered when planning the treatment. It may happen
that the total dose may be limited by the dose to the OAR, in order not to
exceed the limits. A careful assessment of the risks in the normal tissues, with the
possible consequences of loss of tumor control needs to be done by the radiation
oncologist. Not prescribing enough dose to the PTV may be more dangerous than
exceeding the dose constraints in the OAR due to the increased risk of primary
tumor recurrence. Therefore it is essential to consider the severity of the effects,
the possible consequences of the local recurrence and the way the patient will
tolerate RT [37].
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4.2.4 To treat or not treat the axilla?
Depending on the ganglia analysis results, the medical team will decide whether
the ganglia (region identified in figure 1.3) will be also treated with radiation
therapy. In case this region is included in the treatment fields, the strategy for
treating these volumes is adapted.
4.2.4.1 Breast irradiation without axillary involvement
For this type of treatment, the beam isocenter is, at first, chosen to be, approx-
imately, in the center of the breast parenchyma. Depending on the irradiation
technique chosen, the procedure may vary. Specific details for each technique are
provided in section 4.4. The aim is, nonetheless, to cover the all PTV with at least
the 95% isodose and without high hot spots, avoiding the OAR.
4.2.4.2 Breast irradiation with axillary involvement
When axillary irradiation is prescribed, the match line is set at the level of the
caudal edge of the sternoclavicular junction [146]. To prevent divergence of the
tangential into the axillary fields, the isocenter of both sets of fields is chosen to
be the same, at the transition between the superior border of the tangents and
the inferior border of the axillary fields. The isocenter is found with the aid of
an anterior and a lateral fields to determine the center of the volume in these
projections. The tangential fields are defined according to the criteria referred
above. In the past, in 2D planning, the axillary nodes used to be irradiated
with an anterior supraclavicular field (rotated 15◦ in the opposite direction of the
medulla), with the MLC protecting the arm and the umerus, and a posterior field
(low weighted field with a maximum height up to the top of the umerus) defined
with the appropriate MLC protection to the lung, umerus and clavicula.
Nowadays, with a precise contour of the ganglia on the CT images, other fields with
different beam incidences should be chosen to avoid hot spots and high dose on the
lung apices, on the umerus and on healthy tissues [147]. There is a study proving
that the location of the nodes varies according to the patients anatomy being
therefore more precise to draw the nodes involved and conforming the irradiation
fields to the volume delineated [148]. In the case of this study, breast without
axillary irradiation was investigated because with ganglia involved, the treatment
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involves a hemi-field technique which is difficult to accomplish in this linac because
of its small maximum field size of 22× 40cm2.
4.2.5 Contouring and dose prescription
The images acquired in the CT scanner are imported to the TPS. The first task
consists in creating a 3D image where the delineation of the volumes will be made.
The structures typically created for breast treatment are the external contour
(usually called Body, which is compulsory to perform calculations), lungs, bones,
medulla, heart, contralateral breast and the volumes to irradiate, CTV, GTV and
PTV. These structures are delineated by the radiotherapy oncologist. Typically,
the PTV is defined 3 mm subdermally, in the radial direction.
The contouring is considered a subjective task as the identification of these volumes
may vary significantly depending on the person and their background education
[149, 150]. The radiation oncologist is also responsible for the dose prescription to
the target volumes, at this time.
An example of a breast cancer patient CT image 3-dimensionally contoured is
presented in figure 4.4.
4.2.6 Planning the treatment
After the physicians’ contouring and prescription, the dosimetrists’ first procedure
is to define the CT isocenter to register it in the TPS in order to establish the link
between the image and the patient.
The next step is to define the beam isocenter. Its choice depends on whether
axillary nodes irradiation is required. For WBI without axillary involvement, the
isocenter is defined at the center of the PTV whereas for breast irradiation with
axillary involvement, the beam isocenter is set at the transition between the breast
and the axillary ganglia involved.
Actual standards in RT establish a dose of 50 Gy to the tangential fields in stan-
dard fractionation of 1.8–2.0 Gy/fraction using photons of 6 MV or mixed-beam
energies of 6 MV and 15/16 MV. To achieve an optimal treatment, it is necessary
to accurately correlate the target volume and the OAR with the positions and
orientations of the beams used for planning and subsequent treatment.
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Figure 4.4: Example of a cancer patient for breast treatment with the contouring
prepared by the radiation oncologist: in red, the PTV; in pink, the heart, in blue, the
lungs.
A boost1 to the tumor bed can be used according to the physician criteria, usually
varying from 10 Gy to 20 Gy, using either photons or electrons depending on its
location to decrease the risk of tumor relapse in the tumor bed [151, 152]. Large
trials demonstrated this is a safe procedure with local failure rates of 0.5 - 1%
per year of follow-up and acceptable side effects and cosmetics [27]. Significantly
fewer local failures were seen among young patients (<50 years) who received an
additional boost of 16 Gy in 8 fractions to the tumor bed [153].
The clinical validation of the treatment plan(s) consists in analyzing the dose
distribution in the 3D image of the patient. The validated plan by the radiation
oncologist and the medical physicist should verify two goals:
• the calculated dose contains the tumoral lesion with a good coverage;
• and respect the dose constraints for the OAR.
The TPS creates digitally reconstructed radiographs (DRR) for anterior-posterior
(AP), lateral setup beams and tangential treatment fields, to verify the correct
positioning of the patient before the treatment.
1Boost: extra dose to the surgical loca.
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Figure 4.5: Anterior and lateral DRR, on the left and right, respectively
4.2.7 Initial treatment setup
On the first day of treatment, the patient is placed in the same position in the
custom-made board that was used at the time of the CT scan. The patient is
then aligned according to the marks and the AP and lateral SSD (source to skin
distance) are verified. Once it has been determined that the SSD are correct, AP
and lateral port films are acquired and compared to the AP and lateral isocenter
DRR, respectively. If the physician considers the setup satisfactory, the medial
tangential field is set and a port film is obtained and compared to the medial
tangential field DRR. Once approved, one proceeds to the lateral tangent field for
which it is also obtained a port film. After this lateral tangent field port field has
been approved by the physician, its dose delivery is initiated.
4.3 Dose calculation: TPS algorithms
The calculated dose entails different types of uncertainties associated to the TPS
and its calculation algorithm. The slightly unadapted doses can reduce the treat-
ments’ efficacy or increase the complication risk in the healthy tissues. A dose
variation of 5% may lead to 20%-30% variation in the risk of complications in the
healthy tissues [62]. It is expected that reducing the dose uncertainties leads to
more predictable and reproducible results to the prescribed dose, given the per-
sonal variability reactions of the patients. In practice, the radiation oncologist
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validates the dose calculated by an algorithm, if it is within a theoretical accept-
able range. Therefore, the dose calculation method should be the most accurate
to decrease the uncertainty in the dose calculation associated to the treatment.
4.3.1 Commercial RT systems using MC dose calculation
Modern cancer treatment techniques, such as IMRT and stereotactic body radi-
ation techniques have increased the demand for more accurate dose calculation
tools, along with more precise target and OAR volume delineation and precise
delivery. One of the actual opportunities of RT departments is to use fast and
accurate MC dose calculations within the TPS [59, 154].
Several challenges have historically impeded the clinical implementation of MC
dose calculation algorithms. The most significant reason was insufficient compu-
tation available for dose calculations to be performed within a reasonable time
frame. Along with consistent advances in computer science, many variance reduc-
tion techniques have been implemented in today’s MC simulation codes in an effort
to improve efficiency [84, 91, 113, 122, 155–158]. Although still requiring signifi-
cantly more computation than conventional dose calculation techniques, MC dose
calculation times were reduced, in some TPS, to the point of clinical acceptabil-
ity. PEREGRINE (North American Scientific: Nomos Division) was the first TPS
with MC dose calculation for EBRT approved by Food and Drug Administration
(FDA). PEREGRINE, developed at the Lawrence Livermore National Laboratory,
implemented a modified version of the EGS4 library with a new condensed history
electron transport algorithm. VMC codes are also making their way into many of
the latest commercial TPS (CMS Monaco, Elekta PrecisePlan, BrainLAB iPlan,
Nucletron MasterPlan and Varian Eclipse).
Initial implementations were focused on MC dose calculations for electron beam
therapy planning as the performance of analytical electron beam dose deposition
calculations have shown significant inaccuracies (as much as 5-10%) [56, 159–161]
and the modeling of a clinical electron beam can be inherently faster than a pho-
ton beam. In the initial stages, MC was used as a research tool for dosimetry
calculations, and is now being used as the primary dose calculation engine in com-
mercial TPS. This is possible due to the development of special-purpose MC codes
optimized for fast and accurate radiation transport in the MV energy range. The
transport mechanics and boundary crossing implementations are more efficient, re-
sulting in faster convergence, requiring fewer condensed history steps for the same
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precision relative to general-purpose codes such as MCNPX or EGSnrc [56, 77, 82].
In particular, BEAM code system served as a major breakthrough in the devel-
opment of methods for MC in clinical settings due to the detailed simulations
performed in the linac head and associated beam devices, such as the MLC [162]
and enabled the detailed study of particle interactions within each component of
the treatment head.
Currently, MC dose calculations are available in the clinic for conventional RT
and IMRT for photon beams [163, 164] and for treatments with electron beams
[160, 165]. Some of the MC dose engines used in commercial TPS are:
• PEREGRINE [159, 165, 166] used in CORVUS inverse TPS (NOMOS, Pitts-
burgh, PA);
• VMC++ [155] in ONCENTRA TPS [167] (Nucletron B.V., Veenendaal, The
Netherlands);
• macro MC [168] in Eclipse TPS [169, 170] (Varian Medical Systems, Palo
Alto, CA);
• modified version of DPM [171] in Pinnacle TPS [172] (Philips Radiation
Oncology Systems, Madison, WI);
• PENELOPE [173] MC user code PENFAST in ISOgray TPS (DOSIsoft,
Cachan, France);
• XVMC [93, 174] in iPlan (BrainLAB AG, Feldkirchen, Germany), XiO and
Monaco (CMS Inc, St Louis, MO) and PrecisePLAN (Elekta Inc., Norcross,
GA) TPS.
4.3.2 XVMC photon beam dose calculation algorithm
The BrainLAB iPlan MC dose algorithm is based on the x-ray Voxel Monte Carlo
(XVMC) dose algorithm developed by Kawrakow and Fippel [93, 155, 174–178].
Electron transport within XVMC is based on VMC originally proposed for electron
beams [155]. Later, VMC was modified to incorporate photon transport (XVMC)
developed by Fippel [174].
The iPlan MC dose calculation algorithm consists of the following three compo-
nents:
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i. a virtual (multi-source) energy fluence model of interactions within patient-
independent structures of the treatment head, such as the target, flattening filter,
primary collimator, and so on [178];
ii. full MC simulation of interactions within the collimation system (jaws and
MLC) [175];
iii. the MC dose computation engine [174].
4.3.2.1 iPlan MC virtual source model
The virtual energy fluence (VEF) [178] is used to characterize the radiation in-
teractions within the linac head, in the components that are independent of the
patient specific treatment plan. The primary and scatter sources are modeled by
Gaussian-shaped photon sources. The primary photon source accounts for the
primary bremsstrahlung photons produced in the target, while the scatter sources
account for Compton-scattered photons originating from the primary collimator
and flattening filter. The Gaussian source function parameters are iteratively ad-
justed to produce the best agreement between analytical calculations of the energy
fluence and measured profiles in air [178].
4.3.2.2 Beam modeling of the patient-specific collimation
Fippel developed a method for tracking particles through the patient-specific jaws
and MLC [175]. The MLC leaf geometry was modeled and photon interactions are
simulated for physical processes including Compton scattering, photoelectric effect
and pair production by sampling from relevant cross -section data pre-calculated
for tungsten alloy and air. An approximation used is that particles are not trans-
ported through the jaws, improving the calculation efficiency [179]. Other groups
proposed other approaches for the particle transport in the jaws and MLC:
• to perform transport of the first Compton scattered photons only [61, 180];
or
• deposition of the electron energies locally [61, 135, 180], achieving significant
speed up in calculation time, with minimal impact on accuracy.
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4.3.2.3 Patient dose calculation
The XVMC photon dose algorithm is used for MC transport of particles in the
patient. It is a condensed history algorithm [93, 155, 177] with an implementation
where large electron energy transfer collisions are treated in an analog manner,
while small energy loss collisions are modeled using the continuous slow down
approximation [155]. Improvements in calculation efficiency were obtained using
several variance reductions and approximate efficiency enhancing techniques, such
as electron history repetition, photon forcing and Russian roulette [93].
The cross-sections for photon interactions and electron radiative and collision stop-
ping powers are calculated from parametrization of the interaction cross-sections
in a given material with respect to that of the water, as a function of the ma-
terial density [155], requiring a calibration of the CT scanner Hounsfield units
(HU) using materials of known densities through a pre-established HU-to-density
relation.
4.3.3 iPlan MC dose calculation features
The following four options can be changed by the user in the MC dose display
settings window:
• spatial resolution (in mm),
• dose result type (dose-to-water or dose-to-medium),
• mean variance (in mm), and
• MLC model (Precise or Fast).
The spatial resolution parameter defines the size of the MC dose computation grid.
The default resolution size is 5 mm. For small target volumes it is recommended
to use smaller grid sizes (2-3 mm).
The mean variance parameter is related to the statistical uncertainty of the MC
calculation. The mean variance estimates the number of histories required to
achieve this variance per beam in percentage of the maximum dose of that beam
(normalized to that beam). Therefore, the variance in overlapping regions is less
than the specified mean variance. The default setting is 2%.
For the dose result type there are two options: dose to medium (Dm) or dose to
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water (Dw). The MC dose calculation does inherently compute (Dm) - energy de-
posited per unit mass in the tissue of interest. The conversion to (Dw) is performed














is the unrestricted water-to-medium electron mass collision stopping
power averaged over the energy spectrum of the primary electrons.
The MLC model can be set to Precise or Fast modes. In the first mode, all
the features of the MLC geometry, such as the gap between leaves, rounded tip
leaves, leaf thickness, etc., are taken into account whereas with the Fast mode
the calculation times decrease, but does not take into account some details of the
MLC specifications.
Pencil-beam and collapsed-cone algorithms are different implementations of the
superposition/convolution technique. They are based on several approximations
and simplifications such as:
• the linac head is modeled by simple sources, i.e., point sources or parallel
sources;
• the electron transport is modeled on straight lines;
• neglect or simplify modeling the lateral density scaling (slab approximation),
in the case of pencil-beam algorithms;
• discretization of the point-spread function (energy kernel), in the case of
collapsed-cone algorithms;
• neglect or approximate representation of the energy kernel tilt angle to reduce
computation time;
• neglect or estimation of effects such as depth hardening and off-axis softening.
Usually these techniques provide results within seconds but the dose calculation
can be incorrect especially in the head and neck and thorax regions due to the
approximations used.
Several groups have already developed MC models in independent MC codes to
verify TPS algorithms, specially for more complex techniques such as IMRT [135].
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There are evidences pointing to PBC overestimating the doses in air regions such
as lung and head and neck localizations, up to 10% when compared to MC calcu-
lations [181].
Other studies involving verification of TPS (convolution/superposition algorithm:
Collapsed Cone approximation algorithm) with MC (BEAM EGS4-based MC
code) used monitor units calculation comparison particularly for narrow and ir-
regular segments was performed by Francescon et al [182]. Maximum differences
of 8% were found for such segments where there is electronic disequilibrium and
inhomogeneities which become of paramount importance.
Carrasco et al [183] also performed MC simulations using PENELOPE code and
performed comparisons with several TPS correction-based and superposition/-
convolution algorithms for percentage depth doses (PDD) measured with TLD,
metal-oxide semiconductor field-effect transistors (MOSFETs), plane parallel and
cylindrical IC, and beam profiles with films. The superposition convolution algo-
rithm had a better performance than the corrected-based algorithms especially in
the build up region.
In the case of this study, the calculation algorithms the TPS has, are the Pencil
Beam Convolution (PBC) and the commercial Monte Carlo (iMC). The required
data was measured and introduced in iPlan BrainLAB TPS and the data was
afterwards validated according to the BrainLAB requirements and specifications.
This TPS has a license to perform calculation in arc gantry mode which was
adopted for Dynamic Conformal Arc RT (DCART). However, it does not allow the
use of wedges. The modulation was accomplished by using field in field technique
and smaller segments, whenever necessary, to achieve the beam irradiation goals.
Comparison of iPlan algorithms: PBC and iMC
iMC was verified by Künzler et al [184] using gamma analysis performed measure-
ments and compared the results with the calculations. They concluded that, even
in heterogeneous media, the iMC algorithm leads to accurate dosimetric results.
Fragoso et al [185] also performed a dosimetric and clinical evaluation of iMC and
achieved good agreement in homogeneous and heterogeneous media.
Ali et al [186] performed a comparison between PBC and iMC for several patholo-
gies (brain, prostate, lung, head and neck and paraspinal tumors). Dose volume
histogram analysis showed that agreement within 5% for all cases except in lung
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tumors where discrepancies can be up to 30% with MC not covering the lung
tumor against PBC prediction.
Petoukhova et al [187] explored further the heterogeneous pathologies such as
lung and head and neck by performing IC and film measurements and achieved
excellent agreement in homogeneous media for several static shaped and IMRT
fields between iMC and the measurements. In the presence of heterogeneities,
iMC accurately predicts the dose and it accurately takes into account the lateral
electron transport. The sample of patients chosen had breast sizes varying from
350 to 1750 cm3; no correlation between the breast size and the irradiation doses
was in the scope of this study. Das et al [188], in fact, claim there is a relationship
between the breast volume and the CLB doses; however, Zurl et al [189] studies
did not find a relationship between these parameters, after analyzing the anatomic
and field specific parameters.
4.4 External beam delivery techniques
Traditional external beam photon radiotherapy (EBRT) delivery is defined as the
application of uniform or non-uniform intensity beams, without gantry rotation
during beam-on, to irradiate the tumor volume and spare the healthy tissues




Specifically for the breast, all these techniques aim at reaching a balance between
an adequate irradiation of the breast with the sparing of the OAR involved.
4.4.1 3D Conformal Radiotherapy
For many decades, improvements in RT were limited due to the lack of scientific
methods to precisely know the location of the tumors. In the past, external marks
such as contrast materials (liquid or surgical clips), skin-topography or bony land-
marks related to the tumor location were used to roughly define their shape.
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With the development of CT-scanners, RT was boosted: the treatment fields
changed from apertures defined to the edges of the tumor to conformal shaped
fields; linac machines were developed to replace the 60Co equipments; more com-
plex beam modulation was introduced. In this type of therapy, the photon beams
are of uniform intensity across the field. The conformation to the clinical treat-
ment volume is achieved through the use of a heavy alloy shielding placed in the
beam path, or more recently, using the MLC to create conformal radiation fields.
The use of wedges (physical or dynamic) and/or field compensators are optional.
However, using uniform beams, it is expected that tumors with concave surfaces
shall be over-dosed in the non-tumor volume in the concavities.
Conformal breast RT is delivered to the whole ipsilateral breast through tangential
fields with the use of 6 MV photons.
Lateral tangential fields are created to encompass the entire breast following stan-
dard techniques. Due to image segmentation, which allows to take into consid-
eration the critical anatomical structures through volume rendering in the 3D
beam’s-eye-view (BEV) display, it is possible to shape the collimators such that
the critical organs are avoided as far as possible, while ensuring adequate coverage
of the breast.
Gantry angles are adjusted to make the deep tangential borders coplanar to elimi-
nate divergence into the lung, so that the posterior and anterior borders of the PTV
projections coincide guaranteeing that the medial tangent does not pass through
the CLB. The deep edges of the tangential beams pass through the medial and
lateral borders set at simulation. Additional adjustments in gantry and collimator
rotations may be necessary to limit the volume of lung, heart and contralateral
breast in the field. Field collimation is adjusted to follow the slope of the chest
wall, as shown in figure 4.6. The jaws are defined so that the upper and lower
jaws (y1 and y2, when the collimator is at 0
◦) cover the all PTV volume and the
anterior/posterior jaws (x1 and x2) include the PTV and the anterior jaw has at
least a 2 cm fall-off to consider breast movement due to breathing. The MLC
is defined so that it protects the ipsilateral lung (and heart in case of left breast
irradiation). With this technique, it is very often necessary to use pair wedged
modifiers to irradiate adequately the PTV volume. Due to proved increase in scat-
tered doses using physical standards wedges some strategies to perform enhanced
dynamic wedges (EDW) using the jaws to modify the beam while irradiating were
developed and investigated [190–192]. There are cases in which this strategy may
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fail due to high involvement of the OAR. Other options have been studied using
static fields, such as a three-field technique [193–195].
Figure 4.6: Representation of WBI using static tangential fields, 3D CRT technique.
4.4.2 Intensity Modulated Radiotherapy (IMRT)
The basic idea behind IMRT is the possibility to obtain non-uniform spatial inten-
sity distributions using non-uniform beams. Several beams from different direc-
tions of incidence can be used to ultimately achieve the desired dose distribution
in the tumor with the adequate sparing of the surrounding critical structures. By
the mid-1990’s, advances in technology and software allowing the calculation and
delivery of non-uniform fluence maps on 3D patient volumes, together with the
development of the modern MLC, enabled the clinical implementation of a class
of delivery techniques known as intensity modulated radiation therapy (IMRT).
Some investigators claim IMRT represents one of the most important technical
advances in RT since the advent of the medical linac [196].
The modulation aimed with IMRT may be achieved through direct or inverse pro-
cesses implemented in the TPS. Direct planning consists in using several uniform
beams, defined by the user, on a trial-error basis. In inverse treatment planning,
computer algorithms are used to convert a (clinically established) desired dose
distribution into beam intensity maps. The number of fields and gantry angles
are defined by the user and each (open field) beam is divided into a number of
segments (beamlets). A search of beamlet weights is performed by the algorithm
to determine the optimal beamlet weights (fluence map) such that the sum of
weighted beamlet dose distributions is in optimal agreement with the objective
dose distribution, for the given number of fields and gantry angles [197–199]. This
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technique is commonly referred as fluence based optimization. For dynamic treat-
ments, the fluence is executed by the MLC. Its leaf sequence must be derived from
the ideal fluence map [200–202].
Some conclusions reported by the National Cancer Institute (NCI) about IMRT
[196] were the following:
• Reduce normal tissue radiation exposure
• Decrease treatment efficiency by delivering less dose per MU
• Increase the total-body dose received by the patient during delivery
• Increase stress on the linac from increased heating and movement of the MLC
The difference between 3D-CRT and IMRT is illustrated in figure 4.7. In the
particular case of breast RT, the same scheme of beams can be applied both for
3D-CRT and IMRT.
Figure 4.7: Comparison of the principles of a. 3D-CRT and b. IMRT. The first makes
use of uniform fields, whereas the second involves non-uniform fields. Image taken from
[203].
Intensity Modulated Radiotherapy (IMRT) is a treatment technique driven by
computer-optimized planning that envisages optimized field fluence distributions
to obtain highly conformal dose delivery [204], as represented in figure 4.8. IMRT
is explored as a technique to improve breast dose homogeneity by decreasing hot
spots and decrease dose to normal tissues, OAR and acute side effects compared
with conventional RT [140, 192, 205–213]. The first technique developed was
to add sub-fields to the open beams with identical gantry angles, using field-in-
field technique [214–220]. This technique is known as forward-planning IMRT
(f-IMRT). It evolved to varying the gantry angles and the number of fields.
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There are two techniques described in the literature for inverse-IMRT, to modulate
the photon intensity, using the MLC, to ultimately deliver a highly sculpted dose
of radiation:
• step-and-shoot technique [221–223], and
• sliding window technique [224, 225].
With the first technique, a specific MLC is static during irradiation and field-
in-field segments are used to compensate dose in parts of the tissue to irradiate
[220, 226–230]. In the second method, the irradiation beamlets are defined and
optimized making use a dynamic MLC which change the position of the leafs while
the beam is on[211]. Intensity modulated beams were proven to be able to create
homogeneous concave distributions [197].
According to the literature, there are mainly three groups of irradiation for breast
IMRT using: two tangential beams; 4 to 6 fields covering an 180◦ sector avoiding
portals from the contralateral side [231]; 9 or more fields evenly spaced in a 180◦
sector angle [232].
Implementation in clinical practice of IMRT requires additional resources com-
pared to conventional breast treatment because IMRT treatment planning, deliv-
ery and verification is more time consuming and complex [233–235].
Figure 4.8: Representation of WBI using tangential fields, with dynamic MLC during
irradiation, generating fluences and non-homogeneous dose distributions within the
PTV.
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4.4.3 Dynamic Conformal Arc RT (DCART)
Arc beam therapy solutions have also been developed in the past few years, to
deliver the prescribed dose while the gantry rotates. This radiation therapy tech-
nique can also be forwardly or inversely planned, and the MLC dynamically con-
forms to the planning target volume projection while the gantry rotates, being
therefore considered an intensity modulated technique. This technique was first
proposed by Yu in 1995 [236]. However, this technique is demanding in what the
dose calculation is related as the intensity solution space is non-convex and further
developments were only made when Shepard et al [237] improved the optimization
process for the TPS. Multiple arcs may be required to deliver the prescribed dose
distribution.
Varian’s RapidArc delivery system is capable of delivering the entire treatment
with a single rotation of the gantry, being therefore potentially faster in treating
but extremely demanding in quality control tests. This technique presents several
advantages compared to the static IMRT techniques:
• decrease in the number of monitor units delivered;
• faster treatment times;
• reduce patient exposure to scattered radiation;
• consequent decrease in patient movement.
An equivalent solution is offered by Elekta (Elekta AB, Stockholm, Sweden),
known as VMAT (Volumetric Modulated Arc Therapy). Several early studies
compare the effectiveness of RapidArc with other arc treatment modalities [238–
242].
The system used in this work for arc therapy is a previous version to RapidArc
implemented in the Trilogy linac (Varian Medical Systems, Palo Alto, CA). This
linac permits treating in arc mode and the TPS solution used is a forward plan-
ning strategy in which the MLC assumes a different configuration in a pre-defined
gantry rotation interval. This technique may be used in modern linacs, permit-
ting gantry rotation while the beam is on. In the case of a treatment delivered
by arctherapy, the target dose is delivered by a series of arcs, all isocentric and
corresponding to a fixed couch position, as represented in figure 4.9. The ampli-
tude of the arcs is generally inferior to 180◦ avoiding coplanar beams (opposing
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and parallel within the same plan), susceptible of generating high dose gradients
outside the target volume. In DCART, the size and the shape of the irradiation
beams adapt to the target volume projection in a plan perpendicular to the beam
axis which vary with the gantry rotation.
This technique is conformal and the total fluence of the beams is modulated with
the ultimate goal of improving the target volume irradiation and sparing the
healthy tissues. The most simple technique of intensity modulation consists in
manually adapting the parameters of the multileaf collimator (MLC) to obtain
conformational fields (forward planning).
In the case of sequential modulated irradiation, the field is divided into several
beamlets corresponding to a static position of the linac head. The MLC movement
is not continuous, programmed for the different gantry positions. The total fluence
is the sum of the several segments of irradiation. In the dynamic configuration,
the gantry continuously rotates while irradiates with individual movements of each
leaf at a differential speed to define the shape of the field.
More complex treatments (such as RapidArc) have evolved to inverse planning,
that instead of looking for the best dose distribution by direct adjustment of the
beam parameters, the goals are set and the aim is to satisfy the pre-defined criteria.
This strategy increases the efficacy of the treatment as the clinical criteria are set a
priori instead of trying to satisfy them a posteriori. As there are multiple solutions,
it is necessary to solve an inverse problem preferable to the iterative optimization
method. These techniques require extra quality control.
Figure 4.9: Representation of DCART technique using partial arcs used for breast
irradiation.
For WBI, the techniques investigated were:
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1. f-IMRT - forward-intensity modulated RT, using 2 tangential broader fields
and whenever necessary smaller fields, with the same beam incidence as the
tangential fields, to obtain better homogeneity inside the target volume.
2. IMRT2 - inverse planning technique using 2 modulated tangential fields. For
modulation, the MLC assumes different positions during irradiation (sliding
window technique).
3. IMRT5 - inverse planning technique using 5 modulated fields with different
beam incidents within the tangential fields. The sliding window technique
was also used for beam modulation.
4. DCART - forward planning technique using several arc beams, modulated
with conformal MLC adjusted every 10◦ (gantry angle).
4.5 Parameters investigated
For assessing the quality of the beam irradiation plan, during optimization, cu-
mulative dose-volume frequency distribution, in the form of histograms, usually
known as dose-volume histograms (DVH) can be plotted by the TPS. It graphi-
cally summarizes the simulated radiation distribution within a volume of interest
of a patient which would result from a proposed radiation treatment plan. These
DVH permit comparing rival treatment plans for a specific patient by clearly quan-
tifying the uniformity of the dose in the target volume and hot spots in adjacent
normal tissues or organs. However, because of loss of positional information in
the volume(s) under consideration, it should not be the sole criterion for plan
evaluation.
From the DVH it is also possible to evaluate several dosimetric parameters, in
order to quantitatively analyze the dose distributions, in what the coverage and
homogeneity inside the target volume and OAR are concerned. The dose values
were extracted from the DVH, analyzing each structure, according to the volume
that receives a certain dose, or the dose that reaches at a percentage of volume,
relating a posteriori with the tolerance estimated dose.
4.5.1 Evaluation of the PTV doses
For the PTV, the following parameters were analyzed:
Chapter 4. Breast treatment RT techniques 130
• V95% - PTV volume that receives, at least 95% of the prescribed dose;
• V107% - PTV volume that receives, more than 107% of the prescribed dose;
• Dmax - maximum dose the PTV receives;
• HI - homogeneity index;
• CI - conformity index;
• CN - conformation number.
Coverage of the target volume by the 95% isodose curve, V95%
For all the patients and techniques, the PTV percentage volume, that was covered
by the 95% isodose was analyzed, according to ICRU [34, 35] recommendations.
The ultimate goal is that the 95% isodose encompasses the total PTV, which is
difficult to achieve in WBI due to the shape of the breast.
Evaluation of higher doses in the dose distribution
High doses or hot spots, are doses above 107% of the prescribed dose, often ob-
tained in breast dose distributions. Dmax, the point of maximum dose in the
distribution is also determined. One of the goals of the dosimetrist is to decrease
these doses as much as possible, being sometimes not possible to have no doses
higher than 107%, as recommended by ICRU50. Having such high doses also
means the dose distribution is not homogeneous.
Heterogeneity and Conformity Indexes
To evaluate the quality of the dose distribution within the PTV, the following
indexes were assessed:
Heterogeneity Index, HI It is a measure of the degree of heterogeneity of
the prescribed dose (95% isodose) of the plan, defined as the ratio between the





The closer to unity, the more homogeneous, the dose distribution is.
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Conformity Index The conformity index (CI) is a measure of how the pre-
scribed dose fits the contoured PTV: the closest to 1, the most conformal the dose
distribution is. It is determined as the ratio between the VRI (volume covered by





This conformity index does not take into account whether the VRI is surrounding
the PTV and its efficacy is therefore limited.
Conformation Number Due to the limitations of the CI, another conformity







, where TVRI is the target volume covered by the reference (95%) isodose. The
closest to 1, the most conformal is the dose distribution.
4.5.2 Evaluation of the OAR doses
In all the patients, the contour of both lungs, heart and CLB were performed and
were used to assess the doses that reach these specific OAR. The following dose
parameters in the OAR were analyzed:
Ipsilateral lung
The lung right beneath the irradiated breast is a volume that can easily receive
high doses, due to the breast shape and its localization. The following doses were
extracted from the DVH:
• Dmean, the mean dose in the lung;
• V10%, the lung volume that receives at least 5 Gy (10% of the prescribed
dose);
• V20%, the lung volume that receives more than 10 Gy (20% of the prescribed
dose);
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• V40%, the lung volume that receives at least 20 Gy (40% of the prescribed
dose);
• V80%, the lung volume that receives more than 40 Gy (80% of the prescribed
dose).
Contralateral lung
The right lung, contralateral to the PTV being treated is expected to only receive
residual dose. The following parameters were assessed:
• Dmean, the mean dose in the right lung;
• D5%, the maximum dose that is in 5% of the lung;
• V5%, the lung volume that receives at least 2.5 Gy (5% of the prescribed
dose).
Heart
The heart is a sensitive organ and high doses should be avoided. The following
parameters were investigated:
• Dmean, the mean dose in the heart;
• V20%, the heart volume that receives more than 10 Gy (20% of the prescribed
dose);
• V50%, the heart volume that receives more than 25 Gy (50% of the prescribed
dose).
Contralateral breast
The contralateral breast is often in the beam path of medial tangential fields and
it is required that these receive as low dose as possible to avoid second breast
cancer in the other breast. The parameters assessed for the CLB were:
• Dmean, the mean dose in the CLB;
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• V10%, the CLB volume that receives more than 5 Gy (10% of the prescribed
dose);
• V4%, the CLB volume that receives more than 2 Gy (4% of the prescribed
dose).
Body without PTV
The external contour of the body was considered and the PTV was subtracted.
The goal is that this (Body-PTV) volume receives as low dose as possible, meaning
that the dose should be confined to the PTV. The parameters assessed for this
volume were:
• Dmean, the mean dose in the Body-PTV;
• V80%, the Body-PTV volume that receives more than 40 Gy (80% of the
prescribed dose);
• V40%, the Body-PTV volume that receives more than 20 Gy (40% of the
prescribed dose);
• V4%, the Body-PTV volume that receives more than 2 Gy (4% of the pre-
scribed dose).
4.6 Statistical analysis
The statistical tests aim at verifying if the observed differences are significant. For
statistical analysis purposes, there are two types of tests:
• the parametric, and
• the non-parametric.
The parametric tests are used to compare parameters that describe the distribu-
tions, such as the mean, percentage, variance and differences, with normal distri-
bution. The non-parametric tests do not require the dependent variable to have a
known distribution.
Two situations to be considered for statistical analysis are for the comparison tests
to know whether the series of measurements are independent or paired.
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• Independent series: for comparison of two distinct series considering the same
variable;
• Paired series: comparison of two series considering the same variable observed
in the same individuals.
The decision of the statistical tests to perform was made considering that the
test to be applied are non-parametric and the samples are paired, provided that
the sample of this study are the 7 patients (the same individuals along all this
investigation) or the calculation algorithms. The choice was made based on the
diagram depicted in figure 4.10.
Figure 4.10: Diagram on the statistical tests to be used given the type of samples.
(2) stands for 2 samples; (3 or more) means 3 or more samples.
The reported values for each irradiation technique were compared using SPSS
version 20 applying related-samples Friedman’s two-way analysis of variance test
and performing a pairwise comparison between the variables that reject the null
hypothesis (p-value ≤ 0.05, i.e. it is considered that there are significant statistical
differences between the variables under investigation when p-value is inferior to
0.05), for both calculation algorithms, individually. For more details on this test,
please refer to Appendix A (data from http://psych.unl.edu/psycrs/handcomp/).
The Friedman test is a non-parametric test appropriate to compare 2 or more
populations, for paired samples. In this case, the samples are considered paired
because the same parameters are being investigated for the same individual, de-
spite being for different techniques.
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To compare the algorithms, the Wilcoxon test was used (p-value ≤ 0.05), for the
variables under investigation. The samples are also paired, for the same reason
presented before and this test is the most adequate for small samples. Further
details on the application of Wilcoxon test can be looked up at Appendix A (data
from http://psych.unl.edu/psycrs/handcomp/).
4.7 Comparison of different breast planning techniques and
algorithms for radiation therapy treatment
This section contains the article published in Physica Medica, in 2014. This article
compares the 4 breast irradiation techniques under investigation, f-IMRT, IMRT2,
IMRT5 and DCART, using two calculation algorithms from the commercial iPlan
BrainLAB TPS. It contains all the relevant results and conclusions regarding WBI
irradiation using the aforementioned techniques and the differences between the
calculation algorithms referred.
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a b s t r a c t
This work aims at investigating the impact of treating breast cancer using different radiation therapy (RT)
techniques e forwardly-planned intensity-modulated, f-IMRT, inversely-planned IMRT and dynamic
conformal arc (DCART) RT e and their effects on the whole-breast irradiation and in the undesirable
irradiation of the surrounding healthy tissues. Two algorithms of iPlan BrainLAB treatment planning
system were compared: Pencil Beam Convolution (PBC) and commercial Monte Carlo (iMC).
Seven left-sided breast patients submitted to breast-conserving surgery were enrolled in the study.
For each patient, four RT techniques e f-IMRT, IMRT using 2-fields and 5-fields (IMRT2 and IMRT5,
respectively) and DCART e were applied. The dose distributions in the planned target volume (PTV)
and the dose to the organs at risk (OAR) were compared analyzing doseevolume histograms; further
statistical analysis was performed using IBM SPSS v20 software.
For PBC, all techniques provided adequate coverage of the PTV. However, statistically significant dose
differences were observed between the techniques, in the PTV, OAR and also in the pattern of dose
distribution spreading into normal tissues. IMRT5 and DCART spread low doses into greater volumes of
normal tissue, right breast, right lung and heart than tangential techniques. However, IMRT5 plans
improved distributions for the PTV, exhibiting better conformity and homogeneity in target and reduced
high dose percentages in ipsilateral OAR. DCART did not present advantages over any of the techniques
investigated. Differences were also found comparing the calculation algorithms: PBC estimated higher
doses for the PTV, ipsilateral lung and heart than the iMC algorithm predicted.
 2013 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.
Introduction
Breast radiotherapy (RT) is particularly challenging due to
the concave anatomy of the chest wall and breast that make it a
difficult localization to achieve homogeneous dose distributions.
Its complex shape is located near the bodyeair interface. There
are organs at risk (OAR) in the vicinities, such as the lungs, heart
and contralateral breast (CLB) that must receive doses as low as
possible to avoid long term complications. It is also important to
achieve dose homogeneity in target and high doses outside the
target volume should be avoided. Other concerns are the dose to
the CLB which is related to induced second malignancies [1,2],
the increased risk of fatal cardiac events, [3] and of pneumonitis
[2] for women after undergoing RT. As long as the volume to
treat has adequate dose coverage, the side effects should be
minimized.
Breast conserving therapy has become a widely accepted
treatment option in the management of early-stage breast cancer
improving local control [4e8]. The conventional radiotherapeutic
approach after lumpectomy generally consists of delivering 50 Gy
to the entire breast, with conventional wedged tangential fields,
optimized using a single central-axis isodose distribution and a
10e15 Gy boost to the tumor bed [9,10].
Treatment of whole breast using a photon tangential field
technique is still standard within radiotherapy departments, using
isocentric tangential treatment fields, geometrically nondivergent
at their posterior and superior borders, using 6 MV or combined
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6 MV with 10 MV or 16 MV according to the energies available in
each linac, based on the method of Casebow [11], which has been
modified and adapted with the advent of 3D treatment planning
systems (TPS) and the use of beam modifiers, other beam config-
urations, etc. (e.g. Refs. [12e14]).
ICRU [15] recommends the enclosure of the planning target
volume (PTV) within 95% and 107% isodose lines. However, this
may be difficult to achieve with only two standard tangential
beams using wedges technique, typically called 3D-CRT (3D-
conformal RT). More complex treatment planning strategies have
been developed to improve dose homogeneity, namely intensity
modulated RT (IMRT) techniques varying in complexity, ranging
from manual division of beam fields into several segments e
forward-IMRT, f-IMRT e [16e23] to more complex techniques us-
ing inverse planning algorithms to treat using several individual
beamlets [24].
Woo et al. [25] and Bhatnagar et al. [26], in separate experi-
mental studies concluded that tangential-wedged 3D-CRT in-
creases scattered dose into the normal tissues.
Several studies claim that IMRT has the potential to improve
dose homogeneity and conformity in breast radiotherapy
improving cosmetic results [27e31], reducing pulmonary and car-
diac complications and CLB doses [23,32,33].
f-IMRT, using open fields and segments, is claimed to be dosi-
metrically superior to 3D-CRT using wedges and reported to have
similar PTV coverage, better dose homogeneity and lower doses in
the OAR [23,25,34e37].
When comparing 3D-CRT with IMRT (inverse planning), the
implications on the irradiation of the healthy tissues surrounding
are not as conclusive: some studies reported lower doses using
IMRT on the CLB [16,26,33,38], on the heart [39e41], and on the
ipsilateral lung [33,38,41,42] whilst other studies verified lower
doses on the CLB [43] and on the normal tissues [44] using 3D-CRT.
Jagsi et al. [45], comparing different IMRT techniques concluded
tangential beamlet IMRT technique reduced exposure to normal
tissues and maintained reasonable tissue coverage.
It is well-established that 3D-CRT with wedges increases scat-
tered doses [16,23,25,26,34,35]. Therefore in this study f-IMRT with
multiple static fields was used and compared to other techniques
without wedges.
Treatment plans are, in general, evaluated on the basis of dose
calculations. Some comparisons between calculation algorithms
may be found in the literature on breast irradiation, for Pencil
Beam Convolution (PBC) [46] and Analytical Anisotropic Algorithm
(AAA) [47e49]. The calculations using the PBC algorithm are
known to be inaccurate in regions of electronic non-equilibrium,
such as in air cavities or in build-up regions, and inhomogeneity
corrections due to the lung media [50] or irregular body contour,
which are major issues in breast RT [48,51]. Monte Carlo (MC)
simulation methods and techniques are widely reported for their
dose calculation accuracy. Applying MC techniques to dose calcu-
lations in RT has therefore the potential to decrease the un-
certainties when compared to analytical/conventional treatment
planning algorithms, regardless the beam geometry and target
composition [52].
The main focus of the present study is to evaluate and compare
the irradiation plans of four radiotherapy techniques (f-IMRT,
IMRT using 2 and 5 fields e IMRT2 and IMRT5, respectively e and
dynamic conformal arc RT e DCART), relevant for entire breast
irradiation, considering only the 50 Gy plan as the boost plan is
more patient-dependent due to tumor bed localization and
prognostic factors for dose prescription. This study also aims at
comparing two different algorithms, Pencil Beam Convolution,
PBC, and commercial Monte Carlo, iMC, from iPlan (BrainLAB
AG, Feldkirchen, Germany) treatment planning system (TPS)
[53,54] for the techniques under investigation for breast cancer
treatment.
Patients, materials and methods
Patient selection and simulation
7 Patients with left-sided stage I or II breast cancer that were
referred to adjuvant RT after breast conserving surgery (BCS) were
investigated. All the selected patients were randomly chosen
among the 394 patients treated between 2010 and 2011 to left
breast cancer using 3D-CRT. The breast volume of the elected pa-
tients varied from 350 cc to 1750 cc and was not a selection crite-
rion in order to achieve general conclusions on the irradiation
techniques despite the breast size.
CT scanning for treatment planning
The patients were positioned in a standard breast immobiliza-
tion device on the scanner table, in the treatment position with
bilateral arm abduction above the head. Radiopaque wires were
placed around the patients’ breast and marked the superioreinfe-
rior (2 cm above and below the breast tissue) and the midline
lateral borders. CT images of the thorax were acquired, with a
Siemens, Biograph 64R, CT scanner. The slice thickness was 3 mm,
with coverage from above the mandible to several centimeters
below the inframammary fold, to include the entire breasts, com-
plete left and right lungs and heart. The CT data was then trans-
ferred to the iPlan BrainLAB treatment planning system (TPS).
Delineation of target and OAR
All contours were performed in the axial CT slices. For whole
breast RT after BCS, the remaining mammary glandular tissue was
considered clinical target volume (CTV). The heart, ipsilateral lung,
contralateral lung and CLB were considered OAR. Auto contouring
of the body and both lungs was used. For consistency, the delin-
eation of the CTV, planning target volume (PTV), heart and CLB was
performed by the same radiation oncologist. The PTV was defined
by adding a 5 mm margin to the CTV. All structures were confined
to 3 mm from the external surface of the patient. An additional
structure specified as Body-PTV was also created to evaluate the
doses on the body excluding the PTV.
Treatment planning
The treatment plans were generated using iPlan v. 4.1, the
BrainLAB TPS. Four plans to deliver 50 Gy to the PTV in 25 fractions
were developed for each patient: two plans used forward planned
techniques (f-IMRT, and DCART); whereas for the other two plans
(IMRT2 and IMRT5), inverse optimization was applied. The treat-
ment sessions were planned for a Trilogy linear accelerator (Varian
Medical Systems, Palo Alto, CA) equipped with the High Definition
(HD) micromultileaf collimator (MLC) with 120 leaves. The plans
were normalized to a point in the isocenter axial plane inside the
PTV. For all plans, the isocenter was placed in the center of the PTV
volume and the couch rotationwas set to 0; the collimator rotation
was left free to minimize the opening of the main jaws, but nor-
mally was set to 0.
For treating the PTV, specific objectives were established to treat
95% of the PTV with ideally 47.5 Gy but at least 45 Gy, and
maximum hotspots should not exceed 110%. Other goals were to
keep the dose to the OAR as low as possible by setting higher pri-
ority upon avoidance of the contralateral breast, lungs and heart,
without compromising the PTV dose coverage considering
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adaptations from QUANTEC [55] and RTOG 1005 [56] criteria.
Specifically for the OAR, the criteria used for evaluation adopted
were: the ipsilateral lung V20Gy should be lower than 20%, V10Gy
should be inferior to 35%, V5Gy should be inferior to 50%; 5% of
contralateral breast should receive less than 5 Gy; for the heart,
V25Gy was expected to be inferior to 10% and V10Gy not superior to
30%; 10% of the contralateral lung should not receive more than
5 Gy.
The PBC algorithmwas used to calculate dose at each step of the
plan optimization process, for all plans. After optimization, the
plans were recalculated using a dose-to-medium calculation MC
algorithm with 3.0  3.0  3.0 mm3 spatial resolution and 3.0%
mean variance. In iPlan, for IMRT techniques, for iMC, the user can
define 4 levels of priorities, by assigning structures to the following
“importance levels”: 1. 100%; 2. 66%; 3. 33%; 4. 0%. Initially, the
priorities were defined as 100% to the PTV and 33% to the OAR.
These priority levels were continuously adjusted during optimiza-
tion to adequately irradiate the PTV. In case, the objectives were not
met, the input parameters such as the beam gantry and collimator
angles were also adjusted. The optimal parameters were chosen
with beams-eye view display support. For the inverse-planning
techniques, the technique used for intensity modulation of dose
was sliding-window.
f-IMRT
Two tangential 6 MV conformal fields, without wedges e due to
the increased scatter extensively reported in other studies
[16,25,26,41]ewere positioned to cover the PTV. Forward planning
field-in-field MLC compensation was required to fulfill the dose
constraints either to block regions of high doses or to minimize the
irradiated lung and heart volumes without compromising the PTV
coverage. The beam weights, MLC shaping and gantry angles were
varied to ensure the plan met the requirements. Lateral beams
ranged from 120 to 135; medial gantry angles varied between
300 and 310.
IMRT2
This technique used two intensity modulated photon beams
similar to those commonly used in 3D-CRT. For the inverse plan-
ning technique, the gantry angle of the beams was defined and
submitted to inverse calculation with an optimization engine, the
DPL2i (version 4.1) to determine the MLC shaping, monitor units at
each gantry angle and the speed of leaf motion for each field. The
cost (objective) function was based on doseevolume constraints
individually specified for the target PTV and OAR. For IMRT2, two
6 MV opposing tangential conformal fields were defined with
specific and adjustable constraints to adequately irradiate the PTV
and spare the OAR. The lateral and medial gantry angles ranged
from 120 to 135 and 300 to 310, respectively.
IMRT5
Five beams with different gantry angles were defined and
optimized to meet the requirements established for irradiating the
PTV and sparing the OAR. For IMRT5, inverse optimization was also
used. The lateral and medial gantry angles were the same used for
IMRT2; the other 3 fields were placed between these fields for
gantry angles between 80 and 120; 25 and 55; 340 and 350.
DCART
For the dynamic conformal arc technique, two beam arcs were
chosen in medial (gantry angles from 300 to 350) and lateral
(gantry angles from 100 to 150) positions, to avoid direct in-
cidences towards the heart and lungs, by closing the MLC in some
arc positions to protect these OAR. In some plans, additional partial
arcs were added if necessary to improve sparing of normal tissues
while providing adequate target coverage. These plans were
created using a forward-planned technique, in which the linac
delivers the dose while the gantry rotates, by changing the MLC
conformation, every 10.
Statistical analysis/evaluation tools
f-IMRT, IMRT2, IMRT5 and DCART plans were optimized for
seven patients, using the PBC algorithm, taking into account the
goals and constraints previouslymentioned. After optimization, the
plans were recalculated using iMC algorithm. Dose volume histo-
grams (DVH) were calculated and differentmetrics were selected to
compare the techniques.
For the PTV, the parameters V47.5Gy and V53.5Gy were used to
assess maximum doses. The heterogeneity index (HI) of the plans
was defined as the ratio between the minimum dose in the hottest
5% and 95% of the total PTV volume. [57] The conformity index (CI)
was determined as the ratio between VRI (volume covered by the
95% isodose) and TV (target volume). Furthermore, the degree of
conformity [58] was also calculated, as the conformation number,
CN, defined by van’t Riet et al. [59], which simultaneously takes into







where TVRI is the target volume covered by the reference (95%)
isodose.
For all treatment plans, DVH of the OAR (lungs, heart and CLB)
and normal tissue sparing (Body-PTV) were calculated and
compared.
The reported values for each technique were compared using
SPSS v20 [60,61] applying related-samples Friedman’s two-way
analysis of variance test and performing a pairwise comparison
between the variables that reject the null hypothesis (p-
value  0.05, i.e. it is considered that there are significant statistical
differences between the variables under investigation when p-
value is below 0.05), for both calculation algorithms, individually.
To compare the algorithms, the Wilcoxon test was used (p-
value  0.05), for the variables under investigation.
Results
Pencil beam algorithm
Figure 1 shows the dose distributions, for the 4 techniques, for
PBC algorithm, just for one of the patients, for simplicity matters.
Considering the results presented in Fig. 1, PTV coverage by the
95% isodose was expected to be better for IMRT5 as this curve fits
best to the concave shape of the PTV comparatively to the other
techniques. Moreover, it is possible to infer that with IMRT5 and
DCART therewas awider spread of lowdoses into the body and into
the heart, lung and contralateral OAR.
A comparison of the DVHs of the patients enrolled in this study
is presented in Fig. 2.
A detailed statistical analysis for the PTV and the OAR was per-
formed and the results are presented in Table 1. For the PTV, all the
techniques had the expected shape for its adequate irradiation
(Fig. 2(I)). Regarding Dmax criterion, with f-IMRT, in only 57% of the
cases was the goal achieved; for IMRT5, one patient of the 7 studied
cases did not respect this criterion having high hotspots in a small
percentage of PTV volume. There were no significant statistical dif-
ferences between the techniques. As expected from Fig. 1, IMRT5
presented the best mean V47.5Gy values, with 86% of f-IMRT and
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IMRT5 and 71% of IMRT2 andDCART plansmeeting the goal of V47.5Gy
to be superior to 90%. Significant statistical differences were not
found between the techniques. DCART had the lowest V47.5Gy average
with 3 out of 7 plans not reaching, the 90% of PTV coverage; had
higher V53.5Gy average values andwas the techniquewith the highest
percentage of PTV volume with high doses (see Fig. 2(I)). Therefore
DCART was considered the technique with worst PTV coverage.
f-IMRT had a better performance on this parameter compared to
DCART but the IMRT techniques achieved the best results. Con-
cerning the heterogeneity and conformity indexes calculated, IMRT5
was the technique with the most conformed and homogeneous
(average values closer to unity) dose distributions. f-IMRT had the
worst performance for CI. Significant statistical differences were
observed between the techniques for HI, CI and CN.
Considering the results for the OAR presented in Table 1, on the
left lung, f-IMRT did respect all the constraints imposed and had
lower Dmean values; IMRT2 verified all the constraints imposed,
with exception of one case of IMRT2, that did not verify V20Gy;
IMRT5 did not achieve the objectives for V5Gy, in 6 out of 7 cases,
and V10Gy, in 4 out of 7 cases, but verified V20Gy for 5 out of 7 pa-
tients; DCART did not respect V5Gy in 43% of the cases, V10Gy and
V20Gy, in 6 out of 7 patients. Nonetheless, IMRT5 exhibited lower
V40Gy compared to the other techniques, see Fig. 2(IV). On the right
lung (Fig. 2(V)), IMRT5 was the technique with higher doses and
Figure 1. TPS results for the 4 techniques, f-IMRT, IMRT2, IMRT5 and DCART from top to bottom, in axial, sagittal and coronal views, from left to right, respectively, for one of the
patients enrolled in this study, using the PBC algorithm.
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Figure 2. DVH comparison between the 4 irradiation techniques f-IMRT in red, IMRT2 in light blue, IMRT5 in dark blue and DCART in pink, for the (I) PTV, (II) contralateral breast, (III) heart, (IV) left and (V) right lungs and (VI) Body-









































Chapter 4. Breast treatment RT techniques 140
lung involvement (higher Dmean); in fact, V5Gy to be inferior to 10%
was not achieved by 5 out 7 cases and D5% to be less than 5% was
only achieved in 3 out of 7 plans, for IMRT5. On the contrary, IMRT2
presented the lowest Dmean.
Analyzing the CLB results, IMRT5 and DCART were the options
with higher doses for all reported variables (see Fig. 2(II)), meeting
the criteria V5Gy to be inferior to 5% in none and 1 out of 7 plans,
respectively. For the tangential techniques 6 out of 7 cases met V5Gy.
Regarding the heart, f-IMRT and IMRT2 were the techniques
with the best results: V10Gy was achieved for all cases; V25Gy was
only achieved in 57% of the f-IMRT and 14% of IMRT2 plans; for
IMRT5 and DCART, V10Gy was achieved for none and 1 out of 7 cases,
Table 1
PTV and OAR parameters evaluated for f-IMRT, IMRT2, IMRT5 and DCART irradiations, for PBC algorithm. The displayed values are the mean with their respective standard
deviations and p-values calculated using the Friedman test. The values in bold are the variables with significant statistical differences (p-value  0.05). ALARA: As Low As
Reasonably Achievable. PMC: percentage of patients meeting the criteria.
Plans Criteria f-IMRT PMC IMRT2 PMC IMRT5 PMC DCART PMC p-Value
PTV Dmax (%) <110% 109.87  0.67 57% 109.01  1.46 71% 111.31  4.29 86% 109.57  1.01 71% 0.510
V53.5Gy (%) ALARA 2.97  0.69 e 0.19  0.05 e 0.64  0.33 e 5.17  1.47 e 0.008
V47.5Gy (%) 90% 93.41  0.77 86% 92.84  1.04 71% 93.89  0.58 86% 89.87  1.92 71% 0.093
HI Ideally 1 1.14  0.01 e 1.12  0.01 e 1.11  0.01 e 1.17  0.02 e 0.001
CI Ideally 1 1.47  0.10 e 1.34  0.09 e 1.09  0.04 e 1.24  0.04 e 0.002
CN Ideally 1 0.61  0.11 e 0.66  0.09 e 0.82  0.07 e 0.66  0.06 e 0.001
Left lung Dmean (%) ALARA 17.94  1.16 e 18.93  1.53 e 28.40  1.25 e 28.70  1.02 e 0.001
V5Gy (%) 50% 23.54  4.34 100% 27.57  6.03 100% 82.09  6.03 14% 57.50  8.55 43% 0.000
V10Gy (%) 35% 18.92  1.36 100% 23.08  2.07 100% 52.04  6.16 43% 44.94  2.02 14% 0.000
V20Gy (%) 20% 16.34  1.24 100% 18.61  1.69 86% 19.50  0.81 71% 27.73  1.06 14% 0.001
V40Gy (%) ALARA 11.43  0.86 e 10.21  1.49 e 7.79  0.98 e 11.83  1.03 e 0.013
Right lung Dmean (%) ALARA 3.73  2.55 e 1.10  0.09 e 8.61  0.88 e 1.61  0.15 e 0.002
D5% (%) 5 Gy 2.21  0.40 100% 2.41  0.15 100% 17.96  2.03 43% 4.70  0.83 100% 0.000
V5Gy (%) 10% 0.00 100% 0.00 100% 35.82  4.49 29% 0.99  1.13 100% 0.000
CLB Dmean (%) ALARA 2.99  0.30 e 2.90  0.29 e 6.21  1.70 e 5.49  0.75 e 0.001
V5Gy (%) 5% 2.90  0.67 86% 3.39  0.59 86% 21.53  9.66 14% 16.76  3.64 0% 0.001
V2Gy (%) ALARA 14.30  1.25 e 13.11  1.58 e 38.89  14.31 e 40.47  5.92 e 0.003
Heart Dmean (%) ALARA 14.82  1.92 e 16.86  1.70 e 30.79  2.24 e 26.20  2.77 e 0.000
V10Gy (%) 30% 14.69  5.65 100% 20.44  6.25 100% 68.76  20.51 0% 43.63  8.23 14% 0.000
V25Gy (%) 10% 10.62  4.72 57% 13.24  4.63 14% 13.58  6.12 14% 20.26  7.88 14% 0.001
Body-PTV Dmean (%) ALARA 6.13  0.92 e 5.41  0.26 e 8.94  0.57 e 7.33  0.32 e 0.004
V40Gy (%) ALARA 3.23  0.24 e 2.67  0.24 e 2.05  0.10 e 2.59  0.11 e 0.001
V20Gy (%) ALARA 4.49  0.25 e 4.94  0.22 e 5.16  0.23 e 6.41  0.40 e 0.001
V2Gy (%) ALARA 11.81  0.73 e 12.07  0.67 e 43.53  3.64 e 20.74  1.12 e 0.000
PTV Dmax (%) <110% 110.44  1.10 71% 110.31  2.23 43% 112.61  4.29 43% 110.86  1.83 29% 0.864
V53.5Gy (%) ALARA 0.40  0.12 e 0.73  0.58 e 0.30  0.20 e 1.14  0.28 e 0.128
V47.5Gy (%) 90% 73.54  2.52 0% 78.23  2.26 14% 81.67  1.75 0% 74.99  3.59 0% 0.054
HI Ideally 1 1.20  0.02 e 1.18  0.01 e 1.15  0.01 e 1.23  0.02 e 0.001
CI Ideally 1 1.02  0.10 e 0.98  0.07 e 0.86  0.03 e 0.93  0.06 e 0.134
CN Ideally 1 0.56  0.17 e 0.63  0.05 e 0.77  0.04 e 0.61  0.06 e 0.003
Table 2
PTV and OAR mean and standard deviations for f-IMRT, IMRT2, IMRT5 and DCART plans, for iMC algorithm. The displayed values are the mean, standard deviation and p-value
using Friedman’s test. The values in bold are the variables with significant statistical differences (p-value 0.05). ALARA: As Low as Reasonably Achievable. PMC: percentage of
patients meeting the criteria.
Plans Criteria f-IMRT PMC IMRT2 PMC IMRT5 PMC DCART PMC p-Value
PTV Dmax (%) <110% 110.44  1.10 71% 110.31  2.23 43% 112.61  4.29 43% 110.86  1.83 29% 0.864
V53.5Gy (%) ALARA 0.40  0.12 e 0.73  0.58 e 0.30  0.20 e 1.14  0.28 e 0.128
V47.5Gy (%) 90% 73.54  2.52 0% 78.23  2.26 14% 81.67  1.75 0% 74.99  3.59 0% 0.054
HI Ideally 1 1.20  0.02 e 1.18  0.01 e 1.15  0.01 e 1.23  0.02 e 0.001
CI Ideally 1 1.02  0.10 e 0.98  0.07 e 0.86  0.03 e 0.93  0.06 e 0.134
CN Ideally 1 0.56  0.17 e 0.63  0.05 e 0.77  0.04 e 0.61  0.06 e 0.003
Left lung Dmean (%) ALARA 27.32  0.96 e 28.00  1.15 e 18.43  1.40 e 16.86  1.06 e 0.000
V5Gy (%) 50% 26.46  5.44 100% 30.71  6.30 100% 81.83  19.02 14% 57.43  8.67 29% 0.000
V10Gy (%) 35% 20.99  1.35 100% 24.10  1.88 100% 51.44  5.76 29% 43.19  1.97 14% 0.000
V20Gy (%) 20% 16.30  1.22 100% 18.69  1.67 71% 20.59  0.76 71% 26.96  1.04 14% 0.001
V40Gy (%) ALARA 9.27  0.74 e 8.37  1.39 e 5.49  1.29 e 10.71  1.04 e 0.008
Right lung Dmean (%) ALARA 7.75  0.76 __ 8.03  0.86 __ 33.87  4.94 __ 17.99  3.52 __ 0.001
D5% (%) 5 Gy 1.20  0.22 100% 1.25  0.14 100% 16.06  1.70 14% 3.58  0.81 86% 0.000
V5Gy (%) 10% 0.00 100% 0.00 100% 31.93  5.10 29% 0.81  1.0 100% 0.000
CLB Dmean (%) ALARA 2.84  0.30 __ 2.60  0.31 __ 6.23  1.64 __ 4.57  0.74 __ 0.007
V5Gy (%) 5% 3.70  0.68 71% 3.91  0.62 86% 21.58  9.31 14% 13.49  2.88 0% 0.002
V2Gy (%) ALARA 14.63  1.42 __ 13.89  1.93 __ 40.59  13.75 __ 30.56  5.90 __ 0.006
Heart Dmean (%) ALARA 13.56  1.43 __ 16.10  2.19 __ 30.30  2.19 __ 26.36  2.50 __ 0.007
V10Gy (%) 30% 16.14  6.85 100% 23.40  7.33 100% 81.21  22.82 0% 48.90  12.06 14% 0.000
V25Gy (%) 10% 10.06  4.50 71% 13.19  4.59 14% 13.71  5.90 14% 19.99  8.11 14% 0.003
Body-PTV Dmean (%) ALARA 5.79  0.52 __ 4.75  0.39 __ 8.73  0.56 __ 6.87  0.32 __ 0.002
V40Gy (%) ALARA 2.88  0.21 __ 2.33  0.23 __ 1.76  0.11 __ 2.37  0.12 __ 0.001
V20Gy (%) ALARA 4.51  0.24 __ 4.94  0.22 __ 5.16  0.23 __ 6.26  0.37 __ 0.001
V2Gy (%) ALARA 11.54  0.62 __ 10.99  1.75 __ 43.51  3.79 __ 19.30  1.12 __ 0.000
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respectively; for V25Gy, only in 1 plan out of 7 was the goal achieved,
for both techniques. Dmean was lower for f-IMRT and IMRT2, as
expected analyzing Fig. 2(III).
On the Body-PTV, Dmean was higher for IMRT5 and DCART;
IMRT5 was the technique with lower V40Gy but that most spread,
mainly low doses (verified by V2Gy in Table 1 and for doses up to
15 Gy in Fig. 2(VI)) into the body whereas f-IMRT and IMRT2 had
the lowest values for V2Gy and V20Gy.
For the OAR involved in breast cancer treatment, the 4 tech-
niques under investigation had statistical significant differences (p-
value  0.05) for all the variables studied and presented in Table 1.
Monte Carlo algorithm
The final optimized PBC plans were recalculated using iMC al-
gorithm and a detailed analysis was performed. The results are
presented in Table 2.
With the recalculation of the optimized plans using iMC, the
mean values for V47.5Gy criteria did not reach the 90% PTV coverage
for any of the techniques (except one case of IMRT2) andmean Dmax
results were higher than the limit established (110%) for 71% of f-
IMRT, 43% of IMRT2 and IMRT5 and 29% of DCART cases.
Among these results, IMRT5 was the technique with better
V47.5Gy, lower V53.5Gy, best HI and CN; f-IMRT was the technique with
the worst V47.5Gy. IMRT techniques have the closest HI to unity,
presenting therefore the most homogeneous dose distributions.
Considering the conformity indexes, the tangential techniques had CI
closer to unity; however for CN, the best results were achieved by
IMRT5 which means that with the tangential techniques there is a
higher percentage of non-PTV volume being irradiated with 95% of
the prescribed dose because of the limitation of the tangential fields
to confine to the PTV due to the concave shape of the breast PTV.
For the iMC, no significant statistical differences were observed
for the PTV parameters, except for HI and CN.
On the left lung, all plans of f-IMRT respected all the criteria;
IMRT2 did not achieve V20Gy for 2 out of the 7 patients, respecting
V5Gy and V10Gy; for IMRT5 only 1 case verified V5Gy, 2 respected V10Gy
and only 2 did notmeet V20Gy; for DCARTonly 2 cases respected V5Gy
and nomore than 1 case verified V10Gy and V20Gy. With these results,
it is evident that with IMRT5 and DCART higher percentages of lung
received low doses (expressed by V5Gy and V10Gy) particularly when
compared to f-IMRT and IMRT2. However with IMRT5 the percent-
age of lung that received doses above 40 Gy was significantly lower
when compared to the other techniques. On the right lung, all the
variables were significantly higher for IMRT5, with only 1 and 2
cases out of respecting D5% and V5Gy, respectively; DCART (with only
one case not verifying D5% criteria) had lower percentage of volume
involved compared to IMRT5 (with only one and two cases verifying
D5% and V5Gy criteria, respectively) but still had significantly higher
values when compared to the tangential techniques. On the CLB,
similar results were achieved with IMRT5 and DCART spreading
lower doses into this OAR, with 1 and 0 cases out of 7 respecting the
criterion established, respectively. 5 and 6 cases out of 7 had V5Gy
inferior to 5% for f-IMRT and IMRT2, respectively. On the heart, f-
IMRT was the technique with lower mean doses for all cases veri-
fying V10Gy inferior to 30% and 5 out of 7 meeting the criterion V25Gy
to be less than 10%; IMRT2 had higher doses on these parameters
and only 1 case respected V25Gy; IMRT5 had the highest heart vol-
ume involvement for doses up to 10 Gy, with at most one case
respecting the criteria; but DCART was the technique with higher
volume involvement for 25 Gy, with only one case respecting the
criteria. Regarding the Body-PTV, IMRT5 presented the highestmean
values for Dmean and V2Gy and the lowest V40Gy; DCART exhibited the
highest V20Gy. IMRT2 presented the lowest Dmean and V2Gy. There
were significant statistical differences for all the OAR variables
investigated for iMC, which should be carefully taken into account.
Comparison between PBC and iMC algorithms
A comparison between the two algorithms was performed and
the results are presented in Fig. 3, where it is possible to visualize
the doseevolume differences between the two calculations for the
PTV, left lung, CLB and heart, for f-IMRT (I), IMRT2 (II), IMRT5 (III)
and DCART (IV).
Considering the results in Fig. 3, the major differences between
the two calculation algorithms were for the PTV, for doses above
40 Gy, for f-IMRT (I), IMRT2 (II) and DCART (IV) and above 30 Gy for
IMRT5 (III), with PBC predicting higher doses than iMC. The
maximum dose differences observed were of 4 Gy. In the left lung,
iMC also estimated lower doses, mainly for doses above 35 Gy.
The variables with significant statistical differences were further
investigated performing a pairwise comparison between tech-
niques and the results are presented in Table 3.
PBC presented significant statistical differences for V53.5Gy, HI, CI
and CN, whereas for iMC differences were observed for HI and CN.
For the PBC algorithm, for V53.5Gy, the significant statistical dif-
ferences were observed between DCART and the inverse IMRT
techniques. For HI, significant statistical differences were found
between f-IMRT and IMRT5, DCART and the inverse IMRT tech-
niques. CI presented significant statistical differences between
IMRT5 and the tangential techniques; CN exhibited differences
between f-IMRT and IMRT5.
For the iMC algorithm, the statistical significant differences,
found were for HI, between f-IMRT and IMRT5, DCART and the in-
verse IMRT techniques; for the CN between f-IMRT and IMRT5.
The results of the comparison performed for the OAR, for the
variables with significant statistical differences (p-value 0.05), for
PBC and iMC, are presented in Table 4.
The results of a statistical analysis to compare PBC and iMC al-
gorithms using Wilcoxon test are presented in Table 5.
Significant statistical differences (p-value 0.05) were found for
most of the PTV variables investigated (the exceptions were for
Dmax and CN for f-IMRT, IMRT2 and IMRT5; V53.5Gy for IMRT2 and
Table 3
Pairwise comparison using the Friedman’s test between the techniques for the PTV
variables that exhibit significant statistical differences (p-value  0.05). The cells in
white background are related to the PBC algorithm whereas the cells in light gray
background correspond to the iMC results. The values in bold are the variables with
significant statistical differences (p-value  0.05).
f-IMRT IMRT2 IMRT5 DCART
PTV
V53.5Gy
f-IMRT 0.078 0.214 0.178
IMRT2 NS 0.605 0.002
IMRT5 NS NS 0.010
DCART NS NS NS
HI
f-IMRT 0.098 0.030 0.178
IMRT2 0.214 0.605 0.003
IMRT5 0.023 0.301 0.000
DCART 0.147 0.007 0.000
CI
f-IMRT 0.408 0.000 0.098
IMRT2 NS 0.004 0.408
IMRT5 NS NS 0.038
DCART NS NS NS
CN
f-IMRT 0.586 0.001 0.884
IMRT2 0.471 0.137 1.000
IMRT5 0.003 0.471 0.078
DCART 1.000 1.000 0.058
NS e no significant statistical differences.
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IMRT5 that did not exhibit significant statistical differences). For
the left lung, there were significant statistical differences between
PBC and iMC for Dmean and V40Gy, for all techniques, for V10Gy, for
f-IMRT and DCART; for V5Gy, for IMRT2; and V20Gy for IMRT5 and
DCART. On the right lung, the differences were observed for Dmean
and D5% for all the techniques. On the CLB, differences with statis-
tical significance were observed for all the variables for DCART and
IMRT2, except V2Gy, for IMRT2. On the heart, Dmean for IMRT2 and
IMRT5 and V10Gy for DCART also had statistically significant differ-
ences. On the Body-PTV, differences were verified for Dmean (except
for f-IMRT); in all techniques for V40Gy and V20Gy; and for V2Gy, for
DCART.
Discussion
From the results of the optimized plans for f-IMRT, IMRT2,
IMRT5 and DCART it is possible to infer that all techniques present
possible solutions for breast irradiation even though with some
drawbacks that must be taken into consideration. However, with
IMRT5 was the technique with the best HI and CN indexes (see
Tables 1 and 2) for both algorithms.
With IMRT5 larger percentages of healthy tissues, such as the
left lung (V5Gy, V10Gy and V20Gy), right lung (D5% and V5Gy), CLB (V5Gy
and V2Gy), heart (V10Gy) and Body-PTV (V2Gy) received more low
doses compared to the techniques that use only tangential fields
(f-IMRT or IMRT2).
In this study, for PBC, significant statistical differences were
found between the techniques for all the OAR parameters investi-
gated, mainly between the tangential and the non-tangential
techniques. With the use of non-tangential fields/incidences to
the breast, there was a wider spread of doses into the OAR and
healthy tissues surrounding the PTV. Nonetheless with IMRT5,
higher doses do reach lower percentages of left lung (V40Gy) and
heart, sparing these organs to high doses. Especially high-dose
cardiac irradiation is of particular concern according to several
studies [2,3,62,63].
Table 4
Pairwise comparison using the Friedman’s test between the techniques for the OAR variables that exhibit significant statistical differences. The cells in white background are
related to the PBC algorithmwhereas the cells in light gray background correspond to the iMC results. The values in bold are the variables with significant statistical differences
(p-value  0.05).



















f-IMRT 0.535 0.017 0.017
IMRT2 0.918 0.003 0.003
IMRT5 0.007 0.005 1.000
DCART 0.049 0.038 0.469
V5Gy
f-IMRT 0.535 0.002 0.001
IMRT2 0.679 0.013 0.007
IMRT5 0.004 0.013 0.836
DCART 0.004 0.013 1.000
V2Gy
f-IMRT 0.535 0.098 0.007
IMRT2 0.836 0.023 0.001
IMRT5 0.013 0.023 0.301







f-IMRT 0.301 0.000 0.002
IMRT2 0.408 0.007 0.038
IMRT5 0.000 0.005 0.535
DCART 0.003 0.030 0.535
V10Gy
f-IMRT 0.844 0.000 0.011
IMRT2 0.884 0.043 0.586
IMRT5 0.000 0.043 1.000
DCART 0.011 0.586 1.000
V25Gy
f-IMRT 0.062 0.004 0.000
IMRT2 0.062 0.301 0.038
IMRT5 0.004 0.301 0.301









f-IMRT 0.836 0.004 0.062
IMRT2 0.469 0.002 0.038
IMRT5 0.005 0.000 0.301
DCART 0.214 0.049 0.121
V40Gy
f-IMRT 0.062 0.000 0.038
IMRT2 0.030 0.038 0.836
IMRT5 0.000 0.078 0.062
DCART 0.030 1.000 0.078
V20Gy
f-IMRT 0.098 0.038 0.000
IMRT2 0.098 0.679 0.013
IMRT5 0.038 0.679 0.038
DCART 0.000 0.013 0.038
V2Gy
f-IMRT 0.535 0.000 0.013
IMRT2 0.301 0.001 0.062
IMRT5 0.000 0.002 0.147
DCART 0.007 0.098 0.147










f-IMRT 0.214 0.001 0.001
IMRT2 0.535 0.038 0.038
IMRT5 0.038 0.007 1.000
DCART 0.002 0.000 0.301
V5Gy
f-IMRT 0.884 0.000 0.011
IMRT2 0.884 0.043 0.586
IMRT5 0.000 0.043 1.000
DCART 0.011 0.586 1.000
V10Gy
f-IMRT 0.147 0.000 0.001
IMRT2 0.301 0.013 0.062
IMRT5 0.000 0.007 0.535
DCART 0.002 0.038 0.535
V20Gy
f-IMRT 0.062 0.062 0.000
IMRT2 0.098 1.000 0.023
IMRT5 0.078 0.918 0.023
DCART 0.000 0.017 0.023
V40Gy
f-IMRT 0.214 0.007 0.836
IMRT2 1.000 0.147 0.147
IMRT5 0.023 0.023 0.004











f-IMRT 0.408 0.007 0.301
IMRT2 0.679 0.000 0.062
IMRT5 0.000 0.001 0.098
DCART 0.038 0.098 0.098
D5%
f-IMRT 0.756 0.001 0.062
IMRT2 0.679 0.000 0.030
IMRT5 0.000 0.001 0.121
DCART 0.017 0.049 0.147
V5Gy
f-IMRT 1.000 0.003 0.375
IMRT2 1.000 0.003 0.375
IMRT5 0.003 0.003 0.586
DCART 0.375 0.375 0.586
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Our results are in agreement with previous work concluding
that using non-tangential fields increase the homogeneity and
conformity to the PTV, and heart and lung volumes receiving high
doses decrease but more healthy tissues receive low doses
[24,38,39,41,45,64].
In our study, tangential inverse-planning IMRT (IMRT2) did not
verify dose homogeneity improvement or reduction of dose to the
heart or left lung, compared to tangential multi-segmented f-IMRT,
in contrast with previous results [20]. Nonetheless, f-IMRT and
IMRT2 presented the solutions with less percentage of healthy
tissues receiving low and medium doses in the OAR but had worse
conformation CI and CN indexes when compared to the non-
tangential techniques. It was also observed that IMRT2 did not
significantly reduce the doses in the ipsilateral OAR when
compared to f-IMRT, in concordance to the observations made by
Zhou et al. [44]. On the other hand, these techniques presented
higher doses than IMRT5 on the left lung and heart for doses above
40 Gy, due to the concave shape of the breast and the incapacity of
the tangential fields to conform to the breast geometry.
No benefit in using DCART when compared to the IMRT tech-
niques presented before on what the PTV coverage and dose in the
OAR are concerned.
In general, the conclusions achieved concerning the tech-
niques were similar for both algorithms. However, according to
the data and considering Fig. 3 it can be clearly observed that
there were differences between the algorithms, mainly for the
PTV, with the PBC overestimating the higher doses in this
structure, from 12% up to 20%. Furthermore, on the OAR, there
are also relevant differences for the left lung and heart, in the
high doses range (>40 Gy), with PBC also overestimating the
doses in these organs.
These differences may arise from the limitations of the PBC to
estimate the doses on tangential beams due to the lack of electron
equilibrium in the superficial (buildup) region in the irregular
curvature of the breast and the inaccurate management of het-
erogeneities, in particular at the interfaces between air (lung) and
soft tissue as the PBC does not model the rebuild-up and does not
adequately account for electron transport [48e50].
It is presumed that iMC calculations are more accurate than the
PBC algorithm calculations. The major concern becomes that the
most relevant irradiation goal, V47.5Gy to be superior to 90% is not
achieved by iMC algorithm. From the past experience and the re-
sults achieved up to now, PBC was used and the clinical results are
known. Increasing the dose to achieve the V47.5Gy goal with iMC (by
increasing, for instance, the normalization value) would increase
the dose to thewhole breast. The consequences of such a procedure
are not well known and care should be taken when changing the
calculation algorithm, as it may also contribute to an increase in the
dose to the OAR.
Conclusions
This study presents the results from a breast irradiation com-
parison between 4 different techniques: f-IMRT (without wedges),
IMRT2, IMRT5 and DCART. The plans were evaluated based on
criteria adapted from QUANTEC [55] and RTOG 1005 [56].
Sizable discrepancies remain concerning between the 4 tech-
niques investigated on breast irradiation and between the two al-
gorithms studied (PBC and iMC). The dose distributions were
optimized for the PBC algorithm. The PTV was adequately covered
with all the techniques (evaluated by V47.5Gy), considering PBC.
IMRT5 had advantages over the other techniques based on the
dosimetric comparison performed in this study especially in the
high dose region of the left lung and heart, target conformation and
heterogeneity indexes; DCART was the technique with the lowest
V47.5Gy and did not present improvement in sparing the OAR or the
PTV coverage over the IMRT techniques investigated. However, the
non-tangential techniques (IMRT5 and DCART) do increase the
scattered dose and expose larger percentage of healthy volumes to
low and medium doses.
f-IMRT is still the recommended technique for breast irradia-
tion. Nonetheless, in case of high heart or left lung involvement,
IMRT5 should be considered to breast cancer irradiation as it cre-
ates themost conformal distribution at the expense of more normal
tissue receiving low dose.
These observations are valid both for PBC and iMC. However,
statistical significant differences were found between PBC and iMC
calculations, on the variables investigated, mainly in the higher
doses regimen (>40 Gy) for the PTV, left lung and heart.
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Chapter 5
Monte Carlo validation and
simulations of the breast cancer
treatment plans
The main goal of this chapter is to compare the different external beam irradia-
tion techniques used for breast cancer (BC) treatment, using conventional Pencil
Beam Convolution (PBC) and Monte Carlo (MC) dose calculation methods. Two
independent MC methods were used: iMC, the commercial Monte Carlo algorithm
from iPlan BrainLAB treatment planning system (TPS) and an independent model
validated with the state-of-the-art software EGSnrc/BEAMnrc. The irradiation
techniques investigated were:
• forward intensity modulated RT (f-IMRT) using tangential fields,
• intensity modulated RT (IMRT) using 2 fields (IMRT2), and
• IMRT using 5 fields (IMRT5).
Note: DCART was not included as no EGSnrc MC calculations were done due to
the gantry rotation feature of this technique, not yet implemented or validated in
this EGSnrc MC work.
In this study, in order to assess and quantify the accuracy of the absorbed dose cal-
culations determined by an analytical algorithm, the comparison between such cal-
culations and those obtained using an independent MC algorithm were performed
and the discrepancies were analyzed. An independent model of the VARIAN R©
Trilogy R© linear accelerator was used to simulate breast cancer treatments in
147
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EGSnrc [54, 244]. The High Definition micro multileaf collimator (HDMLC),
previously modeled and validated in water-based phantoms [132], was included in
the model. The accelerator model was benchmarked with measurements using ion-
ization chambers and film dosimetry. A comparison between the PBC, iMC and
EGSnrc MC calculations is presented. Measurements were performed in homoge-
neous phantoms to verify absolute and relative dose differences between the PBC
and the MC calculations. Gamma analysis was also used to perform comparisons
between the different calculations. Seven clinical cases were investigated. Dose
volume histograms (DVH) and gamma evaluation were used for the analysis. No
significant differences were found between the MC calculations performed using
the iPlan BrainLAB TPS and the EGSnrc code; however differences were found
both for the homogeneous and patient calculations between PBC and MC. These
differences were more relevant in the build up region and in regions containing
heterogeneities.
5.1 Motivation and goals
In RT, the accurate calculation of absorbed dose is of utmost importance. There-
fore accurate dose calculation methodologies have been developed for EBRT. To
achieve the total desirable accuracy of 3% in dose delivery to a point or volume
[62], it is estimated that the accuracy of computed dose distributions should be
between 1% and 2% [62]. There is a notable effort to develop TPS with increas-
ingly complex algorithms to achieve this goal. The simplest algorithms are point
dose estimates. These methods are reported to be limited in accuracy and fail
to model specific geometries. Deterministic dose calculation methods could have
been developed based on the photon transport equation and using the well-known
interaction cross sections. However, these were not developed for photon beams
as they could not be general enough to deal with the complex geometries involved
in RT and would only work if few events were involved in the particle’s energy
absorption [41].
Given the current use of RT for treating breast cancer using linear accelerator
technology, the influence of the dose algorithms is relevant to accurately determine
the dose in the target volume and estimate the risks in the OAR for assessing
normal tissue toxicity or the risk of secondary cancer. The influence of the choice
of the dose algorithm for breast RT is an important challenge due to its complex
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concave geometry and localization near the rib bones, lung and its proximity to
the interface body-air.
The analytical algorithms are known [52, 245] not to accurately determine the ab-
sorbed doses, especially the algorithms primarily based on equivalent path length
(EPL) for inhomogeneity corrections. The absorbed dose depends on beam spec-
trum, field size, incidence and contaminating electrons. With these algorithms,
electrons derived from primary photon interactions and parts of the linac head
and the air volume downstream to the patient are not taken into consideration
[246]. Convolution-superposition models such as the analytical anisotropic algo-
rithm (AAA) were developed to deal with inhomogeneities through the scaling of
photon and electron scatter kernels anisotropically, depending on the medium [50].
A family of semianalytical dose calculation algorithms based on energy deposition
kernels has been developed, namely convolution and superposition algorithms .
These algorithms have a better performance than correction based algorithms as
they account for penumbra broadening effect in low density media (eg. lung)
[72, 247].
In this work, iPlan TPS was used with two algorithms: PBC and iMC, previously
described in chapter 4. The PBC algorithm is used in clinical routine. The Monte
Carlo independent model details were provided in chapter 3. It was mainly used
to compare the two clinical TPS algorithms.
5.2 Materials and Methods
5.2.1 Phantoms and patients
In order to account for the concave surface of the chest wall and of the breast
of a patient, two phantoms were used in this work. The first phantom, named
BELEM, was built for the specific purpose of this work, to reproduce the breast
shape. It was made using a vegetal fat that was melt and put into a plaster mold
made from a Rando-Alderson female torso. The phantom was cooled in the fridge
and was later removed from the mold and kept in the fridge for conservation. This
phantom is homogeneous and has an approximate density (not assessed) to the
water density. It was placed on top of a set of water-equivalent slabs as presented
in figure 5.1. To perform the dose measurements, a 0.125 cm3 PTW R© model 31010
ionization chamber was placed in a cavity in the phantom specially drilled for the
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Figure 5.1: The Belem phantom. On the left, the breasts made of vegetal fat; on the
right, the breasts are placed on top of a set of water-equivalent slabs to perform the
measurements.
Figure 5.2: The NAOMI phantom. Left homogeneous breast and right breast with a
hole placed on top of a set of water-equivalent slabs to perform the measurements by
placing an EBT2 film within two slices of the phantom.
purpose. CT scans of the phantom were acquired at a Siemens R©, Biograph 64R
PET-CT scanner, with a resolution of 0.0977 × 0.0977 × 0.3 cm3.
The second phantom, NAOMI, was kindly lent by the Department of Fisioloǵıa
Médica y Biof́ısica, Facultad de Medicina, Universidad de Sevilla. Its complete
description can be found in Fernández, B. PhD thesis [248]. It was placed on top of
a set of water-equivalent slabs as depicted in figure 5.2. GAFCHROMIC R© EBT2
films were placed in the coronal plane between the slabs of the NAOMI phantom.
The NAOMI phantom underwent a computed tomography (CT) scan on the same
conditions as the BELEM phantom. The images were imported to the TPS.
Seven left breast cancer patients (stage I or II), referred to adjuvant RT after
breast conserving surgery, were randomly chosen among a population of 394 breast
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patients treated between 2010 and 2011 and their CT images were imported to
the iPlan TPS.
5.2.2 EGSnrc calculations
The Varian 2300C/D Trilogy linac equipped with a HDMLC was accurately mod-
eled for a 6 MV photon beam using the EGSnrc [244] user code with BEAMnrc
[54] and DOSXYZnrc [122] for MC dose calculations. The detailed geometry and
dimensions of all the linac head components were set based on the manufacturer’s
specifications. The simulation results were fully modeled and accurately commis-
sioned against experimental data [132]. The MC simulations were performed in
three stages as illustrated in chapter 3, figure 3.4. The patient-independent part
involved the fixed component modules of the Varian 2300 C/D linac, resulting in a
phase space file scored above the jaws. The first part of the simulation was run once
with 5 × 108 incident particles on the target. The resulting particle coordinates
(particle type, energy, location and direction) were scored in a phase space file for
subsequent use in the next step of the simulation. This patient-independent phase
space file was then used as a source to the patient-dependent part, to simulate the
radiation interactions in the including the jaws and the MLC.
In the second stage, depending on the details exported from the TPS for each
field, output phase space files for the different field sizes and MLC configurations
are obtained, below the MLC. For this patient-dependent part, four independent
runs (with different random number seeds) using the total number of particles
scored in the previous stage (about 4.7× 108) were simulated. he final number of
particles collected in the second phase space file for each beam did largely depend
on the field size beam, on the MLC beam arrangement and on the weight the
field had on planning. The larger main tangential beams had between 5× 107 to
8 × 107 particles in the second stage phase space file. The time each simulation
took did also depend on the field size and on the MLC arrangement. The larger
tangential fields simulation took in average 37.2 hours to be simulated (considered
the tangential fields in f-IMRT, IMRT2; for IMRT5, as there were more beams, in
general, the weight was divided among the 5 fields, taking in average less time - in
average, 22.7 hours for complete simulation). The following transport parameters
were set for the BEAMnrc simulations:
• ECUT = AP = 700keV ,
• PCUT = AP = 10keV
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, where AP and AE are the low-energy thresholds for the production of secondary
bremsstrahlung and knock-on electrons, respectively; while ECUT and PCUT
define the global cutoff energy for electron and photon transport, respectively. In
order to improve the calculation efficiency, and decrease the head simulation times,
various variance reduction techniques were employed:
• i. uniform bremsstrahlung splitting with a photon splitting factor of 20, to
increase the number of photons created in the target;
• ii. russian roulette; and
• iii. the range rejection technique with ESAVE of 0.7 MeV in the bremsstrahlung
target and 1.0 MeV for the other accelerator components.
These outputs were then used as input for the DOSXYZnrc code for dose calcu-
lation in the phantom/patient geometry derived from the CT data. The resulting
phase space files were then combined in a final phase space file using BEAMDP
[119]. To calculate dose in the patient, at the third and last stage of the sim-
ulation process, the final scored phase space files of each individual beam were
used as input for the DOSXYZnrc code [122], to independently simulate in the
CT-based phantom. The planning CT images were manipulated using a DI-
COM RT toolbox in MATLAB [249] to create a phantom-based image, with same
resolution used for TPS calculations, 3.0 × 3.0 × 3.0 mm3. The particles in the
patient-dependent phase space files were recycled several times (less than 20) in
the DOSXYZnrc calculations. MC dose calculations in the CT images were carried
out for:
• ECUT = 0.521MeV , and
• PCUT = 0.01MeV .
The value of the parameter ESTEPE (maximum fractional energy a charged par-
ticle can lose per step) was set to its default value of 25%. The conventional
CTCREATE/DOSXYZnrc conversion ramp using four materials (air, lung, tissue
and bone with the adequate mass density) was considered for the calculations.
Using this program, a CT data set can be converted into the appropriate voxel ge-
ometry for DOSXYZnrc calculations. The material type (composition) and mass
density data within each voxel are derived from the Hounsfield number exported
from the patient CT using a CT conversion ramp. The default ramp for convert-
ing CT to material and density in CTCREATE is shown in figure 5.3. The ICRU
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Figure 5.3: The DOSXYZnrc default ramp for converting CT-number to material
density [95]. Indicated in the figure are the ICRU standardized points for ”Air”, ”Lung”,
”Tissue” and ”Bone”. Note that the CT numbers considered for the DOSXYZnrc
presents an offset of 1000 with respect to the standard definition of Hounsfield number
([-1000, 1000]).
standardized materials used to characterize this ramp are ”Air”, ”Lung”, ”Tissue”
and ”Bone” where material densities between the fixed points are linearly inter-
polated. Note that the CT numbers presents a shift of 1000 with respect to the
standard definition of the Hounsfield number.
The final dose distribution for each phase was the summation of the dose distribu-
tions from all individual beam arrangements. The individual uncertainty for the
final distribution was less than 2%. For each phantom and patient data, the plan
information data, jaw positions, gantry and collimator angles, MLC configuration
and patient isocenter position were exported from iPlan TPS and introduced in
the correspondent input files of the BEAMnrc and DOSXYZnrc codes. The cal-
culations were performed in a cluster of 2.2 GHz AMD Opteron processors at the
Nuclear Physics Center of the University of Lisbon.
5.2.3 Measurements
Two phantoms were used to validate the treatment plans. The BELEM phantom
permitted placing an ionization chamber to perform absolute point dose measure-
ments, referred from now on as absolute dosimetry or absolute dose measurements.
The NAOMI phantom was used to place films inside, as shown in figure 5.2. The
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Figure 5.4: Film analysis. Calibration curve of the EBT2 films using FilmQATM
software. A film was irradiate with different doses, creating a pattern to establish
a correlation between the OD (optical density) measured in the film and the dose
imprinted in the film.
dose film measurements are considered relative as they depend on a calibration
curve also established at the time the validation plans were irradiated, as depicted
in figure 5.4. This will be from now on referred as relative dosimetry.
5.2.3.1 Absolute dosimetry using the BELEM phantom
Dose measurements were performed using a 0.125 cm3 31010 PTW R© ionization
chamber that was placed in the cavity specially drilled in the BELEM phantom,
connected to a UNIDOS E PTW electrometer, with ambient conditions corrections
. All the optimized treatment plans for f-IMRT, IMRT2 and IMRT5 of the seven
patients were irradiated and measurements were performed. The results were com-
pared with the dose determined in the TPS for PBC and iMC and that calculated
with the independent MC calculations. Furthermore, to quantitatively compare
the PBC with the MC simulation plans, the 3D gamma index was calculated in
CERR R© [250] (further details in section 5.2.5.2).
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Figure 5.5: Validation scheme. iPlan calculations were performed for absolute and
relative verifications. For absolute dose validation, measurements were performed using
the BELEM phantom and ionization chambers for comparison with iPlan calculations.
Moreover, MC calculations were performed and compared to the measurements. For
relative dosimetry, the NAOMI phantom was used with EBT2 films for comparison
with the iPlan plans; EGSnrc MC simulations were also compared with iPlan.
5.2.3.2 Relative dosimetry using the NAOMI phantom
An EBT2 GAFCHROMIC film was placed between two slices of the NAOMI
phantom and dose measurements were performed. These measurements were done
for one of the patients, for the three techniques (f-IMRT, IMRT2 and IMRT5)
due to limited resources. After irradiation of the treatment plans, the films were
processed in an Epson 10000XL flatbed scanner and analyzed in the software
FilmQATM [75]. An optical density versus dose, calibration curve was applied for
film measurements (see figure 5.4) and the data was normalized to the maximum
dose on the central axis.
For these plans, calculations were performed on the CT image of the NAOMI using
iMC and the independent MC calculations. The TPS plans were compared with
the corresponding films, using FilmQATM gamma analysis. Furthermore, the MC
results were compared with the TPS calculations, using the 3D gamma evaluation
function in CERR R©.
In figure 5.5, a scheme of the work performed for validation purposes is presented.
5.2.4 Patient dose calculations
EGSnrc MC simulations of the optimized treatment plans on the patients orig-
inal CT images were performed for the 3 techniques under investigation. The
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results were compared to the iPlan results for PBC and iMC, using dose volume
histograms (DVH) and 3D gamma analysis in CERR [250].
5.2.5 Evaluation tools
5.2.5.1 CERR
CERR R© 1 is a software developed in MATLAB c© for radiotherapy research. It was
used to import the 3D dose files created in EGSnrc and iPlan and is able to display
DICOM-RT format [251]. When the DICOM dataset is imported into CERR R©
the whole plan archive is stored in a MATLAB c© binary format. Subsequently,
CERR provides a variety of possibilities such as DVH and treatment planning
comparisons, including gamma evaluation [250].
5.2.5.2 Gamma Map Algorithm
The gamma index was introduced by Low et al [252] and Depuydt et al [253] to
compare and evaluate the dose distribution in 2D and 3D. The gamma-volume
cumulative histograms were developed by Spezi and Lewiset [254] to evaluate
the IMRT treatment plans. Like the DVH, the gamma-volume histograms are
represented in function of a cumulative volume. This permits to quantitatively
compare measured and calculated absorbed dose distribution values.
Fundamentals Modern RT techniques such as 3D-CRT and IMRT often give
rise to complex dose distributions with several low and high dose gradient regions.
A simple comparison with superimposition of two dose maps can quantify the
differences between these maps. However, in the region of high dose gradient, a
small difference in spatial position can result in a large difference in the dose value.
To solve this problem, Low et al [252] proposed a method called the Gamma Map
Algorithm. This method takes into account both the dose difference and the spatial
displacement between the corresponding points on the two dose maps. The gamma
index is based on the comparison of two dose distributions: one considered the
reference dose distribution (Dr) and another is the dose distribution to compare
(Dc).
For a reference point with position pr, receiving a dose Dr, and a dose point to
1CERR: http://www.cerr.info/about.php)
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compare pc, receiving a dose Dc, the distance between the two points pr and pc is
d(pr, pc) and the dose difference is ∆D(pr, pc). The tolerance criteria are defined
by a maximum distance difference (∆dM) and a maximum dose difference ∆DM ,
represented by an ellipsoid envelope, centered in the reference dose point and












For 2D comparison between reference and compared dose distributions, the ac-
ceptance criteria for the Gamma analysis can be depicted as represented as the
ellipsoid in figure 5.6. The size of this ellipsoid is defined by ∆DM and ∆dM .
Figure 5.6: Schematic representation of the theoretical concept of the gamma evalu-
ation method. The reference and compared dose distributions are denoted by (pr, Dr)
and (pc, Dc), respectively. The criteria defining the ellipsoid of acceptance are denoted
by the dose difference tolerance ∆DM and the maximal distance to agreement ∆dM .
Image from [253].
The calculation of the gamma index, γ, requires two user-defined criteria:
• ∆DM in % - represents the maximum acceptable dose difference, in percent-
age;
• ∆dM or DTA (dose-to-agreement) - represents the maximum accepted toler-
ance for the misalignment of the corresponding dose maps due to positioning
uncertainty in the to-compare dose map, in order words, is the spatial dis-
tance between calculated and measured data points that receives the same
absorbed dose.
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The clinically accepted values of ∆DM and ∆dM are generally 3% and 3 mm,
respectively.
The gamma index is calculated for every to-compare dose point and according
to Low et al [252] algorithm, the investigated dose is said to have passed if the












From equation 5.1, it can be seen that the smaller the values of ∆DM and ∆dM ,
the harder it is to pass the gamma comparison.
The coordinate system in figure 5.6 is made up of x, y and D axis. The combination
of x and y axis are represented by the position vector
→
p (x, y) which describes the
direction and the distance between the reference point relative to the to-compare




x2 + y2 (5.3)
The D axis describes the reference and the to-compare dose difference. The passed
and failed values correspond to the compared points that are inside and outside
the ellipsoid, respectively.
Further developments of the gamma algorithm are reported in the literature. In
2002, Depuydt et al [253] introduced a refined gamma algorithm that provided a
faster solution for comparing complex dose distributions. The key difference in
this algorithm is that the gamma indices are either 0 or 1 for failed and passed,
respectively, in the comparison. The quality of the comparison is determined
by how small are a user defined ∆D and ∆d acceptance criteria. Its advantage
is that it provides a simple result which is useful for making quick decisions on
whether the two data sets (measured and calculated dose maps) agree within
the acceptable tolerance. However, this algorithm provides no indication on how
good the agreements between the measured and calculated points are. Bakai et
al [255] also reported another improvement of the Gamma algorithm, extending
Low’s et al algorithm for 3D dose distributions. The algorithm also allows the
distance to agreement criterion to be set for three spatial directions to account
for positioning errors that are not uniform in the anterior/posterior, lateral and
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superior/inferior directions. The flexibility of setting the distance to agreement to
criterion for all three spatial direction in this method was claimed to improve the
gamma calculation time in comparison to Low [252] method.
5.2.5.3 FilmQA
FilmQATM was used to compare the film measurements with the iPlan calcu-
lated plans, either PBC or iMC. The quantitative evaluation tools available in
the FilmQATM software for comparison of dose distributions are the distance-to-
agreement (DTA) method, the dose deviation method and the gamma analysis
method.
The absorbed dose deviation method compares the absorbed dose in the data
points in the reference plan with the corresponding data points that are to be
evaluated. In the FilmQATM evaluation software the criteria for the maximum
acceptable absorbed dose deviation are set regarding to the global absorbed dose.
The FilmQATM software creates an isodose surface by interpolating between the
data points in the reference plan. This isodose surface is compared with measured
data points. A criterion for maximum acceptable DTA can be chosen manually
by the user. The distance between the measured and reference data points with
the same absorbed dose must not exceed the chosen maximum DTA to pass the
evaluation.
The gamma evaluation method described by Low et al [252] applies two comparison
tools, a direct comparison of the absorbed dose deviation and comparison of the
DTA between calculated and measured absorbed dose distributions and provides
a numerical index as a measure of agreement of the two dose distributions. The
gamma evaluation method sets the criteria for both absorbed dose deviation and
the distance to the closest data point in the reference plan.
For 2D absorbed dose distributions the two criteria, the absorbed dose deviation
and the DTA, includes an ellipsoid with the surface representing the acceptance
criterion (figure 5.6).
5.2.5.4 CERR
The dose distributions from the TPS and the EGSnrc MC calculations were com-
pared using the gamma analysis as built into CERR R© software. The acceptance
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criterion was set to 3% dose difference and 3 mm for DTA, in compliance with Low
et al [252] and Korreman et al [256]. The objective with the chosen acceptance
criterion was to reflect a routine clinical condition. CERR displays the gamma
index distribution.
5.3 Results
5.3.1 Comparison using the BELEM phantom
The optimized f-IMRT, IMRT2 and IMRT5 calculation plans were applied to the
BELEM phantom using iPlan Phantom Mapping, both for the PBC and iMC
algorithms. The calculated isodose distributions in the BELEM phantom are
displayed in figure 5.7, for one of the patients enrolled in the study.
Figure 5.7: PBC and iMC calculation of the optimized plans in BELEM phantom,
for f-IMRT, IMRT2 and IMRT5 techniques. In orange, it is represented the IC inserted
in the phantom
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It is possible to visually infer that, in general, PBC predicts higher breast doses
compared to iMC, for all the techniques. The DOSXYZnrc/EGSnrc MC calcula-
tions were performed using the BELEM CT images with the same calculation grid
used in iPlan.
5.3.1.1 Ionization chamber measurements
Dose measurements with the 0.125 cm3 IC were also performed in the phantom
insert for the positioning of the IC as previously explained. The relative dose
differences between the calculations and the measurements performed with the IC
are shown in figure 5.8.
In general, the PBC estimated higher doses (with an average of 2.9%) than the
measured doses and presented higher discrepancies with the measurements that
the iMC or EGSnrc MC calculations. Considering that the uncertainty of the IC
measurements is on the order of 2-2.5% [183] and is 1-2% for the MC simulations,
the MC results are in good agreement with the measurements, both for iMC and
EGSnrc MC.
5.3.1.2 Gamma analysis of the calculated plans
The comparison on the calculated plans for the Belem phantom are now presented.
For analysis, it is considered that for the 3%/3 mm criteria, the results are sat-
isfactory if, at least, 95.0% of the points pass gamma evaluation for the criteria
3%/3 mm; shrinking the criteria to 2% / 2 mm, the percentage of points that is
considered acceptable is reduced to 90.0%.
Using the 3D gamma analysis function from the CERR software, a comparison
between PBC and MC calculations was performed. The results are presented in
figure 5.9. For PBC vs EGSnrc MC, all the plans had more than 93.0% and 88.0%
of the points respecting γ < 1.0 for 3%/3 mm and 2%/2 mm criteria, respectively;
whereas for iMC vs EGSnrc MC, the gamma comparison was superior to 97.0%
for the criteria 3%/3 mm and superior to 94.0% for 2%/2 mm, for all plans. On
average, f-IMRT plans had poorer agreement compared to IMRT2 and IMRT5
plans.
Figure 5.10 shows the 3D gamma analysis for one patient. It can be observed
that the differences between PBC and MC are more significant at the air-body
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Figure 5.8: Absorbed dose (in cGy) calculated in the IC for the PBC (in blue), iMC
(in green) and EGSnrc MC (in purple) and measurement with the 0.125 cm3 IC (in
lighter colors).
interface of the breast and inside the ionization chamber volume. Maximum dose
differences of up to 1.0 Gy in the build-up region, and less than 0.2 Gy in the
homogeneous region can be seen.
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Figure 5.9: Representation of the 3D gamma results for the 7 patients, for f-IMRT,
IMRT2 and IMRT5 (in green, orange and blue, respectively) for the criteria i. 3%/3
mm and ii. 2%/2 mm, in continuous and dashed lines, respectively; on the left for the
comparison between PBC and EGSnrc MC and on the right graph for iMC and EGSnrc
MC.
5.3.2 Comparison in the NAOMI phantom
Film measurements were performed in the NAOMI phantom for only one of the
patients enrolled in this study. PBC, iMC and EGSnrc MC calculations were
compared using 3D-gamma evaluation in CERR software [250].
5.3.2.1 Comparison between TPS and film measurements
Using FilmQATM software, a 2D gamma analysis was performed between the
calculated plans and the film measurements, for the following criteria: 3%/3 mm
and 2%/2 mm. The results are presented in figure 5.11 and summarized in table
5.1. A comparison between iMC and the film measurements was also performed
and is presented in figure 5.12 and the results are summarized in table 5.2.
Table 5.1: 2D gamma analysis of PBC and film measurement in the NAOMI phantom,
using the following criteria: 3%/3 mm and 2%/2 mm.
For f-IMRT, the results with PBC are acceptable, for both criteria, being on the
limit to acceptance (95% for the criterion 3%/3 mm; 90% for 2%/2 mm). For
IMRT2, for both algorithms and 3%/3 mm criteria, the results are satisfactory;
however, for 2%/2 mm, the 90% goal is not reached. For IMRT5, the results were
Chapter 5. MC validation and simulations of the BC treatment plans 164
Figure 5.10: 3D-gamma analysis comparing PBC and EGSnrc MC calculated for
(a.) f-IMRT, (b.) IMRT2 and (c.) IMRT5 for one of the patients, using the BELEM
phantom, are presented, on a transversal, sagital and coronal planes, respectively. On
the left images, the 3D gamma analysis is plotted. The white line represents the profile
presented in the graph, on the right upper side, with PBC (orange line) and EGSnrc
MC (green line) curves. The differences between the profiles of both calculations are
presented in the bottom graphs, on the right.
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Figure 5.11: 2D gamma analysis between PBC and film measurements in FilmQATM
software in the coronal plane where the film was placed in the NAOMI phantom. On
the left, the gamma evaluation representation; on the right side, the gamma analysis
histogram.
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Figure 5.12: 2D gamma analysis of iMC and film measurements in FilmQATM in
the coronal plane where the film was placed in the NAOMI phantom. On the left, the
gamma evaluation representation; on the right side, the gamma analysis histogram.
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Table 5.2: 2D gamma analysis of iMC and film measurement in the NAOMI phantom
using the following criteria: 3%/3 mm and 2%/2 mm.
not satisfactory, with less than 95% or the points not verifying γ < 1%, for none
of the algorithms, for 3%/3 mm; for the criterion 2%/2 mm this 90% goal is not
achieved either. However, the results are significantly better for the iMC than for
the PBC algorithm.
5.3.2.2 Comparison between PBC and iMC using 3D-gamma evaluation
The results of the film dosimetry are not ideal, they are acceptable. Therefore,
the EGSnrc MC simulations were performed and compared to the TPS results. A
3D gamma comparison, using CERR R©, between the plans calculated using PBC
and iMC was performed for the NAOMI phantom. The results are presented in
figure 5.13.
Table 5.3: Average 3D-gamma results between PBC and iMC, with 3%/3 mm and
2%/2 mm criteria, for the NAOMI phantom.
According to the results presented in table 5.3, the agreement between PBC and
iMC was higher than 92.0% all plans for the 3 techniques. The highest differences
in the calculations were at the body-air interface in all the plans, as can be observed
in figure 5.13.
5.3.2.3 Comparison between the TPS algorithms (PBC and iMC) and the
EGSnrc MC using gamma evaluation
The comparison between the TPS calculations (PBC and iMC) and the EGSnrc
MC calculation for the NAOMI phantom was performed using CERR R© and the
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Figure 5.13: 3D gamma calculations for the NAOMI phantom comparing PBC and
iMC algorithms from iPlan for a. f-IMRT, b. IMRT2 and c. IMRT5. On the left,
image of the 3D gamma evaluation; the top graphs on the right side correspond to the
dose profiles marked by the white line traced on the left image determined for the PBC
and iMC dose calculations; the graph below corresponds to the dose difference between
the two calculation algorithms in this line.
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results are presented in figure 5.14 for f-IMRT and summarized in table 5.4, for
the 3 irradiation techniques.
Figure 5.14: 2D gamma analysis for the NAOMI phantom, at the film coronal plane,
comparison PBC (in the upper line) and iMC (in the lower line) with the EGSnrc
MC calculations, respectively for 3%/3 mm criteria, on the left column and 2%/2 mm
criteria, on the right column, for f-IMRT.
Table 5.4: 3D gamma evaluation between the TPS algorithms (PBC and iMC) and
the EGSnrc calculations for NAOMI phantom.
According to the results presented in figure 5.14, PBC exhibits higher differences
relative to the EGSnrc MC calculations than the iMC algorithm. The differences
between the PBC and the EGSnrc MC are more evident at the body-air interface.
The gamma results present, on average, γ < 1.0 for 95% of the points (3% / 3
mm criteria) and all the plans had gamma superior to 90%, for the 2% / 2 mm
criteria.
Chapter 5. MC validation and simulations of the BC treatment plans 170
5.3.3 Patient CT-based calculations
MC simulations were performed for the 7 clinical cases under investigation, for
f-IMRT, IMRT2 and IMRT5. To compare the calculations performed using the
3 algorithms, DVH were plotted for the contoured structures. The results are
presented in figure 5.15. iMC and EGSnrc MC estimate lower doses for the PTV
than PBC, for all the 7 cases. The maximum differences observed between the
PBC and the MC calculations can reach 5 Gy. In the structure ’Body excluding
the PTV’, the differences between the algorithms are more pronounced for doses
higher than 40 Gy. Considering the ipsilateral lung, there are large discrepancies
between the PBC and the MC algorithms particularly for doses higher than 30 Gy.
For the contralateral breast, there are no visually significant differences between
the DVH generated for the different algorithms. In the heart, the most significant
differences between the PBC and MC calculations are for doses below 10 Gy and
for doses higher than 40 Gy.
In order to further analyze the differences between the dose distributions, a 3D
gamma analysis was performed, in CERR, for 3%/3 mm and 2%/2 mm criteria
between the PBC and the EGSnrc MC and subsequently between the iMC and
the EGSnrc MC. The results are presented in tables 5.5 and 5.6, respectively.
Table 5.5: 3D-gamma analysis between PBC and EGSnrc MC calculations, for the 7
patients enrolled in the study, using 3%/3 mm and 2%/2 mm criteria.
Table 5.6: 3D-gamma analysis between the iMC and the EGSnrc MC calculations
using 3%/3 mm and 2%/2 mm criteria.
There is better agreement between the MC techniques than between the PBC
and the EGSnrc MC. The 3%/3 mm criterion is higher than 93.0% between the
PBC and the MC and higher than 97.0% between the iMC and the MC, for all
plans; shrinking the tolerance to 2% and 2 mm, the gamma index is significantly
lower and some plans (3 and 1 out of 7 for f-IMRT and IMRT2, respectively) do
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Figure 5.15: DVH comparison for the 3 calculation algorithms: PBC (continuous
black line) iMC (light grey dots) and EGSnrc MC (dark grey point-line) for f-IMRT,
IMRT2 and IMRT5, from left to right. The histograms are plotted for the PTV and
Body without PTV, in the first line; left lung and contralateral breast, in the second
line and in the heart, in the third line.
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not achieve 90% of points within γ < 1.0, for PBC and MC but the γ < 1.0 is
achieved by more than 92.0% of the points, for all plans comparing iMC and MC.
There is better agreement between the MC techniques than between the PBC and
the EGSnrc MC. The 3%/3 mm criterion is higher than 93.0% between the PBC
and the MC and higher than 97.0% between the iMC and the MC, for all plans;
shrinking the tolerance to 2% and 2 mm, the gamma index is significantly lower
and some plans (3 and 1 out of 7 for f-IMRT and IMRT2, respectively) do not
achieve 90% of points within γ < 1.0, for PBC and MC but the γ < 1.0 is achieved
by more than 92.0% of the points, for all plans comparing iMC and MC. From the
analysis of the DVH in figure 5.15, it may be inferred that the differences between
the PBC and EGSnrc MC calculations are more significant in the lung, in the
higher doses regions. There are also significant differences in the build-up region,
in the body.
5.4 Discussion
New cancer treatment techniques such as IMRT envisage an improved control of
the normal tissue complications and a more accurate absorbed dose in the target
volume. Therefore, accurate dose calculations are required to generate reliable
dose distributions and dose-volume information for treatment planning and plan
evaluations. The choice of the dose calculation algorithm may also affect the final
dose distribution.
Accurate dose calculation is dependent on the introduction of accurate measured
data in the TPS beam configuration. There are limitations in obtaining such
accurate data as the ionization chambers usually used for beam commissioning
provide an over-response at the surface due to the perturbation caused by the
electron contamination in the build-up region [59, 246]. Therefore differences
between the calculated and the delivered dose to the patient in the build-up region
[257] could be anticipated.
The first part of the work aimed at performing absolute dose measurements in
homogeneous home-made phantoms. In general, the PBC algorithm estimated
higher doses than those measured by the ionization chamber. With iMC and
EGSnrc MC calculations, the computed absolute dose was closer to the measure-
ments. Relative measurements were also performed using films in an homogeneous
phantom and using 3D gamma evaluation for analysis. For the two different cri-
teria used. With PBC, there were higher differences between the measurements
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and the calculations, especially in the build-up region, as obtained in previous
independent studies [72, 258, 259].
The TPS calculations were performed based on a HU-ED (Hounsfield Unit to
electron density) calibration curve that was obtained with a specific calibration
phantom which contained tissue-equivalent materials. For the EGSnrc MC cal-
culations, a default CT conversion curve using 4 bins (air, lung, tissue and bone
materials) from EGSnrc was used. Differences between iMC and EGSnrc MC can
be assigned to the different HU-ED curves adopted.
The satisfactory results obtained between the iMC anc EGSnrc MC calculations
further validated the HDMLC model [132] which proves to be a suitable tool to
simulate breast cancer treatments. Therefore, further calculations were performed
on clinical cases for the different verified techniques.
Comparing the DVH resultant from the comparison of the algorithms, the PBC
over-estimates the dose in the higher dose region (for doses higher than 40 Gy) and
presents higher doses in the lung and in the heart, compared to the dose values
computed using the MC techniques. Further verification measurements should
be performed in a heterogeneous phantom to precisely quantify the differences in
the lung and bone. However, PBC is known for its limited accuracy mainly in
heterogeneous media [260, 261].
The use of the commercial MC calculation iMC algorithm in iPlan would be prefer-
able to PBC algorithm but it is still not possible in the actual clinical panorama
due to the large amount of time each plan takes to calculate (the iMC calculations
performed took between 30 to 40 min, and could not be therefore considered for
optimization).
5.5 Conclusions
The aim of the present study was to compare the dose calculation accuracy of the
Pencil Beam Convolution algorithm with a commercial MC algorithm from iPlan
BrainLAB TPS and independent MC (EGSnrc-based code) calculations, in breast
cancer radiotherapy calculations, using measurements with ionization chambers
and radiochromic film.
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The 3 calculation algorithms were compared and there are significant differences
between the PBC algorithm and the MC-based calculations, in the build up region,
in the lung regions.
The first clinical cases using the HDMLC in EGSnrc MC calculations model are
presented and the results are validated against the iMC iPlan BrainLAB algorithm:
there is a good agreement (superior to 97%) between the DVH in the PTV and
OAR and between the 3D-gamma analysis performed.
Chapter 6
Assessment of contralateral breast
doses in breast radiotherapy
Radiotherapy is a double-edged sword: it may heal but it also may induce late
complications.
6.1 Second cancer malignancies
Deterministic effects appear at high doses (several Gy); however, stochastic effects,
such as cancer induction, may occur at much lower doses. Second cancer induction
from radiation therapy is becoming an important issue mainly for two reasons:
• the survival rates are increasing and therefore the risk for a subsequent cancer
also increases [262];
• radiation therapy techniques are evolving envisaging highly modulated beams
to achieve optimal dose conformality to the tumor volume while sparing
healthy tissues [263], for higher doses but with low doses absorption not
being assessed.
Second cancer risk assessment in RT is a struggling and demanding issue due
to the large uncertainties of the dose-response relationship in human tissues. To
better assess the dose-response relationship, Joosten et al [264] advocates that
epidemiological studies on second cancer risk should not only incorporate in-field
but also out-of-field dosimetry.
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The TPS systems are accurate at determining in-field doses, however their accu-
racy in out-of-field dose calculations for peripheral doses may not be that accurate
[265, 266]. Peripheral doses are typically determined using measurements in water
phantoms [267, 268] or Monte Carlo methods [269–271].
6.1.1 Carcinogenic Effect of Radiation
The potentially carcinogenic effect of ionizing radiation is well known and has been
extensively investigated. Early experiences in the 1900s were based on individuals
accidentally exposed while working, for example, radium dial painters, uranium
miners and in physics or chemistry research. Most of our understanding of radia-
tion effects on humans, including functional dose-response relationships, is largely
based on incidence and cancer mortality for solid cancers and leukemia among
atomic-bomb survivors in Japan [272–274]. Those nuclear explosions caused acute
radiation exposures over a very short period of time. Such exposures cause differ-
ent biological damage mechanisms than those experienced by radiotherapy patients
who are treated with prolonged exposures in fractionated intervals. Many research
groups have directly studied second cancer incidence rates among radiotherapy pa-
tients. Epidemiological data have shown that an exposure to ionizing radiation
above 50 - 100 mSv increases the risk of, for example, second prostate cancer [275]
and second breast cancer in patients 30 years after the initial treatment [276].
Large studies were also done for breast cancer cases after treatment of childhood
cancer with radiation [277, 278].
Criteria for classifying second cancers were originally defined by Cahan et al [279]:
• the second tumor occurs in locations irradiated by primary or secondary
therapeutic beams,
• the histology of the second tumor is different from that of the original disease
so a metastasis is excluded,
• the existence of a latency period, typically of several years,
• the second tumor was not present at the time of radiation treatment and
• the patient does not have a cancer-prone syndrome.
It is believed that the therapeutic dose aims at killing all tumor cells thus leaving
little chance for cell mutation. For this reason, dosimetry studies of second cancers
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often focused on regions that were ’outside the treatment volume’. Treatment-
related second cancers are the direct consequence of treatment success to the first
cancer.
6.1.2 Second malignancies after Radiotherapy
As a part of an epidemiological study on cervical cancer, Stovall et al [280] de-
veloped a systematic dosimetric method for determining tissue doses for about
20.000 patients who were treated for cancer of the uterine cervix at many insti-
tutions in the United States, Canada and Europe from 1916 to 1975. This work
was among the most significant dosimetry efforts related to second cancer studies.
The authors measured and calculated doses from external-beam radiation therapy
involving several treatment machines, using an anthropomorphic female phantom.
6.2 Second malignancies after Primary Breast Cancer Ra-
diotherapy
In 2004, Roychoudhuri et al [281] published a study on second cancers of the lung,
colon, oesophagus and thyroid gland, malignant melanomas, myeloid leukemias
and second primary breast cancers, investigating second cancers in patients who
either have, or have not, received radiotherapy alongside surgery for breast cancer.
It was observed an elevated relative risk for lung cancer (at 10-14 years and over
15); myeloid leukemia (at 1-5 years); second breast cancer (at 5-10 years and over
15); and oesaphageal cancer (at over 15 years). Other reviews on induction of
second malignancies after using radiation, in different organs and using different
techniques were done by Fowble et al [282], Xu et al [267] and Grantzau et al [283].
The EBCTCG study published in 2005 [27] observed an excess cancer incidence
among women who underwent RT that mainly involved contralateral breast cancer
and lung cancer, and an excess mortality from causes other than breast cancer that
mainly involved heart disease and lung cancer. Based on much smaller numbers,
there was also a moderately significant excess mortality from pulmonary embolism
and excess incidence of oesophagus cancer, leukemia and soft tissue sarcoma (see
table 6.1).
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Table 6.1: Effect of radiotherapy on incidence of second cancers before recurrence of
breast cancer, and on mortality from causes other than breast cancer (23500 women in
46 trials of adding radiotherapy, and 9300 in 17 trials of radiotherapy vs more surgery).
Taken from [15].
Contralateral Breast Cancer
Long-term survival after breast cancer diagnosis increased in the last years due to,
in part the earlier detection but also to improved treatment options. Therefore,
it is important to devote more attention to the breast cancer survivors and, in
particular to secondary breast cancer.
Some studies suggest that CLB cancer rates range from 10% to 15% at 15 years
after treatment and are higher for longer term survivors [284–286].
The risk of a breast cancer survivor developing a second breast cancer is much
higher than the risk of a comparable healthy woman developing a first breast
cancer [287].
There is a general consensus that the understanding of the etiology of second
breast cancers is still very limited, but there are some factors that can be pointed
as precursors of second breast cancers such as genetics, family history, lifestyle,
lobular histology, multicentric disease and young age at diagnosis. Due to the
lack of knowledge in these broad fields, prophylactic approaches are investigated
to reduce the risks of second breast cancer for all breast cancer survivors. For
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estrogen receptor-positive primary breast cancer patients, tamoxifen is pointed
out to reduce the risk of a second breast cancer [285, 288, 289].
Other adopted options are regular screening, oophorectomy (surgical removal of
an ovary or ovaries) [290], chemotherapy [29], prophylactic CLB mastectomy [291]
or prophylactic CLB irradiation [292]. Clearly, these procedures present risk to
the patient, and cause significant morbidity.
CLB cancer after breast irradiation and the possible impact of RT on the develop-
ment of CLB cancer has been a matter of study in the last years [293–295]. Among
the scientific community it is not consensual that the treatment of breast cancer
with ionizing radiation increases the risk of CLB cancer. Many studies report no
significant differences between treatment with and without radiation [296–300].
However, Harvey et al [301] found evidence that there is an increased risk of CLB
cancer for women treated with radiation. Others groups reported an increased
incidence of CLB cancer at 10 or more years after the treatment of primary breast
cancer with radiation [302, 303] and for women under 45 years old [294, 304].
Several epidemiological studies were performed and the ones with more patients
involved are the following:
• Basco et al [305] investigated 14000 breast women in British Columbia who
were treated with mean CLB doses of 1.5 Gy, between 1946 and 1982; they
registered 194 of contralateral breast cancer (about 1.4%);
• Boice et al [304] studied 41109 primary breast cancer women in Connecticut,
between 1935 and 1982, with mean doses in the CLB of 2.8 Gy, and 655
second contralateral breast cancer were notificated (about 1.6%);
• Storm et al [306], published the results from a study in Denmark, in which
56540 women with breast cancer between 1943 and 1978; 529 of these women
had a second breast cancer (about 0.9%);
• Stovall et al [307] published their results from a large study with 1399 pa-
tients, treated between 1985 and 1999. They concluded that RT did not
play a significant role in the development of a second primary breast cancer;
however, with young women with breast cancer had an elevated long-term
risk of developing a CLB cancer.
It is necessary important to point out, at this stage, that the older studies include
patients treated with a variety of RT techniques (orthovoltage X-rays or 60-Co)
and dosages are obsolete nowadays.
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Several studies estimate that the mean dose absorbed by the CLB in case of
WBI with 50 Gy using conventional tangential beams, varies from 0.5 to 2 Gy
[190, 308–314]. There is significant evidence of increased CLB cancer risk in young
women (less than 40 years old at time of treatment) [284, 304, 307, 315]. Some
studies highlight that the risk of CLB cancer increases with dose of radiation
[304, 307, 315]. Thus, despite having a curative intention, the ionizing radiation
has a carcinogenic effect on adjacent locations to the primary irradiation, and
therefore the CLB dose should be minimized as long as it does not compromise
the primary treatment, especially in younger women.
The transition from conventional 2-dimensional (2D) RT to 3D conformal RT (3D-
CRT) involved a reduction in the volume of normal tissues receiving a high dose,
with an increase in dose to the target volume that includes the tumor and a limited
margin into the normal tissues [316].
Early breast cancer radiation treatment is commonly performed with a tangential
technique. To achieve better dose homogeneity and dose coverage within the
treated breast, hard wedges are very often used. However, it is accepted that
wedged fields result in higher contralateral breast doses than the corresponding
open fields [312, 314, 317]. Replacing the physical wedge by a virtual wedge 1
would reduce the dose in the CLB significantly [318].
When now changing from tangential static fields to field-in-field and IMRT tech-
niques, which naturally may imply using more fields, there is a need to investigated
the influence of these new techniques with regard to their roles as risk factors for
secondary breast cancer in the CLB [263, 307, 319].
Indeed, there is not a consensual opinion on whether the IMRT techniques increase
or not the doses in the CLB. On one side, there is the argument that with the higher
conformation that may be achievable with these modulated techniques, the OAR
are exposed to lower doses [228, 233, 310, 320, 321]; but increased machine time,
increase in monitor units and consequent increase of leakage and volume exposed
normal tissue including the CLB were reported by other groups [314, 322].
Different strategies have been used to assess the dosimetric distribution in the
CLB, mainly using point detectors: thermoluminescent detectors (TLD) [190, 308,
309, 311, 312, 318, 323] and diodes [308, 324]. More recently, Saur et al [314] per-
formed measurements in an anthropomorphic female phantom using GafChromic
1Virtual wedge: automatic programmed wedge effect produced by closing the jaws.
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EBT films. The studies concluded that the dose distributions in the CLB are inho-
mogeneous and that there are differences between different irradiation techniques.
The aim of this study is to characterize the CLB dose using different breast irra-
diation techniques, and, on the basis of these results, identify the technique that
provides the least dose to the CLB. This study includes dose calculations using
the PBC, iMC and EGSnrc MC for comparison.
6.3 Material, Methods and Patients
This chapter results from the work presented in the previous chapters and it has
particular emphasis on the CLB doses calculated on the seven left breast cancer
patients.
The 7 patients that had the contouring of the CTV, planning target volume (PTV),
heart and CLB were done by the same radiation oncologist for the sake of consis-
tency. The PTV was defined by adding a 5 mm margin to the CTV. All structures
were confined to 3 mm from the external surface of the patient. An additional
structure specified as Body-PTV was also created to evaluate the doses on the
body excluding the PTV. An example of a patient delineation can be seen in
figure 6.1.
The patient dose calculations were optimized for the iPlan (BrainLAB AG, Feld-
kirchen, Germany) TPS v. 4.1, as previously presented in chapter 5 using the PBC
calculation algorithm. All the plans were then recalculated for iMC and EGSnrc
MC.
The validation of the EGSnrc MC dose calculations was performed with film
dosimetry and absolute dose measurements using an ionization chamber and pre-
sented in chapter 5. The validation results presented were performed for a 2.0 Gy
PTV irradiation.
According to the 3D gamma evaluation performed in chapter 5, the highest dose
differences (see figure 5.13) were observed in surface doses, including the CLB
region closer to the treated area, between PBC and iMC algorithms. Further
comparison between film measurements and the TPS calculations reveals the sig-
nificant dose differences are also detected at the skin (see figures 5.11 and 5.12)
and in the CLB. The CLB, in breast RT calculations is exposed to low doses,
mainly scattered radiation from the linac head and from photon interactions in
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Figure 6.1: Contouring example in one of the patients enrolled in the study, in an
axial view. In blue, it is represented the contralateral breast contour; in pink, the heart;
the inner red corresponds to the CTV whereas the outer red represents the PTV.
the phantom/patient. These doses may not be accurately handled, in particular
by the PBC algorithm, due to its features.
In the present work, the aim is to determine the CLB doses. Therefore, the EGSnrc
MC calculations presented in chapter 5 will be used for a detailed analysis. The
patient dose calculations were performed for a total prescribed dose of 50.0 Gy
with the CLB receiving mean doses from 2.5% up to 7.5% of the prescribed dose
(1.25 Gy and 3.75 Gy). The calculated data was introduced in SPSS version 20
(IBM software) for statistical analysis.
6.4 Results
It is particularly important to remark that the priority of the irradiation plans
was set in order to adequately cover the PTV volume with the 95% isodose curve,
avoiding as much as possible the OAR.
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6.4.1 Breast irradiation plans
The curves obtained for the 3 calculation algorithms: PBC, iMC and EGSnrc MC,
for f-IMRT, IMRT2 and IMRT5, for one of the patients are presented in figures
6.2, 6.3 and 6.4, respectively.
Figure 6.2: f-IMRT irradiation example for one of the patients, using the 3 calculation
algorithms.
From the figures 6.2, 6.3 and 6.4 it is possible to observe the irradiation of the
contoured structures, in axial, coronal and sagital planes, from left to right.
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Figure 6.3: IMRT2 irradiation example for one of the patients, using the 3 calculation
algorithms.
Comparing the irradiation techniques, it is possible to notice that with IMRT5
(figure 6.4) there is a wider spread of low doses into the body and OAR than with
the tangential techniques (figures 6.2 and 6.3). However, the 47.5 Gy isodose is
more conformed to the PTV volume than in the tangential options.
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Figure 6.4: IMRT5 irradiation example for one of the patients, using the 3 calculation
algorithms.
6.4.2 Dose Volume Histogram analysis
For a detailed analysis, the DVH of all the patients for the three irradiation tech-
niques were determined for the CLB and the PTV and are presented in figures
6.5 and 6.6, respectively. For the CLB, the aim is to have as low dose as possible;
the best DVH corresponds to low doses in this organ; for the PTV, the goal is to
irradiate the all volume with the prescribed dose, avoiding higher doses (≤ 107%)
in and outside the PTV.
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Figure 6.5: Dose volume histograms of the seven patients enrolled in the study, for
the CLB, for the 3 calculation algorithms (PBC on top, iMC, in the middle and EGSnrc
MC in the bottom) for f-IMRT, in orange; IMRT2, in blue; and IMRT5, in green. The
aim is to obtain the lowest doses within this organ.
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Figure 6.6: Dose volume histograms of the seven patients enrolled in the study, for
the CLB, for the 3 calculation algorithms (PBC on top, iMC, in the middle and EGSnrc
MC in the bottom) for f-IMRT, in orange; IMRT2, in blue; and IMRT5, in green. The
aim is to irradiate all the PTV with the prescribed dose.
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As expected from the irradiation plans, the DVH explicitly shows that for IMRT5,
the CLB receives higher doses for doses up to 15 Gy, especially for 2 out of 7 pa-
tients. The DVH present higher doses independently of the calculation algorithm.
The plans were optimized for the PBC algorithm and the plans were adapted so
that the 95% isodose covered the target volumes. Therefore, the PBC HDV is
expected to respect this criteria. Just by simply looking at figure 6.6 it is difficult
to verify that the MC algorithms satisfy this condition, despite having the expected
shape for a PTV adequate irradiation.
6.4.3 Statistical analysis
For further analysis of the dose differences, a detailed evaluation of specific doses
was also performed. Some parameters were extracted from the DVH and the
results were introduced in SPSS for comparison. The results are plotted in figures
6.7 and 6.8.
From figure 6.7 it is possible to observe that IMRT5 has significantly higher doses
in the CLB, for all parameters investigated, than the tangential (f-IMRT and
IMRT2) techniques. However, for all the variables, IMRT5 presents higher CLB
doses, and the values for f-IMRT and IMRT2 (the tangential techniques) do not
present significant differences.
In absolute dose values, considering Dmean, the CLB receives 1.50 ± 0.39 Gy
and 1.45 ± 0.38 Gy, for f-IMRT and IMRT2, respectively, whereas, the mean
dose for an IMRT5 plan is 3.11 ± 2.25 Gy. For the MC algorithms, the results are
similar, IMRT5 presenting at least twice more mean dose values than the tangential
techniques. Concerning the CLB volume that receives at least 5 Gy, it increases
from 2.44 ± 1.61% and 3.23 ± 1.40% for f-IMRT and IMRT2, respectively, to
19.46 ± 12.58%, for the IMRT5, as determined using the EGSnrc MC algorithm
(increasing about a factor of 6). Regarding the volume of CLB that receives at
least 2 Gy, the considerations are similar, with IMRT5 having more contralateral
healthy breast receiving this dose (eg. for the iMC calculations: for f-IMRT and
IMRT2, 14.63 ± 3.76% and 13.89 ± 5.11% of right breast receive 2 Gy, whereas,
for IMRT5 the CLB percentage is 40.59 ± 36.37%).
The results between the 3 calculation algorithms present differences, in the CLB:
• Dmean presents similar median values for all the techniques with slightly lower
values for EGSnrc MC;
Chapter 6. Assessment of CLB doses in breast RT 189
Figure 6.7: Diagram with mean and maximum and minimum doses in the CLB
obtained for the 7 patients, for Dmean, V5Gy and V2Gy, from top to bottom, for f-IMRT
(blue), IMRT2 (green) and IMRT5 (rose) and the three calculation algorithms: PBC
(continuous line), iMC (dotted line) and EGSnrc MC (slash-dot-slash line).
• V5Gy and V2Gy median values are slightly lower for the EGSnrc MC than for
the iMC.
Concerning the PTV irradiation, there are significant differences (see figure 6.8),
considering the different calculation algorithms:
• for all the techniques and variables investigated, iMC and EGSnrc MC present
lower PTV coverage than the PBC predicted;
• in general, the EGSnrc MC predicted lower doses than the iMC;
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Figure 6.8: Diagram with mean, maximum and minimum doses in the PTV obtained
for the 7 patients, for V95%, V107% and D5%, from top to bottom, for f-IMRT (blue),
IMRT2 (green) and IMRT5 (rose) and the three calculation algorithms: PBC (contin-
uous line), iMC (dotted line) and EGSnrc MC (slash-dot-slash line).
• taking into consideration the V95% as an irradiation quality parameter, IMRT5
is the technique with better PTV coverage, according to the MC techniques;
• considering PBC, f-IMRT is the technique with higher doses above 107% but
considering the calculations with the MC algorithms, that does not seem to
happen and there are no significant differences, considering this criteria;
• the EGSnrc MC and the iMC predict lower doses than the PBC for the 5%
of PTV volume (D5%) that receive higher doses.
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In summary, IMRT5 is the technique that best conforms to the PTV is also the
one that causes more doses into the OAR and, in particular, to the CLB.
6.4.3.1 Comparison of the calculation algorithms
To clearly investigate the variables investigated related to the CLB (Dmean, V10%
and V4%), a statistical analysis was performed. Friedman’s test (see details of this
test in Appendix A) was applied to the variables using SPSS IBM v20 and it
is assumed that there are significant statistical differences between the variables
considering a p-value inferior to 0.05. The results are displayed in table 6.2.
Table 6.2: Friedman’s statistical analysis on the CLB, comparing the calculation
algorithms. The values reported are p-values; significant statistical differences are con-
sidered for p-values ≤ 0.05.
CLB Dmean V10% V4%
f-IMRT 0.021 0.002 0.004
IMRT2 0.012 0.004 0.050
IMRT5 1.000 0.104 0.495
According to the results reported in table 6.2, for f-IMRT and IMRT2 there are
significant statistical differences between the 3 calculation algorithms. So, for
further investigation when significant statistical differences were found, a pairwise
comparison between the algorithms was performed to identify where the differences
come from (see table 6.3).
Table 6.3: Pairwise analysis of the variables with significant statistical differences on
the CLB for Dmean, V10% and V4% variables, comparing the calculation algorithms.
p-values are reported.
f-IMRT IMRT2
iMC EGSnrc MC iMC EGSnrc MC
Dmean
PBC 0.048 0.048 0.010 0.855
iMC - 1.000 - 0.184
V10%
PBC 0.544 0.098 0.048 1.000
iMC - 0.002 - 0.002
V4%
PBC 1.000 0.004 0.326 1.000
iMC - 0.048 - 0.048
According to the analysis performed for the CLB (see table 6.2), there are only sta-
tistical significant differences (p-value ≤ 0.05) between the tangential techniques
(reason why IMRT5 does not show up on table 6.3), for the 3 variables under
investigation. For Dmean, there are significant statistical differences between the
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PBC and the MC calculation algorithms; for V10% the differences are between the
MC techniques and also between iMC and PBC for IMRT2; for V4%, the differ-
ences are between the MC techniques and for f-IMRT between PBC and EGSnrc
MC (see table 6.3).
A detailed statistical analysis was also performed for the PTV to better under-
stand if the PTV coverage is affected by the irradiation technique according to
the calculation algorithms predictions. The results are presented in tables 6.4 and
6.5.
Table 6.4: Friedman’s statistical analysis on the PTV, comparing the calculation
algorithms. The values reported are p-values; significant statistical differences are con-
sidered for p-values ≤ 0.05 (values in bold).
PTV V95% V107% D5% HI CI CN
f-IMRT 0.021 0.012 0.001 0.066 0.003 0.054
IMRT2 0.005 0.254 0.016 0.002 0.004 0.887
IMRT5 0.002 0.074 0.034 0.002 0.002 0.042
Table 6.5: Pairwise analysis of the variables with significant statistical differences on
the CLB for V95%, V107%, D5%, HI, CI and CN variables, comparing the calculation
algorithms. p-values are reported.
f-IMRT IMRT2 IMRT5
iMC EGSnrc MC iMC EGSnrc MC iMC EGSnrc MC
V95%
PBC 0.048 0.048 0.023 0.010 0.002 0.098
iMC - 1.000 - 1.000 - 0.544
V107%
PBC 0.184 0.010 - - - -
iMC - 0.855 - - - -
D5%
PBC 0.184 0.001 0.326 0.015 0.098 0.069
iMC - 0.184 - 0.687 - 1.000
HI
PBC - - 0.002 0.544 0.002 0.544
iMC - - - 0.098 - 0.098
CI
PBC 0.184 0.003 0.048 0.004 0.002 0.098
iMC - 0.425 - 1.000 - 0.544
CN
PBC - - - - 0.069 0.247
iMC - - - - - 1.000
With exception of V107% for IMRT2 and IMRT5, HI for f-IMRT and CN for IMRT2,
all the variables present significant statistical differences (p-value ≤ 0.05, values in
bold) (see table 6.4). With the pairwise comparison for the techniques (presented
in table 6.5), all the differences with statistical significance if existent are between
PBC and the MC calculation algorithms.
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6.4.3.2 Comparison of the irradiation techniques
A statistical analysis focused on the irradiation techniques was also performed,
considering the CLB and the PTV irradiation. The CLB results are presented in
tables 6.6 and 6.7.
Table 6.6: Friedman’s statistical analysis on the CLB, comparing the irradiation
techniques. The values reported are p-values; significant statistical differences are con-
sidered for p-values ≤ 0.05, values in bold.
CLB Dmean V10% V4%
PBC 0.006 0.004 0.050
iMC 0.018 0.018 0.018
EGSnrc MC 0.004 0.002 0.002
Table 6.7: Pairwise analysis of the variables with significant statistical differences on
the CLB for Dmean, V10% and V4% variables. p-values are reported.
PBC iMC EGSnrc MC
f-IMRT IMRT2 f-IMRT IMRT2 f-IMRT IMRT2
Dmean
IMRT2 1.000 - 1.000 - 1.000 -
IMRT5 0.069 0.010 0.033 0.069 0.004 0.048
V10%
IMRT2 1.000 - 1.000 - 1.000 -
IMRT5 0.004 0.048 0.023 0.098 0.002 0.098
V4%
IMRT2 1.000 - 1.000 - 0.544 -
IMRT5 0.326 0.048 0.023 0.098 0.002 0.098
According to the Friedman’s analysis, there are significant statistical differences
for all the investigated variables, for all the calculation algorithms. Performing a
pairwise comparison, most of the significant statistical differences are found be-
tween f-IMRT and IMRT5 or between IMRT2 and IMRT5, irrespective of the
calculation algorithms, as displayed in table 6.7 .
Table 6.8: Friedman’s statistical analysis on the PTV, comparing the irradiation
techniques. The values reported are p-values; significant statistical differences are con-
sidered for p-values ≤ 0.05.
PTV V95% V107% D5% HI CI CN
PBC 0.368 0.089 0.066 0.028 0.004 0.002
iMC 0.050 0.042 0.054 0.028 0.102 0.012
EGSnrc MC 0.050 0.317 0.565 0.066 0.651 0.012
On the PTV, there are significant statistical differences for the CN (all algorithms);
using iMC, for V95%, V107% and HI; using PBC, for HI and CI variables (see table
6.8).
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Table 6.9: Pairwise analysis of the variables with significant statistical differences on
the CLB for V95%, V107%, D5%, HI, CI and CN variables, comparing the calculation
algorithms. p-values are reported.
PBC iMC EGSnrc MC
f-IMRT IMRT2 f-IMRT IMRT2 f-IMRT IMRT2
V95%
IMRT2 - - 1.000 - 1.000 -
IMRT5 - - 0.048 0.326 0.048 0.326
V107%
IMRT2 0.184 - 0.247 - - -
IMRT5 - - 0.069 1.000 - -
HI
IMRT2 0.184 - 0.544 - - -
IMRT5 0.033 1.000 0.023 0.054 - -
CI
IMRT2 1.000 - - - - -
IMRT5 0.004 0.048 - - - -
CN
IMRT2 0.544 - 0.855 - 0.855 -
IMRT5 0.002 0.098 0.010 0.1844 0.010 0.184
From table 6.9, all the variables that present significant statistical differences are:
between f-IMRT and IMRT5 (only CI presents differences between IMRT2 and
IMRT, for the PBC algorithm). This means that the coverage of the PTV was
guaranteed with all the irradiation techniques, even though differences might be
found between f-IMRT and IMRT5. However, despite the adequate irradiation
of the PTV, the irradiation techniques affect the dose in the CLB. Clearly, using
non-tangential fields, there is a wider spread of ’low” doses into the CLB and other
OAR that must be taken into consideration particularly for women with long-term
survival chances, to avoid second contralateral breast cancer.
6.5 Conclusions
The doses reported are affected by the patient’s anatomy but some trends might
be identified:
• it is accepted and assumed that the PBC does not accurately estimate skin
doses, including the CLB dose, from the results presented in chapter 5. These
results are in agreement to other groups results [314];
• the PBC algorithm does clearly overestimate the dose in the PTV when
compared to the MC calculation strategies, due to inaccuracies in calculation,
probably due to secondary electrons as pointed out in other phantom studies
[269, 308] not accounted for by the PBC algorithm. in the build-up region
(skin) and in the presence of heterogeneities;
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• according to the results obtained with a standard tangential technique for-
wardly planned IMRT, mean doses of 1.42 ± 0.41 Gy and 1.26 ± 0.45 Gy,
for iMC and EGSnrc MC respectively, are administered to the CLB; an in-
versely calculated IMRT tangential technique results in mean doses of 1.30 ±
0.41 Gy and 1.22 ± 0.64 Gy, for iMC and EGSnrc MC respectively; whereas
using non-tangential fields (IMRT5) lead to a significant increase of about
50% increase the CLB mean dose (3.12 ± 2.17 Gy and 3.02 ± 2.13 Gy, for
iMC and EGSnrc MC respectively);
• concerning the PTV coverage, the best PTV coverage is obtained for IMRT5
with the prescribed 95% isodose better conformed to the target volume, spar-
ing the OAR from high doses.
From the results presented in chapter 5, differences either due to the calculation
algorithms and/or the irradiation techniques in the CLB were expected.
It is recommended that the PBC is replaced by another calculation algorithm, if
not Monte Carlo, at least a superposition/convolution algorithm. With this TPS
it would make sense to use iMC. However, the large calculation times make it
incompatible for clinical purposes.
The use of tangential techniques is the best option to spare the CLB from low
dose irradiation. According to the literature, increasing the dose in the CLB,
especially for women under 45 years old may lead to higher incidence of secondary
induced CLB cancer [6]. This should be taken into consideration when planning
to go for new irradiation techniques with beam angles different from the standard
tangential beams, such as IMRT5, DCART or VMAT.
This work could be further improved if EGSnrc MC calculations could be per-
formed in a breast phantom with heterogeneities to assess the dose volume his-
tograms in the phantom.
Furthermore, other dosimetry techniques - not available for this work - could be





One of the main objectives of this dissertation work consisted of studying and
assessing the dosimetric and clinical performance of new, emerging and complex
techniques and to find out whether they can be applied to breast irradiation treat-
ments, improving dose delivery conformation and the RT treatment outcome.
Several general questions regarding these new and emerging RT techniques were
addressed, such as:
a. Do they allow a more accurate dose delivery?
b. Do they allow an adequate dose conformation to the target volumes?
c. Do they allow to achieve a reduction of the doses in the OAR and in the healthy
tissues surrounding the tumor?
d. Can these techniques be used without restrictions?
Concerning the calculation algorithms,
e. How do they perform in heterogeneous media?
f. Do they effectively overcome the shortcomings and limitations from current
non-MC TPS?
g. How effective are existing MC simulations and algorithms implemented in
state-of-the-art TPS using MC in achieving a more accurate dose delivery to the
PTV, reducing the doses in the OAR and in the surrounding healthy tissues?
h. Can they be used without restrictions?
197
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7.1.1 MC modeling and simulation of the Trilogy Varian linac
To achieve this goal, a struggling effort was done to model and simulate the lin-
ear accelerator used, the Trilogy Varian linac. The most thrilling task was to
model, simulate and validate, for the first time using Monte Carlo methods with
the EGSnrc MC code, the High Definition MLC. The HDMLC component mod-
ule was validated in water (in chapter 3 and further used for breast EGSnrc MC
calculations (in chapter 5). Thereby, the linac Trilogy from VARIAN Medical Sys-
tems (Palo Alto, CA) was successfully modeled and validated, using measurements
performed not only in water but also in breast-shaped phantoms.
7.1.2 Comparison of the dosimetric performance of TPS using MC
simulations and algorithms in breast cancer RT
To perform this investigation, a deep bibliographic research was performed. Dose
calculations on breast patients in clinical environment were performed regarding
the topic of this research. To further complement and enhance the approximate
calculations made on the treatment planning system, Monte Carlo dose calcula-
tions were done. The Monte Carlo approach was the most accurate method for
dose calculation in such complex calculations as it is the radiation interaction with
matter in the breast context, due to the different media involved in this treatment
location.
In chapters 4 and 5, the results of breast irradiation were obtained and an inter-
comparison was performed for the following 4 different techniques,
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The plans were evaluated based on criteria adapted from QUANTEC [325] and
RTOG 1005 (protocol from RTOG. www.rtog.org/ClinicalTrials/ProtocolTable/
StudyDetails.aspx?action openFile&;FileID1 9366). The comparison performed
for 7 patients was performed on the TPS iPlan BrainLAB, using 2 calculation
algorithms: PBC and iMC. The dose distributions were optimized for the PBC
algorithm and afterwards, recalculated using iMC.
Sizable discrepancies remain concerning between the 4 techniques investigated on
breast irradiation and between the two algorithms studied (PBC and iMC). The
PTV was adequately covered with all the techniques (evaluated by V47.5Gy), con-
sidering PBC. IMRT5 had advantages over the other techniques based on the
dosimetric comparison performed in this study especially in the high dose region
of the left lung and heart, target conformation and heterogeneity indexes; DCART
was the technique with the lowest V95% and did not present improvement in sparing
the OAR or the PTV coverage over the IMRT techniques investigated. However,
the non-tangential techniques (IMRT5 and DCART) did increase the scattered
dose and expose larger percentage of healthy volumes to low and medium doses.
f-IMRT is still the recommended technique for breast irradiation. Nonetheless, in
case of high heart or left lung involvement, IMRT5 should be considered to breast
cancer irradiation as it creates the most conformal distribution at the expense
of more normal tissue receiving low dose. These observations were valid both
for PBC and iMC. However, statistical significant differences were found between
PBC and iMC calculations, on the variables investigated, mainly in the higher
doses regimen (≥ 40 Gy) for the PTV, left lung and heart.
The EGSnrc MC implementation was further validated against iMC calculations
performed using iPlan, the BrainLAB TPS, in chapter 5.
Thereby, the primary goal of comparing different irradiation techniques was also
accomplished using the TPS iPlan from BrainLAB and further compared with the
independently calculated EGSnrc Monte Carlo plans.
The major conclusions regarding the irradiation techniques studied, f-IMRT, IMRT
and IMRT5 are the following:
• f-IMRT and IMRT2, are the tangential techniques using mainly two beam
incidences, a lateral and a median. These options are adequate for PTV
irradiation but are not as conformed to the target volume as dose distribu-
tions with different beam incidences; furthermore, the healthy tissues in the
vicinities (such as the left lung and heart, which are right beneath the PTV)
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may receive higher doses. Between the two irradiation techniques, there is
no preference for any of the techniques.
• IMRT5, a technique using five different incident beams on the target volume,
between the traditional tangential beams. With this technique, more homo-
geneous and conformal dose distributions are obtained. The heart and left
lung may thereby receive a lower percentage of doses above 30 Gy, due to
better conformation to the PTV, as published by Popescu et al [232]. How-
ever, the healthy tissues in the vicinities do receive significant more doses
below 20 Gy, in agreement with Ayata et al [326], such as the heart, left lung
and the CLB, as particularly studied in chapter 6.
In summary, IMRT5 is the technique that best conforms to the PTV is also the
one that causes higher doses into the OAR and, in particular, to the CLB. In table
7.1, the main features of each technique are presented.
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Besides studying the irradiation techniques, a comparison between different calcu-
lations was also performed. The calculation algorithm generally used for clinical
purposes in this TPS is the Pencil Beam Convolution. Nonetheless, this ana-
lytical algorithm is, nowadays, not the most indicated for accurate dose calcula-
tions, due to the well-documented limitations referred throughout this dissertation
[46, 49, 69–71]. In fact, this algorithm was inaccurate at determining doses in het-
erogeneous media and in build-up regions. Table 7.2 presents some considerations
on the calculation algorithms used for dose calculation in this work.
Table 7.2: Calculation algorithms comparison. Main features of the algorithms
used:PBC, iMC and EGSnrc MC.
PBC iMC EGSnrc MC
Accuracy in Acceptable Good Good
homogeneous media (2% - 5%) (≤ 2%) (≤ 2%)
Accuracy in Not accurate Good Good
heterogeneous media (≥ 5%) (≤ 2%) (≤ 2%)
Calculation time Few min 30 - 60 min hours - days
The MC algorithms presented some differences probably due to the different CT
ramp used for the dose calculations. After this study, at the clinic we are doing a
major effort to acquire the data for using another calculation algorithm, the AAA
(Anisotropic Analytic Algorithm).
Concerning the PTV irradiation, there are significant differences (see figure 6.8),
considering the different calculation algorithms:
• for all the techniques and variables investigated, iMC and EGSnrc MC present
lower PTV coverage than the PBC predicted;
• in general, the EGSnrc MC predicted lower doses than the iMC;
• taking into consideration the V95% as an irradiation quality parameter, IMRT5
is the technique with better PTV coverage, according to the MC techniques;
• considering PBC, f-IMRT is the technique with higher doses above 107% but
considering the calculations with the MC algorithms, that does not seem to
happen and there seem to exist no significant differences, considering this
criteria;
• the EGSnrc MC and the iMC predict lower doses than the PBC for the 5%
of PTV volume (D5%) that receive higher doses.
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7.1.3 Dose in the CLB
In absolute dose values, considering the PBC algorithm, Dmean, the CLB receives
1.50 ± 0.39 Gy and 1.45 ± 0.38 Gy, for f-IMRT and IMRT2, respectively; whereas,
the mean dose for the IMRT5 plans is 3.11 ± 2.25 Gy. For the MC algorithms,
the results are similar, IMRT5 presenting at least twice more mean dose values
than the tangential techniques. Concerning the CLB volume that receives at least
5 Gy, it increases from 2.44 ± 1.61% and 3.23 ± 1.40% for f-IMRT and IMRT2,
respectively, to 19.46 ± 21.58%, for the IMRT5, as determined using the EGSnrc
MC algorithm (increasing about a factor of 6). Regarding the volume of CLB that
receives at least 2 Gy, the considerations are similar, with IMRT5 having more
contralateral healthy breast receiving this dose (eg. for the iMC calculations, for
f-IMRT and IMRT2, 14.63 ± 3.76% and 13.89 ± 5.11% of right breast receive 2
Gy, whereas, for IMRT5 the CLB percentage is 40.59 ± 36.37%).
Regarding the ultimate goal of this study, to conclude on CLB doses, according
to the patient data results obtained for the different calculations algorithms, non-
tangential techniques do increase the low doses in the OAR, mainly in the CLB 6.
Special attention has to be addressed to this issue before going into more complex
multi-beam incidence or arc techniques despite not being yet clear among the
scientific community what the consequences of increasing the low doses in the CLB.
It is therefore considered that despite better PTV homogeneity and conformity
there is an increased risk of CLB cancer development, when using non-tangential
techniques.
7.1.4 Usefulness of MC based TPS for breast cancer RT
Overall, the main findings reported in this thesis pinpoint the usefulness and pow-
erful predictive power of the Monte Carlo methods in support of RT Treatment
Planning Systems, allowing a more accurate dosimetric assessment therefore im-
proving the dose delivery to the tumor volume and the efficacy and outcome of
the treatments. They also seem to contribute to a better assessment of the dose
in the OAR and to the healthy tissues surrounding the tumor volume therefore
presumably contributing to decrease the risk of second cancer induction in those
tissues and organs.
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7.2 Limitations and difficulties
The topic of this work was an excuse for a much broader investigation on Monte
Carlo techniques. Throughout this work, many difficulties were faced and over-
come making the path to the final much more interesting. Many restrictions were
made to the initial plan as it is not possible to include all the aspects in this inves-
tigation. The first decision was to investigate only breast cancer without axillary
involvement due to the maximum field size of the Trilogy linac used throughout
this investigation, not being wide enough to perform modulated fields larger than
22 cm in the head-feet direction. To investigate the arc rotation technique, it was
necessary to use the iPlan BrainLAB TPS which does not permit the use of wedges
(neither physical nor virtual ones). The path started to delineate itself with the
constraints into equation.
The first real difficulty was, however, to obtain the accurate linac data to imple-
ment the linac model. However, with persistence and the fundamental help of
Professor Doutor Pedro Vaz, we managed to obtain the data from Varian Med-
ical Systems. Modeling and simulating the linac using Monte Carlo techniques
is a very complex task which was accomplished with success. However, model-
ing and simulating the HDMLC using EGSnrc was a much more struggling and
demanding, not initially planned task. However, this was the most rewarding
goal accomplished due to the interest the EGSnrc responsibles have put into it.
The model was already included in the last EGSnrc release; Varian also used the
simulation results for their own propaganda of the MLC.
Investigating the CLB doses is also an extremely complex task due to the nature of
the radiation involved: mainly low scattered doses mainly coming from linac head
scatter, linac head leakage and patient scatter. Unfortunately we did not have an
adequate breast phantom that gathered all the necessary aspects (breast shape,
adequate for measurements, with heterogeneities) to perform all the measurements
we initially aimed at. Several attempts were made to make such a phantom. We
were fortunate to have a RandoAlderson breast phantom for a very short period of
two weeks with which we were able to make a plaster mould and then perform the
experiments mentioned in the previous chapters. The first try consisted on making
a wax phantom; however, when we tried to cut the wax to put a film or a ionization
chamber it broke and we did not succeed. We then tried with a suggestion from
a biomaterials Professor trying to perform a bulk photopolymerization of methyl
methacrylate but we did not succeed, either (probably because we did not have the
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proper conditions to execute the procedure and the final product got too hard to
cut). The next attempt was to make a gelatin/jelly phantom and it sort of worked
until it melt just before the measurements. The vegetal fat phantom, made with
Végétaline, was the most successful phantom we obtained. To perform a perfect
straight cut was also difficult and that was when attending a conference in Seville, I
heard about this phantom and Professor Antonio Leal from Universidad de Sevilla,
Spain, was very kind in permitting to use it for two weeks.
7.3 Future work
There are still struggling questions to address related to breast cancer which are
of major interest. Amongst them:
• The involvement of biological models seems to be most appropriate way to
go to find out the influence of low doses in the CLB.
• The next challenging task is to prepare the EGSnrc MC to calculate dynamic
arc conformal RT treatments and compare them with the TPS calculations.
• Another study of interest is to investigate the influence of breast implants
and their influence on the calculations.
• Sensitivity and uncertainty analysis and studies of the parameters influencing
the accuracy of existing MC TPS.
• Risk estimates of second cancer induction in the CLB or in other OAR, in







Friedman's Two-way Analysis of Variance by Ranks -- Analysis of k-Within-Group Data with a  
  Quantitative Response Variable 
 
Application: This statistic has two applications that can appear very different, but are really just two variations of the same statistical 
question.   In one application the same quantitative variable is measured at two or more different times from the same sample (or from 
two or more samples that have been matched on one or more important variables).   In the other application, two or more comparable 
quantitative variables are measured from the same sample (usually at the same time).  In both applications, Friedman's test is used to 
compare the distributions of the two or more quantitative variables. 
Thus, it is applied in the same data situation as an ANOVA for dependent samples except that it is used when the data are 
either from a too-small sample, are importantly non-normally distributed, or the measurement scale of the dependent variable is 
ordinal (not interval or ratio).  It is important to remember the null hypothesis, and to differentiate it from the null for the dependent 
ANOVA.  
 
 There are two specific versions of the H0:, depending upon whether one characterizes the k conditions as representing a 
single population under two or more different circumstances (e.g., comparing treated vs. not treated  or comparing different 
treatments -- some consider this a representation of two or more different populations) or as representing comparable variables 
measured from a single population (as in the example below).  Here are versions of the H0: statement for each of these 
characterizations. 
 
H0:  The populations represented by the k conditions of the have the same distribution of scores. 
 
To reject H0: is to say that the populations represented by the different  conditions differ in some way, center, spread and/or shape.  
When the forms of the distributions from the two samples are similar (as is often the case -- check the size and symmetry of the 
IQR), then rejecting H0: is interpreted to mean that populations (or circumstances) tend to have some pattern of larger and smaller 
scores (different medians) among them. 
 
H0:  The population has the same distribution of scores on the different measures represented by the conditions. 
 
To reject H0: is to say that the distributions of the variables are different in some way, center, spread and/or shape.  When the 
forms of the distributions are similar (as is often the case -- check the size and symmetry of the IQR), then rejecting the H0: is 
interpreted to mean that the variables have some pattern of larger and smaller scores (medians) among them. 
 
The data:  In this analysis the one variable is the type of animal (fish, reptiles, or mammals), and the response variable is the 
number of animals on display.  From our database, we use three variables reptnum (number of reptiles on display), fishnum 
(number of fishon display) and mamlnum (number of mammals on display).   These scores are shown for the 12 stores below 
(reptnum, fishnum, ). 
 
12,32,34   14,41,38   15,31,45   12,38,32    7,21,12     4,13,11   
10,17,22    4,22,9    14,24,20    4,11,8      5,17,19    10,20,8 
 
Research Hypothesis:  The data come from the Pet shop database.  The researcher hypothesized that stores would tend to 
display more fish than other types of animals, fewer reptiles, and an intermediate number of mammals. 
 
H0: for this analysis:  Pet stores display the same number of reptiles, fish and mammals. 
 
 
Step 1  Rearrange the data so that scores from each subject are in the appropriate columns, one for each condition.  
 
    reptnum     fishnum    mamlnum 
12  32  34 
14  41  38 
15  31  45 
12  38  32 
 7  21  12 
 4  13  11 
10  17  22 
 4  22   9 
14  24  20 
 4  11   8 
 5  17  19 
10  20   8 
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Step 2   Rank order the scores SEPARATELY FOR EACH SUBJECT'S DATA with the smallest score getting a value of 1.  If there 
 are ties (within the scores for a subject) each receives the average rank they would have received. 
 
           rank      rank       rank 
     reptnum   fishnum    mamlnum     reptnum   fishnum    mamlnum 
  12  32  34    1     2    3 
  14  41  38    1     3         2 
        15  31  45    1         2         3 
        12  38  32    1     3         2 
         7  21  12    1         3         2 
         4  13  11    1     3         2 
        10  17  22    1     2         3 
         4  22   9    1         3         2 
        14  24  20    1         3         2 
         4  11   8    1     3    2 
         5  17  19    1     2      3 
  10  20   8    2     3    1 
 
 
Step 3   Compute the sum of the ranks for each condition. 
 
 
       rank      rank       rank 
       reptnum   fishnum    mamlnum 
   1     2    3 
   1     3         2 
   1         2         3 
   1     3         2 
   1      3         2 
   1     3         2 
   1     2         3 
   1         3         2 
   1         3         2 
   1         3    2 
   1     2      3 
   2     3    1 
 
                            R1 = 13    R2 = 32   R3 = 27   
 
 
Step 4   Determine  the number of subjects. 
 
  N = 12 
 
Step 5   Determine the number of conditions. 
 
  k = 3  
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Step 6    Compute Friedman's F, using the following formula (you should carry at least 3 decimals in these calculations). 
 
 
        12       
F =  ---------------- * ∑ R2   -  [3 * N * (k + 1)]  
       [N * k *(k+1)]      
 
 
      12 
 =  -----------------  * [132 + 322 + 272]  -  [3 * 12 * (3 + 1)]  
     [12 * 3 * (3+1)] 
 
 
      12     
  =  -----  * [169 + 1024 + 729]  - 144  =  [.083*1922] - 144    =   15.526 




For small samples (k < 6 AND N < 14): 
 
Step 7   Determine the critical value of F by looking at the table of critical values for Friedman's test 
 
  F(k=3, N=12, α = .05)  =  8.67 
 
Step 8  Compare the obtained F and the critical F values to determine whether to retain or reject the null hypothesis.   
 
-- if the obtained F value (from Step 6) is larger than the critical value of F, then reject H0: 
 
  -- if the obtained F value is less than or equal to the critical value of F, then reject H0: 
 
 For the example data, we would decide to reject the null hypothesis, because the 
 obtained value of F (15.526) is greater than the larger critical F value (8.67). 
 
For large samples (k > 5 OR N > 13): 
  
Step 9   Determine the critical value of F by looking at the table of critical values for the Chi-Square test (df = k - 1). 
  (As an example, here is how you would apply this version of the significance test to these data.)  
 
   Χ²  (df = 2, p=.05)  =  5.99 
 
Step 10  Compare the obtained F and the critical Χ² values to determine whether to retain or reject the null hypothesis.   
 
-- if the obtained F value (from Step 6) is less than or equal the critical value of Χ², then retain H0: 
 
-- if the obtained F value is larger than the critical value of Χ², then reject H0: 
 
 For the example data, we would decide to reject the null hypothesis, because the 
 obtained value of F (15.526) is greater than the larger critical Χ² value (5.99). 
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Step 11   IF you reject the null hypothesis, determine whether the pattern of the data completely supports,  partially supports, or 
  does not support the research hypothesis. 
 
  -- IF you reject the null hypothesis, AND if the pattern of data agrees exactly  with the research hypothesis, then the  
     research hypothesis is completely supported.  
 
  -- IF you reject the null hypothesis, AND if part of the pattern of the data agrees with the research hypothesis, BUT part
    of the pattern of the data does not, then the research hypothesis is partially supported.  
         
 -- IF you retain the null hypothesis, OR you reject the null BUT NO PART of the pattern of the data agrees with the      
    research hypothesis, then the research hypothesis is not at  all supported. 
 
By the way:  To properly determine whether the hypothesized pattern of differences was found, one should perform pairwise         
comparisons (using Friedman's test);  the report of the results given below makes use of these follow-up tests (although the 
computations are not shown). 
 
By the way:  Usually the researcher hypothesizes that there is a difference between the conditions.  Sometimes, however, the 
research hypothesis is that there is NO difference between the conditions.  If so, the research hypothesis and H0: are the same!  
When this is the case, retaining H0: provides support for the research hypothesis, whereas rejecting H0: provides evidence that 
research hypothesis is incorrect. 
 
 
 For the example data, we would decide that the research hypothesis is partially 
supported, because the null hypothesis was rejected, and because, as hypothesized, 
there were fewer reptiles displayed than mammals or fish.  However, there was not a 




Step 12  Reporting the results  
 
 You will want to compute medians and IQR values to help describe the data before reporting the results of the 
significance test.  With multiple-group designs it is often easier to present these data in a table.  As for the other 
statistical tests, the report includes the "wordy" part and the statistical values based upon which you based your 
statistical decision.  If you reject H0:, be sure to describe how the groups differed, rather than just reporting that there 
was "a difference". 
 
 
Table 1 summarizes the data for the numbers of animals displayed at the stores.  
There was a significant difference among the distributions of the three types of 
animals (based on Friedman's test, X²(2) = 15.526, p = .0003.  Pairwise Friedman's 
tests (p < .05) revealed that, as hypothesized, fewer reptiles were displayed than 
either fish or mammals.  However, contrary to the research hypothesis, there was not a 




Summary of the number of animals of each type displayed in the pet stores. 
              
 
                                Type of Animal 
            
 
                   Fish             Mammals           Reptiles 
            
 
Mdn               21.50             19.50             10.00 
Q1          17.00              9.50              4.25 
Q3    31.75             33.50             13.50 
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Wilcoxin’s Test -- Analysis of 2-Within-Group Data with a Quantitative Response Variable
Application: This statistic has two applications that can appear very different, but are really just two variations of the same statistical
question.   In one application the same quantitative variable is measured at two different times from the same sample (or from two
samples that have been matched one or more important variables).   In the other application, two comparable quantitative variables are
measured from the same sample (usually at the same time).  In both applications, Wilcoxin's test is used to compare the distributions of
the two quantitative variables.
Thus, it is applied in the same data situation as a t-test or ANOVA for dependent samples except that it is used when the
data are either from a too-small sample, are importantly non-normally distributed, or the measurement scale of the dependent
variable is ordinal (not interval or ratio).  There are two versions of the Wilcoxin test, one for small samples (i.e., N < 50, but some
suggest N < 10), and one for large samples.  It is important to remember the null hypothesis, and to differentiate it from the null for
the dependent t-test.
There are two specific versions of the H0:, depending upon whether one characterizes the two conditions as representing
a single population under two different circumstances (e.g., comparing treated vs. not treated  or comparing two different treatments
-- some consider this a representation of two different populations) or as representing comparable variables measured from a single
population (as in the example below).  Here are versions of the H0: statement for each of these characterizations.
H0:  The two populations represented by the different conditions of the have the same distribution of scores.
To reject H0: is to say that the populations represented by the two conditions differ in some way, center, spread and/or shape.
When the forms of the distributions from the two samples are similar (as is often the case -- check the size and symmetry of the
IQR), then rejecting H0: is interpreted to mean that one population tends to have larger scores (or a larger median) than the other.
H0:  The population represented by the sample has the same distribution of scores on the two different measures represented by
the conditions.
To reject H0: is to say that the distributions of the variables are different in some way, center, spread and/or shape.  When the
forms of the distributions are similar (as is often the case -- check the size and symmetry of the IQR), then rejecting H0: is
interpreted to mean that one variable tends to have larger scores (or a larger median) than the other.
The data:  In this analysis "grouping" variable is the type of animal (reptiles or fishes), and the response variable is the quality
rating.  From our database, we use two variables reptgood (reptile quality rated on a 1-10 scale) and fishgood (fish quality rated
on a 1-10 scale).   These scores are shown for the 12 stores below (reptqual, fishqual).
2,6  8,5   9,3   7,3  4,7  7,9   4,9   4,8   5,6   9,9   7,7   2,8
Research Hypothesis:  The researcher hypothesized that a store's fish would be of higher quality than its reptiles, because of the
greater difficulty obtaining and maintaining healthy reptiles.
H0:  for this analysis:  The quality ratings of reptiles and fish displayed by pet stores have the same distributions.
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Step 2   For each pair of scores, compute the difference between the scores and then find the absolute value of this difference.
      absolute
reptgood fishgood difference   difference
2 6 -4 4
8 5  3 3
9 3  6 6
7 3  4 4
4 7 -3 3
7 9 -2 2
4 9 -5 5
4 8 -4 4
5 6 -1 1
9 9  0 0
7 7  0 0
2 8 -6 6
Step 3   Rank order the absolute differences, with the smallest absolute difference getting a value of 1.  Cases with the same 
absolute difference each receive the average rank they would have received.
By the way:  If an absolute difference has a value of 0, then the data from that subject is dropped from the analysis and the sample
size is adjusted accordingly.  Why?  This statistical test is based upon comparisons of the number and direction of the inequalities in
the data set (e.g., how many times reptgood > fishgood and how many times reptgood < fishgood), to determine if one variable has
a different distribution than the other.   Subjects for which reptgood = fishgood don't contribute to making this decision.  What if there
are several subjects with tied scores?  The more subjects with tied scores (which are dropped), then it more difficult is to reject H0: -
- which should make sense, since tied scores suggest that the distributions are equivalent.
    rank of
      absolute     absolute
reptgood fishgood difference   difference   difference
2 6 -4 4 6
8 5  3 3 3.5
9 3  6 6 9.5
7 3  4 4 6
4 7 -3 3 3.5
7 9 -2 2 2
4 9 -5 5 8
4 8 -4 4 6
5 6 -1 1 1
9 9  0 0 --
7 7  0 0 --
2 8 -6 6 9.5
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Step 4   Compute the signed rank absolute difference, as the rank of absolute difference (from 5 th column)with the same sign as the
difference (from 3 rd column).
    rank of signed rank
      absolute     absolute       absolute
reptgood fishgood difference   difference   difference      difference
2 6 -4 4 6   -6
8 5  3 3 3.5    3.5
9 3  6 6 9.5    9.5
7 3  4 4 6          6
4 7 -3 3 3.5         -3.5
7 9 -2 2 2         -2
4 9 -5 5 8   -8
4 8 -4 4 6         -6
5 6 -1 1 1         -1
9 9  0 0 --          --
7 7  0 0 --          --
2 8 -6 6 9.5         -9.5
Step 5   Compute the sum of the positive signed rank absolute differences (T+) and the sum of the negative signed rank absolute 
differences (T-).
T+  =  3.5 + 9.5 + 6  =  19    T- = 6 + 3.5 + 2 + 8 + 6 + 1 + 9.5 = 36
Step 6  The summary statistic, called W, is the SMALLER of T+ and T-
W = 19
Step 7  Determine N as the number of subjects who contributed signed rank absolute difference values.
N = 10
For small samples (N < 50 -- though some suggest N < 10):
Step 8    Determine the critical values of W using the table.
With N = 10, the critical value of W (p = .05) is 8
Step 9   Compare the obtained W and the critical W values to determine whether to retain or reject the null hypothesis. Be sure to 
notice that the decision rule for this statistics is "backwards" from most of the others -- smaller values of W are 
more likely to lead to rejecting H0:  !!
-- if the obtained W value (from Step 6) is larger than the critical value of W, then retain H0:
 -- if the obtained W value is less than or equal to the critical value of W, then reject H0:
For the example data, we would decide to retain the null hypothesis, because the 
obtained value of W (19) is greater than the larger critical W value (10).
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For large samples (one or both groups with N > 20):
Step 10  With samples this large, the value of W has approaches a normal distribution, and so the null hypothesis can be tested by 
a Z-test.
          W - (N*(N + 1)/4)           19 - (10 * (10 + 1) / 4)
Z = -----------------------  =  ------------------------------
       N*(N+1)*((2*N)+ 1)      10 * (10 + 1) * ((2*10) + 1)
        -------------------        -----------------------------
     √         24  √ 24
      19 - 27.5             -8.5
= -----------------  =   --------   =   -.87
    √ 2310 / 24     9.81
Step 11  Compare the obtained Z value and the critical Z value to determine whether to retain or reject the null hypothesis.
-- if the absolute value of the obtained Z is less than 1.96, then retain H0:
-- if the absolute value of the obtained Z is greater than 1.696, then reject H0:
For the example data, we would decide to retain the null hypothesis, because the
absolute value of the obtained Z (.87) is less than the critical value of 1.96.
For both small and large samples:
Step 12  IF you reject the null hypothesis, determine whether the data support or do not support the research hypothesis.
-- IF you reject the null hypothesis AND the condition that was hypothesized to have the larger scores does, then the 
research hypothesis is supported
-- IF you retain the null hypothesis OR you reject the null hypothesis BUT the condition that was hypothesized to have the
larger scores actually has the smaller scores, then the research hypothesis is not supported.
By the way:  Usually the researcher hypothesizes that there is a difference between the conditions.  Sometimes, however, the
research hypothesis is that there is NO difference between the conditions.  If so, the research hypothesis and H0: are the same!
When this is the case, retaining H0: provides support for the research hypothesis, whereas rejecting H0: provides evidence that
research hypothesis is incorrect.
For the example data, we would decide that the research hypothesis is not
supported, because the null hypothesis was retained.
Step 12  Reporting the results
As for the other statistical tests, the report includes the "wordy" part and the statistical values upon which the you made
your statistical decision.  Be sure to tell which condition tended to have the larger scores, and whether or not this agrees with the
research hypothesis. You should compute sample medians and IQR values to help describe the data,
Contrary to the research hypothesis, there was no difference between the
distribution of quality ratings given to fish (Mdn = 6.00, IQR = 4.00 - 7.75) and those
given to reptiles (Mdn =7.00, IQR = 5.25 - 8.75) in these stores, based on Wilcoxin
test, W = 19, p > .05.
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oncologique, 11(6-7):287, 2007.
[140] BD Smith, DW Arthur, TA Buchholz, BG Haffty, CA Hahn, PH Harden-
bergh, TB Julian, LB Marks, DA Todor, FA Vicini, and et al. Accelerated
partial breast irradiation consensus statement from the american society for
radiat oncol (astro). Int J Radiat Oncol Biol Phys, 74(4):987–1001, 2009.
[141] BV Offersen, M Overgaard, N Kroman, and J Overgaard. Accelerated par-
tial breast irradiation as part of breast conserving therapy of early breast
carcinoma: a systematic review. Radiother Oncol, 90(1):1–13, 2009.
[142] M Mannino and J Yarnold. Accelerated partial breast irradiation trials:
Diversity in rationale and design. Radiother Oncol, 91(1):16–22, 2009. doi:
10.1016/JradonC2008.12.011.
[143] D J Sher, E Wittenberg, A G Taghian, J R Bellon, and R S Punglia. Partial
breast irradiation versus whole breast radiotherapy for early-stage breast
Bibliography 230
cancer: a decision analysis. Int J Radiat Oncol Biol Phys, 70(2):469–76,
2008.
[144] D W Arthur, M M Morris, and F A Vicini. Breast cancer: new radiation
treatment options. Oncol, 18(13):1621, 2004.
[145] B D Smith, S M Bentzen, C R Correa, C A Hahn, P H Hardenbergh, and
et al. Fractionation for whole breast irradiation: An american society for
radiat oncol (astro) evidence-based guideline. Int J Radiat Oncol Biol Phys,
81(1):59–68, 2011.
[146] T Edlund and D Gannett. A single isocenter technique using ct-based plan-
ning in the treatment of breast cancer. Med Dosim, 24(4):239–45, 1999.
[147] W Xiaochun, T K Yu, M Salehpour, S X Zhang, T L Sun, and T A Buchholz.
Breast cancer regional radiation fields for supraclavicular and axillary lymph
node treatment: is a posterior axillary boost field technique optimal? Int J
Radiat Oncol Biol Phys, 74(1), 2009.
[148] Y M Kirova, V Servois, F Campana, R Dendale, M A Bollet, F Laki,
N Fournier-Bidoz, and A Fourquet. Ct-scan based localization of the inter-
nal mammary chain and supra clavicular nodes for breast cancer radiation
therapy planning. Radiother Oncol, 79(3):310–5, 2006.
[149] C Hurkmans, J Borger, B Pieters, N Russell, E Jansen, and B Mijnheer.
Variability in target volume delineation on ct scans of the breast. Int J
Radiat Oncol Biol Phys, 50(5):1366–72, 2001.
[150] E Weiss and C F Hess. The impact of gross tumor volume (gtv) and clin-
ical target volume (ctv) definition on the total accuracy in radiotherapy.
Strahlenther Onkol, 179(1):21–30, 2003.
[151] P Romestaing, Y Lehingue, C Carrie, R Coquard, X Montbarbon, J Ardiet,
N Mamelle, and J Gerard. Role of a 10-gy boost in the conservative treatment
of early breast cancer: results of a randomized clinical trial in lyon, france.
J Clin Oncol, 15(3):963–8, 1997.
[152] H Bartelink, J Horiot, P Poortmans, H Struikmans, W Van den Bogaert,
A Fourquet, J Jager, W Hoogenraad, S Oei, C Wárlám-Rodenhuis, et al.
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[217] Á. Gulybán, P Kovács, Z Sebestyén, R Farkas, T Csere, G Karácsonyi,
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dose distributions and organs at risk (oar) doses in conventional tangential
technique (ctt) and IMRT plans with different numbers of beam in left-sided
breast cancer. Rep Pract Oncol Radiother, 16:95–102, 2011.
